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Effect of brain death and donor treatment on organ
inflammatory response and donor organ viability 
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Department of Surgery, Groningen Kidney Transplant Center, University Hospital,
Groningen, The Netherlands
Published in Current Opinion of Organ Transplantation, Volume 9(2), June 2004, pp 110-11510 11
- Abstract -
Purpose of review:
In the past, brain death in the donor has been recognized as an important risk factor for the 
success of solid organ transplantation. Brain death-related systemic changes that may influ-
ence potential donor organs do not seem to be restricted to hormonal and hemodynamic 
alterations. This review shows that at present there is convincing evidence for an inflam-
matory response in the donor organs as a direct result of brain death. This may be caused 
by systemic factors released from the brain as a result of its damage. Also, new research is 
reviewed suggesting the presence of other processes that occur at organ level in brain death.
Recent findings:
In most organs, there is currently proof that the endothelium is activated, combined with 
the expression of adhesion molecules. The amount of leukocyte invasion in the tissue dif-
fers between organs. Recently, by using a microarray technique, the authors discovered the 
upregulation of several genes in brain death, which could be divided into three groups: genes 
involved in inflammation and coagulation, cell division and fibrosis, and protection and 
repair processes.
Summary:
These findings in brain death of an inflammatory response at organ level together with a first 
attempt of the organ to protect itself offer new opportunities in donor treatment and preser-
vation. By focusing attention on the specific blocking or stimulating of these processes, graft 
survival may be enhanced. The first studies in this direction already show promising results 
for graft survival.10 11
- Introduction -
Over the past few decades, solid organ transplantation has become an accepted therapy in 
the treatment of end-stage organ failure. Despite all the achievements including standardi-
zation of techniques, better understanding and treatment of complications, and the develop-
ment of a new generation of immunosuppressive drugs in the 1980s, the ultimate goal of a 
lifelong uncomplicated graft survival has not yet been reached. To date, chronic rejection and 
organ dysfunction still remain large problems. More recently, it has become clear that the 
occurrence of these late events is correlated with early injury incurred around the donation 
and transplantation period. In this respect, during the past few years, more attention has 
been paid to the condition of the donor in addition to other risk factors such as the surgical 
procedure or the incompatibility of donor and graft [1].
Most organs used in clinical transplantation have been retrieved from heart-beating, brain-
dead patients. For several patient categories –for instance, those waiting for a donor heart– 
this is inevitable. Because of a persistent shortage of donor organs, however, organs from 
living related or unrelated donors and, to a lesser extent, from nonheart-beating donors have 
become more accepted for transplantation over the past few years [2]. This extension of the 
donor pool has been primarily applied in kidney transplantation, although now both living 
and nonheart-beating donors are becoming accepted treatment modalities for liver and lung 
transplantation as well.
Well-matched living donor–recipient combinations were known to have superior transplant 
results over cadaveric donor kidneys. However, during the past few years, it has become obvi-
ous that fully mismatched living unrelated grafts also show better outcomes in survival rates 
than kidneys retrieved from brain-dead cadaveric donors with a similar matching grade for 
HLA antigens. Terasaki et al. [3] describe the survival of transplanted kidneys from different 
donors based on a large database. Cheng et al. [4] show very clearly the advantage of living 
donation above all other possibilities in liver transplantation for hepatocellular carcinoma. 
This difference in results could not be fully attributed to prolonged cold ischemia times 
for grafts procured from brain-dead donors, because no significant effect of cold ischemia 
time on kidney transplantation outcome was seen with preservation times as long as 24 
hours [3–5]. This pointed at the fact that the aspect of living versus dead obviously played 
a significant role in the quality and viability of donor organs. Thus, the authors and others 
started to focus on the role and effects of brain death on the function and outcome after 
transplantation [6,7]. Reporting for the research group of Tilney, Gasser et al. [6] reviewed 
the detrimental effects of brain death on peripheral organs. Much of the success in organ 
transplantation is dependent on the ability to recognize, prevent, and possibly repair aspecific 
inflammatory and specific immune responses triggered during the donor period and intensi-
fied during ischemia and reperfusion.12 13
- Concept of Brain Death -
The concept of brain death did not come into use until the 1960s. This can be explained by 
the development of mechanical ventilators not much earlier. In 1959, the French neurologists 
Mollaret and Goulon described a state of irreversible coma without reflexes (the coma
dépassée) after massive cerebral injury that required mechanical ventilation [8]. The coma-
tose state would typically end in death after several days or weeks. A few years later, the 
concept was picked up in the rest of the world. To deal with this upcoming problem of 
deceased patients with intact circulation, a committee was installed in 1968 at Harvard 
Medical School, followed by other committees in several countries, which formulated criteria 
for brain death so that in these cases, ventilators could be turned off [9].
Brain death was thus medically and legally defined as a state of nonfunctioning of the brain, 
thereby requiring mechanical ventilation to support certain basic functions for a limited 
time. This development has formed a legal basis for using deceased patients as organ donors. 
Nowadays, brain death is seen as irreversible nonfunction of the brain as a central integra-
ting organ regulating the body. This disintegration will therefore lead to disruption of several 
regulatory systems in the body, thereby affecting the potential donor organs.
- Mechanisms and Systemic Changes in Brain Death -
Irreversible cerebral injury leading to brain death usually results from intracranial hemor-
rhage or traumatic brain injury. In both instances, there is an increasing mass effect in the 
brain caused by intracranial volume expansion. This results in compression of brain tissue 
and a compromised liquor drainage and venous return, thereby inducing cerebral hypoxia 
and edema leading to an ongoing increase in intracranial pressure. Then brain stem compres-
sion occurs, with herniation of the brain stem into the foramen magnum, thereby causing 
respiratory arrest. Finally, complete brain ischemia precedes brain death. Mertes [10] pro-
vides a nice introduction to the physiologic aspects of brain death and their consequences in 
organ transplantation.
At first, some amount of viable tissue can still remain in the brain-dead patient. Total 
ischemia and necrosis of the spinal cord usually follow after destruction of the brain. 
Similarly, in some patients, the pituitary gland temporarily keeps its function. However, in 
most cases, the complete and irreversible loss of all brain stem functions can be established 
by clinical neurologic examination. The unresponsive patient shows an absence of brain 
stem reflexes and absolute apnea on stopping the mechanical ventilation. In most countries, 
confirmatory tests besides clinical examination such as electroencephalography or cerebral 
angiography are required to confirm the diagnosis of brain death.
Increases in intracranial pressure and brain ischemia lead to a series of major pathophysi-
ologic changes usually referred to as the autonomic storm. After a few minutes of excessive 
parasympathetic activity during the onset of brain death, the body reacts with an initial 12 13
attempt to overcome increased intracranial pressure by severe vasoconstriction and, thereby, 
an increase in blood pressure, known as the Cushing reflex. This vasoconstriction occurs 
because of the fulminant release of endogenous catecholamines and probably causes a rela-
tive hypoperfusion in peripheral organs. Progressive paralysis of the spinal cord sympathetic 
pathways then leads to sympathetic deactivation with a decline in systemic vascular resis-
tance to levels of less than 50% of baseline values. The period that follows is characterized by 
hemodynamic instability with hypotension and hypoperfusion of abdominal organs. In this 
phase, catecholamine levels drop to below baseline levels [10].
Other endocrinologic disturbances have also been widely reported. In most brain-dead 
patients, the function of the posterior pituitary gland is completely affected, as reflected by 
the onset of diabetes insipidus. However, in some patients, parts of the posterior lobe of 
the pituitary gland have been proven to be preserved. Also, patients have been described 
in whom circulating anterior pituitary hormones such as growth hormone, adrenocortico-
tropic hormone, and thyroid-stimulating hormone were detected until 1 week after brain 
death. Even so, most patients have a nonfunctioning hypothalamic-pituitary-thyroid axis. 
Whether substitution with triiodothyronine, cortisol, and insulin has beneficial effects on 
donor condition still remains contradictory. Novitzky [11] reported a reversal of anaerobic 
to aerobic metabolism and an improved hemodynamic status, but Gifford [12] failed to find 
any correlation between hormone levels and outcome parameters. Finally, levels of cortisol, 
insulin, atrial natriuretic peptide, and the renin-angiotensin-aldosterone axis do not seem to 
alter dramatically with onset of brain death.
During these systemic changes, many substances circulate through the body that are also 
seen during inflammatory responses. Shortly after brain death, high levels of cytokines 
such as interleukin-1 ß and interleukin-6, soluble cytokine receptors like sIL-2 receptor 
and sTNF receptor II, and vasoactive substances like endothelin-1 can be detected in the 
peripheral blood of the patient [13,14]. Lopau et al. [14] measured the full hormonal state of 
the brain-dead human donor. These substances may well originate from the brain as in less 
severe forms of brain damage such as acute ischemic stroke. A rise in both systemic soluble 
proinflammatory cytokines and soluble adhesion molecules could also be detected [15,16], 
whereas subarachnoid hemorrhage is known to cause a release of endothelin-1 in serum 
[17,18]. Likewise, in traumatic brain injury not followed by brain death, high interleukin-6 
levels were detected in serum [19].
- Pathophysiologic Effects on Organs during Brain Death -
As stated before, peripheral organs suffer from the effects of brain death. The specific nature 
of the stress stimulus or stimuli in brain death to which organs respond remains to be inves-
tigated. Systemic hemodynamics—that is, hypertension at the onset of brain death and
subsequent hypotension and hypoperfusion—may be held responsible for the upregulation 
of several detrimental factors and the induction of an inflammatory endothelial reaction. 14 15
These hemodynamic changes probably cause an amount of endothelial shear stress followed 
by a period of vasoconstriction leading to temporary ischemia of the abdominal organs. 
These same factors, shear stress and ischemia, are known to be able to activate the endo-
thelium and cause an inflammatory response [20,21].
On the other hand, brain damage itself may cause a release of known or as yet unknown 
factors that trigger a response on the level of the organ itself. Possible candidates for these 
factors are cytokines, soluble adhesion molecules, or vasoactive substances such as endo-
thelin-1. Indeed, molecules involved in inflammation could well be responsible for a part of 
the detrimental effects on organs, because the beginning of an inflammatory response on the 
organ level has now been reported for several organs.
Heart
During the onset of brain death, catecholamines are released not only in the systemic circula-
tion but also locally in the heart. These local concentrations, derived from sympathetic nerve 
endings, are far higher than plasma norepinephrine levels and are well capable of inducing 
various types of myocyte necrosis, such as contraction band necrosis, coagulation necrosis,
and myocytolysis. Administration of similar high doses of exogenous catecholamines to 
experimental animals showed the same effects of necrosis [10]. This damage is further 
increased by massive calcium uptake of myocytes, stimulated through their ß-receptor. Sym-
pathectomy and calcium antagonists have been shown to reduce cardiac damage substan-
tially. Wilhelm et al. [22] described the systemic changes to the heart induced by brain death. 
Also, as in other organs, endothelial cells are injured by brain death, which is a beginning 
for cardiac allograft vasculopathy, the limiting factor in prolonged cardiac survival [23]. This 
process happens during a diffuse inflammatory reaction with expression of cytokines and 
adhesion molecules in the heart [24].
Lungs
The rapid hemodynamic changes that occur during brain death have detrimental effects on 
the lungs as well. As the heart receives an increased venous return of blood during the period 
of extreme vasoconstriction, the left atrial pressure exceeds the pulmonary artery pressure 
for a few seconds, causing a temporary circulatory stop and pulmonary hypertension in 
the capillaries of the lung. The lung tissue that is exposed to this type of pressure becomes 
severely injured, and the capillary integrity within the lungs is disrupted, causing pulmonary 
edema and interstitial hemorrhage [25]. Obviously, the prerequisite of mechanical ventilation 
in brain death has an additional adverse effect on the condition of the lungs.
The detrimental effects of brain death can also be found at a cellular level. Fisher et al. [26] 
found increased gene expression levels of interleukin-8 and growth-related gene-α after brain 
death compared with control ventilated patients. These interleukin-8 levels strongly corre-
lated with the extent of neutrophil infiltration in the lungs.14 15
Liver
Although quite difficult to establish, evidence is mounting that the phase of brain death has 
similar negative effects on liver viability to those observed in other organs [27,28]. Histologic 
changes to liver tissue induced by brain death are described in some studies. Nagareda et 
al. [29] described the results of sequential liver biopsies in humans as long as 48 days after 
onset of brain death. Because of the Japanese system, which until recently did not allow 
brain-dead patients to be used as organ donors, this unique study shows histologic features 
of brain-dead livers after a prolonged period of brain death [29]. Central venous congestion 
during the first days after onset of brain death is reported. This is probably caused by brain 
death-induced circulatory failure. No significant central fibrosis, fatty metamorphosis, 
piecemeal necrosis, or periportal fibrosis was observed. Sometimes intrahepatic cholangitis 
was observed, generally more than 5 days after onset of brain death. Cholangitis was most 
likely caused by the known effect of medication or vagal denervation leading to gallbladder 
cholestasis and altered hepatic bile flow [30].
The onset of brain death does not seem to have an effect on the metabolic function of the
liver [31,32]. Brain death did, however, have a negative effect on the preservation rate 
of ATP production after heat loading, also a viability assay for mitochondrial function. 
Although such an impairment might not affect graft function in uncomplicated transplanta-
tion situations, under unfavorable effects on posttransplant liver function are likely [33]. 
Effects of the use of vasoactive drugs to overcome brain death-induced hypotension on liver 
metabolism have also been subject of several studies. Although consensus still has not been 
reached, certain vasoactive drugs seem to have an effect on liver metabolism. Dopamine use 
in the donor has been shown to increase the incidence of primary graft failure, probably by 
reducing the redox state of liver mitochondria [32]. Vasopressin alone or in combination 
with epinephrine has no negative effects on the metabolic function of the liver [34].
To unravel the detrimental effects of brain death on the potential donor organ, the authors 
developed an animal model simulating brain death after intracranial trauma. In this model, 
brain death is induced by inflation of an intracranial balloon catheter in the anesthetized rat. 
In the rat brain-death model, tissue damage, as reflected by standard serum parameters, was 
profound: a threefold rise in serum creatinine and AST levels of more than 150 IU were 
detected after 6 hours of brain death [35]. These livers were used in a liver transplant model. 
Even without cold preservation, graft survival already decreased with 25% after transplan-
tation of livers derived from brain-dead donors [36]. The decreased organ survival after 
brain death is shown very clearly in the study by Van der Hoeven et al. [36] using a rat liver 
transplant model. In an isolated perfused liver model, livers from brain-dead donors showed 
far more decrease in function (lower bile production and active transport mechanisms) and 
increase in injury parameters (higher transaminases and LDH; Unpublished data).
Histologically, an infiltration of leukocytes, particularly of PMNs and macrophages but also 
a small increase in T cells, is seen after brain death. Also, expression of cell adhesion mole-
cules intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) 
is increased [35]. The detrimental effects of brain death on the liver are also demonstrated 16 17
by the occurrence of apoptosis of hepatocytes, as assessed by caspase 3 activity and TUNEL 
assay after only 6 hours of brain death [37].
Kidney
Epidemiologic studies were the first to show the detrimental effects of brain death on organ 
quality in kidneys. A good comparison can be made between recipients of cadaveric kidneys 
and the large number of recipients of living related and unrelated donor kidneys [3].
From the onset of brain death through the catecholamine storm until brain death induced 
hypotension, kidney perfusion can be significantly compromised in potential organ donors. 
Because decreased kidney perfusion is regarded as a major cause of kidney damage [38], the 
effect of brain death on kidney viability has been studied. Viability has been verified by his-
tologic examination. Morphologic changes in potential donor kidneys before organ procure-
ment have been found. A limited degeneration of tubular lining cells can be seen from the 
day of onset of brain death, increasing with the duration of the agonal phase. These degen-
erative changes are more extensive in the distal than in the proximal tubuli. Also, progres-
sion of arterial intimal proliferation, periglomerular fibrosis, and periglomerulitis are found 
after the onset of brain death [39]. In a study investigating effects of brain death on rabbit 
kidneys, however, only slight tubular and glomerular changes were observed.
Although increases of inflammatory cytokines and invading neutrophils could already be 
found in animal models and human studies after brain death, a massive invasion of recipient 
macrophages and T cells and an upregulation of adhesion molecules (both selectins and Ig 
superfamily members) and HLA-DR antigens could be found after reperfusion compared 
with reperfused nonbrain-dead controls in human and rat kidney grafts [40,41].
In our rat brain death model, the authors not only detected rises in serum creatinine, indica-
ting decreased kidney function, but also demonstrated a progressive inflammatory response 
in the donor kidney. Leukocyte influx increased twofold in the kidney after 6 hours of brain 
death. Adhesion molecules VCAM-1 and ICAM-1 were clearly more expressed in brain-
dead donor organs. The immediate early gene FOS was found in kidney biopsies from
brain-dead animals only [42].
Similar to the results of the rat studies, the authors’ findings were increased levels of cell ad-
hesion molecules E-selectin, ICAM-1, and VCAM-1 in human cadaveric kidneys compared 
with control biopsies from living related kidneys [43]. Recently, an isolated perfused kidney 
model was developed as well. Using this model, a dramatic decrease in function (almost no 
urine production, sodium retention) in kidneys from brain-dead donors and, even more, in 
kidneys from non heart-beating donors was [44].
Recently, the authors isolated mRNA from fine-needle kidney biopsies from human brain-
dead and living donors. With reverse-transcription polymerase chain reaction, the authors 
studied expression of several genes possibly involved in brain death. Despite the heteroge-
neous background of the donors, the authors found elevated levels of HO-1 and hsp70 in 
brain-dead donors. HO-1 and hsp70 encode proteins with several cytoprotective properties 
against ischemia, heat, and toxins. Furthermore, after correlating donor variables with gene 16 17
expression, a strong association was found between elevated AST and ALT serum levels and 
increased HO-1 gene expression. This also indicates a damage response on brain death, al-
though it is not entirely clear whether HO-1 expression in the kidney and serum AST/ALT 
are both manifestations of systemic stress and organ damage or whether elevated AST/ALT 
levels are produced by the kidney itself [43].
- Systematic Assessment of Pathways Involved in
the Reaction on Brain Death -
Although knowledge regarding brain death has broadened during the past few years, the 
undoubtedly complex mechanisms by which brain death leads to these processes remain 
unclear. To unravel these regulatory pathways further, the authors recently performed micro-
array studies with RNA derived from brain-dead rats [45]. DNA microarrays enable the 
expression analyses of multiple genes simultaneously. In this technique, isolated RNA is la-
beled and used as a probe on an array containing several thousands of spotted genes involved 
in a wide range of biologic pathways. By using oligonucleotide microarrays containing 5000 
unique rat sequences, 72 genes were identified as being differentially expressed, which was 
confirmed by reverse-transcription polymerase chain reaction for a selected number of genes.
Further analyses of the data enabled the authors to categorize a substantial number of these 
genes in different functional groups: (1) upregulation of inflammation and coagulation (with 
adhesion molecules like e-selectin, cytokines like interleukin-1α and interleukin-6, chemok-
ines (eg, MCP-1), and α-fibrinogen and ß-fibrinogen involved in coagulation), (2) upregula-
tion of cell division and fibrosis (with cell cycle arrest gene KIM-1
putatively involved in regeneration of proximal tubular cells and fibrosis genes collagen
α1 and 2), (3) upregulation of genes involved in protection and repair (heat shock
proteins, antiapoptotic genes, and the oxygen-radical scavenger MnSOD), and (4) down-
regulation of several genes involved in metabolism and transport of the kidney.
Also, genes encoding transcription factors and proteins involved in signal transduction were 
identified, of which an extended number have been shown to be regulated by key transcrip-
tion factors as NF-κB and Egr-1.
These results indicate not only that deleterious processes such as inflammation and fibrosis 
occur in brain-dead donor organs but also that genes involved in protection and repair
processes are activated. More research about the mutual interaction of these processes must 
be conducted in the future.18 19
- Conclusion -
These exciting results of microarray studies outline further studies needed to explain the 
process of brain injury and brain death in a potential donor in detail. The exact mechanisms 
and pathways responsible for the reduced graft quality are still largely unknown. No detailed 
models and hypotheses have been published to date. Also, there have been few brain death 
intervention studies published.
The authors have shown that brain death in the rat has definite effects on three important 
groups of genes: genes involved in inflammation and coagulation, cell division and fibrosis, 
and protection and repair. From a general idea of preventing injury, artificial upregulation 
of the heat shock protein heme oxygenase-1 has been correlated to an improvement in both 
kidney graft function and survival after brain death [46]. However, in this study, HO-1 was 
induced with the toxic substance cobalt-protoporphyrin, thereby rendering this approach 
unsuitable for a translation to the human situation. Other, less toxic upregulators of heat 
shock proteins like HO-1 may thus prove to be a great advance in treatment.
Another promising approach is to block or suppress the proven inflammatory processes and 
to test its effect on transplantation outcome. Until now, very few intervention studies have 
been performed to test whether inflammation could be suppressed. This is not surprising, 
because not many groups have used a functional brain death animal model. Until now, only 
the administration of soluble P-selectin glycoprotein ligand during brain death in a rat kid-
ney transplant model has been tested [47,48]. Recipients of treated kidneys showed survival 
times comparable with living donor controls and significantly better than the untreated 
allografts. This approach shows promising results, even while focusing only on a very small 
aspect of the process of brain death.
The authors speculate that the activation of T cells later during brain death will also lead to 
injury and result in an increased rate of rejection. To block the specific immune system with 
the potential of decreased immunogenicity, improved function and less rejection may also be 
a starting point of further study.18 19
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- Rationale - 
The unphysiologic state of donor brain death (DBD) is a risk factor for donor kidneys
used in transplantation. Even totally mismatched living-unrelated grafts have better survival 
outcomes than kidneys retrieved from DBD donors with a very reasonable HLA match. 
Brain death has been known to affect the circulatory and hormonal state of the donor. In 
this thesis, we have focused on the progressive pro-inflammatory response to brain death in 
the kidney and tried to characterize these effects prior to transplantation. The Introduction 
of this thesis describes the current knowledge and concepts regarding the nature of brain 
death and its effects on organ quality. Irreversible cerebral injury leading to brain death is 
usually the result of intracranial hemorrhage or traumatic brain injury. A mass effect in the 
brain leads to a herniation of the brain stem with loss of stem reflexes and respiratory arrest. 
Shortly after brain death, high levels of proinflammatory cytokines can be detected in the 
peripheral blood of the donor. In most peripheral organs (heart, lung, liver and kidney),
aspects of an ongoing inflammatory response can be detected. On the other hand, an
upregulation of protective proteins can be found in brain death. Microarray analysis is a 
powerful tool to study this response in more detail.   
In Chapter 3, we focus on the kidney to study the effects of BD on inflammatory response 
and stress-related heat shock proteins at organ level. We obtained kidney biopsy specimens 
and serum during organ retrieval from BD and living organ donor controls. With these 
biopsy specimens immunohistochemistry and semiquantitative reverse transcriptase-
polymerase chain reaction were performed. These data, as well as clinical and laboratory 
parameters from BD donors were recorded and related to outcome data of recipients of 
those kidneys. 
Many BD donors have a higher endotoxin load and more bacterial translocation from the 
gut compared to living donors. This endotoxemia might trigger a decrease in vascular integ-
rity leading to increased permeability of the intestine by influencing the Angiopoietin-Tie 
ligand-receptor system, which could also lead to the increased inflammatory response seen 
in peripheral organs. A decreased Angiopoietin 1/Angiopoietin 2 ratio is associated with in-
creased morbidity and mortality during sepsis, while an increased ratio can maintain vascular 
integrity and dampen the inflammatory response. This ratio was studied in donor serum in 
Chapter 4, as well as the amount of Lipopolysaccharide Binding Protein (LBP) as a quan-
tification of endotoxemia. As Ang-2 primes endothelium to respond to VEGF, these levels 
were also studied in serum. Serum levels were related to clinical transplant outcomes.
Whether or not duration of brain death is a factor in organ quality is uncertain. Leakage 
of detrimental substances from the brain into the circulation of BD donors and the rise in 
cytokine and chemokine expression in their organs during brain death suggests that early 
organ retrieval in BD donors is beneficial. On the other hand, the expression of protective 24 25
heat shock proteins could be seen as a mechanism by which the body tries to repair present 
damage. Scarce data suggests that a longer BD period might actually be better for donor 
organ quality. In Chapter 5 of this thesis, we report a large retrospective analysis using data 
from the OPTN database that analyzes the effects of duration of brain death (BDdur) on 
outcome after kidney transplantation. 20,773 kidney donor and recipient couple data were 
studied. In this chapter, BDdur was calculated as the period between declaration of brain 
death and aortic cross clamping. We calculated the effect of BDdur on delayed graft function 
(DGF), acute rejection and one- and three-year graft survival using binary logistic regression 
and Cox regression models. 
The prediction of organ quality at an early time point, i.e. during donor evaluation and
management, is still difficult, although donor treatment and evaluation during brain death 
would offer a great time frame for improvement of both allocation algorithms and the donor 
organ itself. Therefore, in Chapter 6 we have tested several interesting novel urine markers
to discover kidney specific injury at an early stage. We evaluated urinary levels of lactate 
dehydrogenase (LDH), kidney injury molecule-1 (KIM-1), heart-type fatty acid binding 
proteins (H-FABP), alanine aminopeptidase (AAP), malondialdehyde (MDA), N-acetyl-
ß-D-glucosaminidase (NAG) and interleukin-18 (IL-18). These markers were compared to 
urinary creatinine and urinary protein as classic parameters of kidney function. Two different 
populations were studied: urine samples were collected from 40 kidney donors during 
donation, and another set from 29 transplant recipients during the first 10 days after kidney 
transplantation. Biomarker levels were related to delayed graft function, acute rejection and 
kidney function up to one year after transplantation using regression analyses. 
As KIM-1 apparently has a high sensitivity for kidney injury, and is upregulated early during 
kidney injury, we studied this molecule in more detail in Chapter 7. We evaluated Kim-1
expression using real-time PCR, in situ hybridization, immunohistochemistry and a 
Luminex assay in a standardised rat brain death model. In this standardized model, brain 
death is induced by intracranial balloon inflation. Sham operated animals were compared to 
animals that had been brain dead for 0.5, 1, 2 or 4h. Results were confirmed in human DBD 
donors and linked to transplantation outcome parameters. 
Ultimately, our goal is to intervene during brain death, aiming at a better balance between in-
jury and repair, hopefully resulting in better graft survival and transplantation. In Chapter 8, 
we study the administration of (carbamylated) erythropoietin in brain death in a rat model. 
In this experiment we used our standardised brain death animal model and after organ 
retrieval we evaluated kidney function with the Isolated Perfused Kidney (IPK) model. We 
tested the administration of EPO, carbamylated EPO (cEPO, which is a modified molecule 
without the erythropoietic properties of EPO), or a vehicle, and compared these groups with 
sham operated animals.26 2726 27
chapter
1 3  23 
Effect of Brain Death on Gene Expression and Tissue 
Activation in Human Donor Kidneys 
Willemijn N. Nijboer1,2; Theo A. Schuurs1; Joost A. B. van der Hoeven1; Susan Fekken1;
Janneke Wiersema-Buist1; Henri G. D. Leuvenink1; Sijbrand Hofker1,2; Jaap J. Homan van der Heide2;
Willem J. van Son2; Rutger J. Ploeg1,2
1 Surgery Research Laboratory, University Hospital Groningen, Groningen, The Netherlands.
2 Kidney Transplant Centre, University Hospital Groningen, Groningen, The Netherlands.
Published in Transplantation Volume 78(7), 15 October 2004, pp 978-98628 29
- Abstract -
Background:
 After kidney transplantation, decreased graft survival is seen in grafts from brain dead (BD) 
donors compared with living donors. This might result partly from a progressive nonspecific 
inflammation in the graft. In this study, we focused on the effects of BD on inflammatory 
response (adhesion molecules, leukocyte invasion, gene expression) and stress-related heat 
shock proteins in the human kidney. Research outcomes and clinical donor parameters were 
then linked to outcome data after transplantation.
Methods:
Kidney biopsy specimens and serum were obtained during organ retrieval from BD and
living organ donor controls. Immunohistochemistry and semiquantitative reverse tran-
scriptase-polymerase chain reaction were performed on the biopsy specimens. Clinical and 
laboratory parameters from BD donors were recorded and connected to outcome data of the 
recipients of the kidneys studied.
Results:
After brain death, immunohistochemistry showed an increase of E-selectin (P<0.01) and 
interstitial leukocyte invasion (P<0.05) compared with controls. Also, reverse transcriptase-
polymerase chain reaction showed a threefold increased heme oxygenase-1 (P<0.05) and 
Hsp70 (P<0.01) gene expression after BD. Levels of monocyte chemotactic protein-1 and 
transforming growth factor-ß were twice as high after brain death but did not reach signifi-
cance. Transplantation outcome was influenced by several donor variables: positively most 
notably by donor treatment with desmopressin and negatively by high serum urea levels
during brain death and by high intercellular adhesion molecule and vascular cell adhesion 
molecule expression in the kidney. Heme oxygenase-1 proved to have a protective function, 
but only in kidneys from living donors.
Conclusions:
The presence of interstitial leukocytes and the early adhesion molecule E-selectin in BD 
donor kidneys indicates an early-phase inflammatory process during organ retrieval. Elevated 
levels of monocyte chemotactic protein-1 and transforming growth factor-ß suggest a role for 
monocytes/macrophages in this phase. We suggest that BD causes a stress-related response 
against which protective heat shock proteins are formed in the future graft. This stress 
response may be too severe to be fully counteracted by elevated heat shock proteins. Which 
systemic and/or local factors trigger brain death-related graft injury is currently under
investigation.28 29
- Introduction -
In the last two decades, kidney transplantation has become the treatment of choice for end-
stage renal failure. The main source of donor organs for kidney transplantation has been 
heart-beating brain dead (BD) patients. Because of a persistent shortage of donor organs, 
however, living (un)related donors and, to a lesser extent, kidneys from non-heart-beating 
donors have been increasingly accepted for transplantation during the last several years. 
Transplantation in well-matched living donor-recipient combinations is known to have 
superior results compared with cadaveric kidney transplantation. However, during the past 
several years it has become obvious that fully mismatched living-unrelated grafts have also 
shown better survival outcomes than kidneys retrieved from BD donors with a reasonable 
match for HLA antigens (1). This difference in results cannot be fully attributed to pro-
longed cold ischemia times for grafts procured from BD donors, because no significant effect 
of cold ischemia time on kidney transplantation outcome was seen with preservation times 
up to 24 hr (1). Thus, other risk factors are responsible and should explain the difference in 
success rates between living and cadaveric kidney transplantation.
Recently, we and others have focused on the unphysiologic state of brain death as a key 
player and potential risk factor that influences graft survival. Brain death has been known 
to affect the circulatory and hormonal state of the donor (2,3). Attempts to neutralize these 
effects by monitoring blood pressure and by hormone suppletion therapy have not reversed 
these adverse effects. To unravel the detrimental effects of brain death on the potential donor 
organ, we developed an animal model that simulates brain death after intracranial trauma. In 
our rat brain death model, we were able to demonstrate a progressive inflammatory response 
in the donor liver, kidney, and lung, which occurred within 1 hr after induction of brain 
death and resulted in histologic damage, decreased function, and lower graft survival (4-8). 
Also, in human donors, an up-regulation of inflammatory markers has been reported and 
related to ischemia/reperfusion injury. In those studies, however, most kidney biopsy speci-
mens were taken after cold ischemia and at the moment of reperfusion of the organ (9,10).
To assess the effects of brain death without any influence of subsequent ischemia and reper-
fusion, in this study we used kidney biopsy specimens from human donor grafts, obtained 
during the donor operation just before organ retrieval and the start of cold preservation. We 
investigated the effect of brain death in the clinical donor situation and compared kidneys re-
trieved from heart-beating cadaveric donor organs to control kidneys from living (un)related 
kidney donors, thereby focusing on inflammation and stress response. We have investigated 
the presence of adhesion molecules, gene expression of genes involved in inflammation, and 
gene expression of heat shock proteins. In addition, we have linked a number of clinical 
donor parameters and blood sample laboratory outcomes as well as our findings concerning 
inflammation and stress response with posttransplantation outcome data. On the basis of 
our data in this limited series, we suggest some explanations based on donor characteristics 
for part of the differences in delayed graft function, acute rejection, patient and graft survival 
rates, and kidney function in kidney transplant recipients.30 31
 - Materials and Methods -
Patients and Biopsy Material
From 1998 through 2002, kidney biopsy specimens were obtained during organ retrieval 
from a consecutive series of BD (n=27) and living donors (n=34). The latter were used as 
controls.
Age and gender were recorded for both BD and living donors. The following variables were 
recorded for BD donors: height, weight, blood group, history of smoking, alcohol abuse or 
chronic illnesses, cause of death, duration of brain death, duration of intensive care unit 
(ICU) stay, medication during ICU stay, duration of ventilator support, diuresis, cardiac 
arrest during ICU stay, and number of hypotensive periods (defined as >15 min systolic 
pressure < 80 mm Hg). Pertinent donor and clinical parameters for BD and living donors 
are listed in Table 1.
Table 1   Demographics of donor parameters
         
  Cadaver  Living
Donor parameters  (N=27)  (N=34)
Donor sex (M:F)  7:20  12:22
Donor age (years ± SD)  42 ± 16.5  48 ± 9.6
Related : unrelated  N/A  20:14
Cerebral trauma vs cerebral hemorrhage (T:H)  8:19  N/A
Multi/single organ donor (M:S)  15:12  N/A
Ventilator support (days mean± SD)  1.83 ± 1.90  N/A
Inotropic support  24/27  N/A
Desmopressin treatment  21/27  N/A
Episode of cardiac arrest  3/27  N/A
Hypotensive period (>15 min. syst. pressure < 80 mmHg)  7/27  N/A
Brain death duration (start autonomic storm; h.min ± SD)  17.59 ± 5.43  N/A
Rate of urine output (ml/hr ± SD)  262 ± 215  N/A
Urine output final hour (ml ± SD)  319 ± 202  N/A
Blood urea at T=3 (last sample before org. retr.; mmol/liter ± SD)  4.0 ± 1.8  N/A
Serum creatinine at T=3 (μmol/liter ± SD)  73 ± 23  N/A30 31
Biopsy specimens were taken just before (approximately 15 min) organ retrieval and preser-
vation using a Pro-Mag 2.2 Biopsy Gun with a 16-gauge needle (Manan Medical Products). 
Specimens were embedded in Tissue-Tek (Sakura Finetek Europe, Zoeterwoude, The
Netherlands) and frozen immediately in isopentane on dry ice (-80°C). Specimens were 
stored at -80°C until analysis.
Blood samples were collected from BD donors during their ICU stay at four different time 
intervals: T=0, last sample taken before declaration of brain death; T=1, first sample taken 
after declaration of brain death, at the moment of the donor report to Eurotransplant; 
T=2, at the end of the ICU stay; and T=3, just before organ preservation. For all time 
points, standard blood hematologic and biochemical analyses were performed (hemoglobin, 
hematocrit, leukocytes, platelets, sodium, potassium, urea, creatinine, lactate dehydrogenase, 
alanine aminotransferase, aspartate aminotransferase, conjugated and unconjugated bilirubin, 
alkaline phosphatase, total protein, albumin, and prothrombin times).
Immunohistochemistry
Cryostat tissue sections (4 μm) were stained with monoclonal antibodies using an indirect 
immunoperoxidase technique. Monoclonal antibodies were directed against all human leu-
kocytes (CD45, leukocyte common antigen [LCA]; Dako, Glostrup, Denmark), intercellular 
adhesion molecule (ICAM)-1 (CD54, Hu5/3), vascular cell adhesion molecule (VCAM)-1 
(CD106, E1/6), and E-selectin (CD62E, H18/7; all three courtesy of Dr. Grimbrone,
Boston, MA). After thorough washing, the sections were incubated with appropriate horse-
radish peroxidase-conjugated secondary antibodies (Dako). The reaction was developed 
using 3-amino-9-ethylcarboxide/H2O2. Sections were counterstained using Mayer’s hema-
toxylin solution (Merck, Darmstadt, Germany). Negative antibody controls were performed.
Quantitation of immunohistochemical staining was assessed by light microscopy. ICAM-1, 
VCAM-1, and E-selectin stainings were scored as negative (-, no staining), weakly positive 
(+), moderately positive (++), or strongly positive (+++). Microscopic examination and 
comparisons were always performed with biopsy specimens simultaneously stained. In the 
sections stained for human leukocytes, quantitation was performed by counting the total 
number of positive cells per microscopic field at ×400 magnification. The total number of 
microscopic fields evaluated per tissue section was six to eight, covering the total section.
Reverse Transcriptase-Polymerase Chain Reaction
Total RNA was isolated from single biopsy specimens, using the SV Total RNA Isolation 
Kit (Promega, Madison, WI) following the manufacturer’s instructions. In brief, frozen 
tissue samples were mechanically disrupted and lysed in lysis buffer containing guanidine 
thiocyanate. RNA was precipitated out of the solution with ethanol and bound to the silica 
membrane of the Spin Basket by centrifugation. DNA was removed by incorporating a 
DNase treatment step, and total RNA was eluted from the membrane by adding nuclease-
free water. RNA (50 ng) was then reverse transcribed into cDNA in a total volume of 20 μL 
using 0.5 μg of T11VN oligos (Invitrogen, Paisley, UK) and the Sensiscript RT Kit (Qiagen, 
Valencia, CA).32 33
Polymerase chain reactions (PCRs) were performed in a total volume of 50 μL containing 
gene-specific primer pairs (1 μM each; Table 2), 0.2 mM dNTPs (Invitrogen), 5 μL of PCR 
buffer (final MgCl2 concentration 1.5 mM), 1.25 U of Taq polymerase, and 2 μL of cDNA 
using the HotStarTaq DNA Polymerase Kit (Qiagen) following the manufacturer’s instruc-
tions. PCR was performed on a T1 Thermocycler (Whatman Biometra, Göttingen, Ger-
many) under the following conditions: a hot start at 95°C for 15 min, followed by a number 
of cycles consisting of a denaturation step at 94°C for 40 sec, an annealing step at a primer 
pair-specific annealing temperature (Table 2) for 40 sec, and an extension step at 72°C for 
60 sec. The number of cycles was selected to allow for amplification within the linear range. 
Gene-specific primer sequences were chosen using the noncommercial Internet program 
Web Primer (http://genome-www2.stanford.edu/cgi-bin/SGD/web-primer ) on published 
sequences from the Entrez Nucleotides database from National Center for Biotechnology 
Information (NCBI). Each RNA sample was verified for the absence of genomic DNA by 
performing reverse transcriptase (RT)-PCR reactions in which the addition of the reverse 
transcriptase enzyme was omitted.
After amplification, 10 μL of PCR product was run on a 2% agarose gel (Hispanagar,
Burgos, Spain), stained with ethidium bromide, and scanned on Imagemaster VDS
(Amersham Biosciences, Little Chalfont, UK) using LISCAP software. PCR product abun-
dance was quantified using Imagemaster 1D prime v2.00 (Amersham) and normalized for 
the abundance of the ß-actin signal from the same cDNA.
Table 2   Primer sequences used
Gene  Primers   Annealing temp   
       
β-actin  5’-TTCCTGGGCATGGAGTCCTGTGG-3’   58˚C   
  5’-CGCCTAGAAGCATTTGCGGTGG-3’   
TNF-α  5’-CAGACTTCCTTGAGACACGGA-3’   60˚C   
  5’-CAATGAGTGACAGTTGGTCACC-3’ 
IL-1β  5’-AAAGGCGGCCAGGATATAACTG-3’    58˚C   
  5’-TTCTGTCAGGCGGGCTTTAAG-3’
IL-6  5’-CTGGGCACAGAACTTATGTTG-3’   52˚C   
  5’-TTAAGCTTCACGTGACACACTC-3’
IL-8  5’-TTGCCAAGGAGTGCTAAAGAAC-3’   55˚C   
  5’-TTCTCCCGTGCAATATCTAGGA-3’ 
MCP-1  5’-TCAAACTGAAGCTCGCACTC-3’   53˚C   
  5’-GTTCAAGTCTTCGGAGTTTGG-3’
TGF-β  5’-CTGCGGATCTCTGTGTCATT-3’   56˚C   
  5’-CTCAGAGTGTTGCTATGGTG-3’
iNOS   5’-CCTATCGCACCCGAGATG-3’   53˚C   
  5’-GCAGGATGTCTTGAACGTAGAC-3’
HO-1  5’-GACTGCGTTCCTGCTCAACAT-3’   59˚C   
  5’-GCTCTGGTCCTTGGTGTCATG-3’
Hsp70  5’-CCGTGCATTATTACGACTCTCTC-3’   54˚C   
  5’-GAAAGCAGGCGATAAGATGG-3’32 33
Data Collection and Statistical Analysis
Clinical donor data as well as donor blood analyses were recorded during organ retrieval pro-
cedures in our region by the transplant coordinator on call. As transplant outcome results, 
we recorded the presence of delayed graft function in the first week after transplantation, 
episodes of acute rejection in the first year, patient and graft survival at 1 and 3 years, and if 
available, serum creatinine and creatinine clearance values at 1 and 3 years. If, according to 
Eurotransplant, kidneys had been transplanted outside our donor region, the nephrologist 
of the transplant center concerned was approached; otherwise data were collected from our 
own patient files.
Statistical analysis was performed using the computer program SPSS version 11.0. Results 
of RT-PCR and immunohistochemistry are expressed as arithmetic means ± standard
error of the mean. Statistical comparisons between unpaired groups were performed by the 
Mann-Whitney test. Relations between clinical or laboratory data and outcome variables 
were studied using univariate regression analysis. For dichotomous outcome variables, such 
as survival, we used univariate logistic regression analysis, assigning the “events” occurrence of 
delayed graft function, patient mortality, and return to hemodialysis a dummy variable of 1. 
All differences were considered to be significant at P less than 0.05.34 35
- Results -
Immunohistologic Differences Between BD and Living Donor Kidneys
Presence of leukocytes
Leukocyte invasion in organ tissue reflects an inflammatory response. Therefore we stained 
for CD45 as the common leukocyte antigen (LCA) and we subsequently scored the kidney 
biopsy specimens. No significant differences were observed in overall infiltration of leu-
kocytes between living and BD kidneys (Table 3). In the BD group, however, a significant 
increase in the presence of interstitial leukocytes was found (living 1.3±0.7 vs. BD 2.2±1.3, 
P<0.01).
Endothelial adhesion molecules
Kidney biopsy specimens were stained for E-selectin and scored in a semiquantitative fash-
ion. In BD, a significant increase in E-selectin was detected (living, very weakly positive; BD, 
moderately positive; P<0.01).
Also, kidney biopsy specimens were stained for ICAM-1 and VCAM-1. No significant 
differences in ICAM-1 and VCAM-1 expression could be detected between living and BD 
kidneys; moderately positive levels of ICAM-1 and weakly positive levels of VCAM-1 were 
detected in both living and BD kidneys. Expression of E-selectin and ICAM-1 and VCAM-
1 was seen as a diffuse staining in both glomeruli and tubuli.
Gene Expression Levels in BD and Living Donor Kidneys
Donor kidney biopsy specimens from 12 living donors and 10 heart-beating BD were also 
evaluated for expression of the genes involved in inflammation and stress response using
RT-PCR (Fig. 1).
Table 3    Immunohistochemical analysis of antigen expression (-, +, ++, +++) or antigen 
positive cellular infiltrate in the kidney glomeruli and interstitium (g/i) of brain dead and 
living related donor kidney biopsies.
Ab  living   BD 
   
CD45    
     glomeruli  2.3±1.5   1.9±1.6  
     interstitium  1.3±0.7   2.2±1.3* 
E-selectin   +/-   ++     
ICAM-1  ++   ++   
VCAM-1  +   + 
 
Mean number of antigen positive cells per microscopic field are shown at 400x magnification 
± SD. *p<0.01 compared to LR. See Materials and Methods for grading.34 35
Figure 1
mRNA expression of the heat shock proteins HO-1 and Hsp70 are upregulated signifi-
cantly after BD (P<0.05). For all genes, except iNOS, dispersion in outcomes was larger in 
BD compared to living donors.36 37
Expression of genes involved in inflammation
To study inflammation, gene expression levels of the proinflammatory cytokines interleukin 
(IL)-1ß, IL-6 and tumor necrosis factor (TNF)-α were investigated. For IL-1ß and IL-6,
no significant difference in expression was found between living and BD kidney biopsy
specimens. TNF-α could not be measured in these samples.
We also analyzed gene expression of monocyte chemotactic protein (MCP)-1 and IL-8. 
MCP-1 is involved in chemoattraction of monocytes and T cells, whereas Il-8 is especially 
important in the chemoattraction of neutrophils. Expression of MCP-1 was found to be up-
regulated in BD versus living donor biopsy specimens, although the difference did not reach 
statistical significance in the numbers assessed (MCP-1: living, 1.16±0.67; BD, 2.11±1.13; 
P=0.07). For IL-8, no difference in expression was found between living and BD kidney 
biopsy specimens.
Transforming growth factor (TGF)-ß plays an important role in wound healing and tissue 
remodeling. We found a twofold increase in the expression of TGF-ß in BD; however, the 
difference was not statistically significant, possibly because of the large standard deviation of 
samples. In addition, the expression of inducible nitric oxide synthase (iNOS), an enzyme 
involved in the production of nitric oxide (NO), was evaluated. No significant difference in 
iNOS expression was found between living and BD kidney biopsy specimens.
Expression of heat shock proteins
Because major stress factors such as hemodynamic and hormonal changes take place during 
brain death, we also assessed the gene expression of the protective proteins heme oxygenase 
(HO)-1 and Hsp70. After brain death, gene expression of HO-1 and Hsp70 was increased 
3-fold and 2.5-fold, respectively, compared with living kidney biopsy specimens (HO-1: 
living 0.68±0.28 vs. BD 1.81±1.77, P<0.05; Hsp70: living 0.54±0.20 vs. BD 1.32±0.54, 
P<0.01).
Clinical Transplant Outcomes
Next, outcome variables after kidney transplantation were studied. Recipients of a kidney 
from a BD donor were compared with recipients of a kidney from a living donor. A signifi-
cantly higher delayed graft function rate was found in the BD group compared with the 
living group in the first week after kidney transplantation (BD 24%, living 3%; P<0.01). 
Patient and graft survival rates at 1 and 3 years after transplantation were compared, as well 
as serum creatinine levels and creatinine clearance at different time intervals. Survival rates 
and creatinine levels were inferior in the BD group compared with the living group. Patient 
survival at 1 year after transplantation was 90% in the BD group versus 100% in the living 
group. Patient survival after 3 years was 83% in the BD group and 93% in the living group. 
Graft survival after 1 and 3 years was 85% and 76% in the BD group versus 91% and 88% in 
the living group. Serum creatinine levels reached 152 μmol/L (BD) versus 132 μmol/L 
(living) at 1 year and 165 μmol/L (BD) versus 132 mmol/L (living) at 3 years. Finally, creati-
nine clearance levels were 65 mL/min in the BD group versus 66 mL/min in the living group 36 37
at 1 year and 62 mL/min in the BD donor group versus 74 mL/min in the living group
at 3 years.
Relations Between Donor Data and Clinical Transplant Outcomes
We studied the relationships between clinical parameters, gene expression levels and im-
munohistochemistry results of donors, and outcome variables observed in recipients, using 
univariate regression analyses. Results are shown in Table 4.
From these analyses, high levels of blood urea in the donor during brain death seem to 
increase the risk of delayed graft function, rejection, and high serum creatinine levels in the 
recipient at 1 and 3 years after transplantation. Surprisingly, donor treatment with desmo-
pressin decreased the risk of rejection and high serum creatinine levels after 1 and 3 years as 
well. The duration of brain death did not influence transplantation outcomes much; how-
ever, length of donor stay at an ICU, connected with duration of mechanical ventilation and 
urinary catheter placement, did have an effect on increased serum creatinine levels after both 
1 and 3 years.
Higher ICAM as well as VCAM staining in the kidney, although not increased in the BD 
group compared with the living group, is associated with higher serum creatinine levels and 
lower creatinine clearance. Remarkably, HO-1 does have a protective effect on serum creati-
nine levels at 1 and 3 years only in the group of living donor kidneys and not in the group 
of BD donor kidneys, where it is overexpressed. No differences in gene expression of iNOS 
were noticed between BD and living kidneys; however, iNOS expression was associated
with a protective effect on serum creatinine levels at 3 years after transplantation, both in 
recipients receiving a cadaveric and those receiving a living kidney.38 39
Table 4    Regression analyses of transplant outcome variables
Outcome variables  Causal variables  Donor   Beta (SE)   Signifi-  Explained
        cance  Variancea
Delayed graft function,   Urea during brain death (T2)  BD   0.162 (0.06)   0.01   35%
first week  ICAM in interstitium kidney   BD   0.762 (0.35)   0.03   18%
Episodes of rejection,    Desmopressin donor treatment  BD   -1.051 (0.27)   0.000   31%
first year  Urea during brain death (T2)   BD   0.994 (0.05)   0.05   11%
Patient survival,    Serum creatinine during onset  BD   0.064 (0.03)   0.05   48%
1 year after Tx  of brain death (T1) 
  Total bilirubin during  BD   0.163 (0.08)   0.03   35%
  brain death 
Kidney survival,    Serum creatinine during  BD   0.056 (0.03)   0.03   41%
1 year after Tx  onset of brain death (T1)
  Duration donor operation   BD   0.020 (0.01)   0.03   25%
Serum creatinine level,  Length donor ICU stay   BD   6.926 (3.45)   0.06   13%
1 year after Tx  Time urinary catheter donor   BD   8.126 (3.35)   0.02   19%
  Duration donor ventilation   BD   18.316 (4.90)   0.001   36%
  Donor treatment with desmopressin  BD   -95.904 (32.01)  0.006   26%
  Urea during brain death (T2)   BD   15.636 (5.02)   0.005   28%
  ICAM in interstitium kidney   BD   23.883 (8.83)   0.01   20%
  ICAM in interstitium kidney  Living  7.937 (4.94)   0.12   11%
  VCAM in interstitium kidney   BD   24.711 (9.99)   0.02   17%
  VCAM in interstitium kidney   Living   4.649 (10.43)   0.66   1%
  HO-1 expression in kidney   BD   -3.140 (7.28)   0.67   2%
  HO-1 expression in kidney   Living   -63.472 (20.66)   0.01   70%
Creatinine clearance,  ICAM in interstitium kidney   BD   -2.040 (6.89)   0.77   1%
1 year after Tx  ICAM in interstitium kidney   Living   -6.960 (2.87)   0.02   47%
  LCA in interstitium kidney   BD   -3.857 (9.43)   0.69   1%
  LCA in interstitium kidney   Living   15.153 (4.31)   0.004   49%
Serum creatinine level,  Length donor ICU stay   BD   10.798 (4.50)   0.02   18%
3 years after Tx  Time urinary catheter donor   BD   12.265 (4.34)   0.009   24%
  Duration donor ventilation   BD   26.139 (6.32)   0.000   41%
  Donor treatment with desmopressin  BD   -11.981 (42.45)   0.005   28%
  Urea during brain death (T2)   BD   18.068 (7.05)   0.017   21%
  Donor age   BD   1.762 (0.86)   0.05   14%
  VCAM in interstitium kidney   BD   36.725 (13.05)   0.01   21%
  VCAM in interstitium kidney   Living   20.470 (9.40)   0.04   18%
  iNOS expression in kidney   BD   -93.418 (45.98)   0.07   31%
  iNOS expression in kidney   Living   -39.277 (13.51)   0.02   51%
  HO-1 expression in kidney   BD   -1.016 (8.95)   0.91   0%
  HO-1 expression in kidney   Living  -74.703 (31.43)   0.05   41%
Creatinine clearance,  Donor age   BD   -0.704 (0.315)   0.04   23% 
3 year after Tx
 a Nagelkerke N. Comput Biomed Res. 1981; 14(3): 240.  
LCA, leukocyte antigen.38 39
- Discussion -
In the past years, attention has been given to brain death as a potential key factor affecting 
posttransplantation function and graft survival in organ transplantation. Brain death has 
been known for many years to induce major systemic circulatory and hormonal changes such 
as hypotension and catecholamine release (2). Previously, our group and others have demon-
strated an intense aspecific inflammatory response in donor organs after brain death in an 
animal brain death model (4–7,11). Several studies have shown a similar reaction in human 
donors, but most of them have used kidney biopsy specimens that were obtained after cold 
ischemia at the time of reperfusion (9,10,12). In this study, we analyzed several factors pos-
sibly responsible for early kidney damage by obtaining kidney biopsy specimens at the mo-
ment of organ retrieval in the donor, just before perfusion and the start of cold ischemia. We 
have focused on factors associated with the inflammatory response and with cellular stress.
These results have been linked to clinical follow-up data. Some differences seen between 
BD and living donor kidneys did not reach statistical significance, possibly because of the 
relatively small groups; however, they do correspond well with the results from larger series 
that have been previously published (1).
To study the inflammatory response, we investigated the expression of endothelial adhesion 
molecules and the influx of leukocytes in the kidney graft. One of the first groups of adhe-
sion molecules to be expressed during inflammation are selectins. Of those, E-selectin is ex-
pressed on activated endothelial cells and is particularly important for slowing the rolling of 
leukocytes. Another group of adhesion molecules is the IgG superfamily including ICAM-1 
and VCAM-1. Also, these molecules are expressed on the endothelium, where they can bind 
to integrins that are situated on leukocytes and facilitate their extravasation.
Our results show an increased presence of E-selectin after brain death, but not of the adhe-
sion molecules ICAM-1 and VCAM-1. Also, we found a significant difference between BD 
and living donor kidneys in the presence of leukocytes in the interstitium, although leuko-
cyte numbers remained small. This corresponds with the findings of Kusaka (11), who re-
ported an increased protein expression of E-selectin after brain death in the rat. In a seeming 
contrast to our findings, Koo et al. (9) not only found high levels of endothelial E-selectin 
in BD human kidney biopsy specimens after cold ischemia but also a marked increase in 
ICAM-1 and VCAM-1 expression. Because E-selectin is an adhesion molecule that is up-
regulated in the early phase of inflammation, our observations may represent a stage in brain 
death that occurs too early to detect differences between BD and living donor kidneys in 
ICAM-1 and VCAM-1 protein expression. This explanation fits well with our findings that 
the amount of ICAM, VCAM, and LCA staining in our biopsy specimens is associated with 
elevated serum creatinine values after 1 and 3 years and poorer creatinine clearance after 1 
year, which was most profound in our BD donor group. This could mean that BD might 
have caused a further increased inflammatory reaction beyond the time point at which we 
obtained our biopsy specimens.40 41
In addition, we have investigated the gene expression levels of several cytokines and chemo-
kines involved in inflammation. Our results showed no difference in gene expression of 
IL-1ß and IL-6 as proinflammatory cytokines that are produced mainly by macrophages and 
play important roles in the process of inflammation. Although expressed in positive controls 
(results not shown), TNF-α could not be detected in any sample. In humans, others have 
examined the presence of TNF-α, IL-1ß, and IL-6 in the circulation of BD patients and 
shown increased IL-6 levels only (13). In the rat model, however, gene expression of TNF-α, 
IL-1ß, IL-6, and MCP-1 was clearly up-regulated after 6 hr of brain death (5,11). The
biopsy specimens we obtained were derived from human donors who had been brain dead 
for approximately 18 hr before organ retrieval (average duration of BD: 17 hr 59 min ± 5 
hr 43 min), according to clinical documentation. Several studies have shown TNF-α, IL-1ß, 
and IL-6 mRNA to increase rapidly (ie, within 1 hr) after a specific stimulus and decline
after 8 hr (14). In our sample of a heterogeneous population, differences in expression of 
these genes between living and BD donor kidneys might therefore not be detectable.
MCP-1 gene expression, as a chemokine especially involved in the attraction and diapedesis 
of monocytes, was increased during BD, whereas IL-8 gene expression, a chemoattractant 
for polymorphonuclear neutrophils, was not. This could indicate that, during brain death, 
monocytes are preferentially attracted to the kidney. This corresponds with the results from 
the Oxford group, who showed that the major leukocyte population in pre-reperfusion kidney 
biopsy specimens consists of macrophages/monocytes (10,15). Our results also show an 
increased gene expression of TGF-ß during BD. TGF-ß is a protein that is associated with 
wound healing and tissue repair after injury. Because the expression of MCP-1 and TGF-
[beta] and the subsequent influx of monocytes/macrophages are involved in atherogenesis 
during atherosclerosis (16), and because both play a role in chronic transplant dysfunction, 
we speculate that an early influx of monocytes in the graft, as a consequence
of chemokine expression such as MCP-1, could be a trigger for long-term damage of the 
kidney graft.
The state of brain death, as reflected by the systemic hormonal and hemodynamic changes, 
should be considered as a major stress factor for donor organs. Therefore, we have measured 
gene expression of two heat shock proteins, HO-1 and Hsp70. These heat shock proteins are 
formed as a reaction to many noxious stimuli, such as energy depletion, hypoxia, acidosis,
ischemia/reperfusion, cytokines, reactive molecules, and hyperthermia (17,18). Heat shock 
proteins prevent protein denaturation and thus protect cells from damage, whereas HO-1 
catalyses the oxidation of pro-oxidant heme molecules to biliverdin, iron, and carbon mon-
oxide. Several studies have shown that induction of heat shock proteins attenuates ischemia/
reperfusion injury (19–21). Despite the fact that our heterogeneous sample of biopsy 
specimens was of a modest size, we were able to detect a significant up-regulation of gene 
expression of HO-1 and Hsp70 in kidneys from BD versus living donors. Interestingly, in 
our group of living donor kidney recipients, elevated HO-1 expression in the transplanted 
kidney had a strongly positive effect on declining 1- and 3-year serum creatinine levels in the 
recipient. However, this was not seen in the group of BD donor kidneys. Hsp70 expression 40 41
seemed to have a beneficial effect on survival in both the living and BD groups; however, this 
was not statistically significant in our small population. Therefore, we believe that BD itself 
causes such a great amount of damage to the kidney, that the protective effect of HO-1 could 
be insufficient, thus it does have a beneficial effect in kidneys from living donors. Alternatively, 
as Dennery (22) has shown, HO-1 might not only be beneficial but seems to act optimally 
only within a “window of opportunity.”
Surprisingly, we found no effect of duration of brain death on transplant outcome variables. 
Kunzendorf et al. (23) have shown that kidney grafts retrieved from donors with a brain 
death duration of more than 470 min exhibited a significantly higher primary graft function
rate and graft survival rate compared with kidneys from donors with a shorter duration of 
brain death. Nevertheless, this could be explained by the fact that the duration of brain death 
in their patients was quite short: less than 8 hr, whereas our donors had a brain death dura-
tion of 18 hr before perfusion, on average. In our study, a longer stay at an ICU, associated 
with a longer treatment with mechanical ventilation and increased duration of indwelling
urinary catheters, all influenced serum creatinine levels in the recipient negatively. Also, 
donor treatment with desmopressin, thereby probably ensuring a better-maintained homeo-
stasis, had positive effects on rejection and serum creatinine values in the recipient. We 
believe that donors with a prolonged stay at an ICU are at an increased risk of developing 
complications that may have effects on the future donor organs.
The specific nature of the stress stimulus or stimuli to which kidney cells respond with the 
production of heat shock proteins, and the relation between the extent of stress and the 
formation of an inflammatory response in brain death, remain to be investigated. Systemic 
hemodynamics, such as changes in blood pressure (ie, hypertension at the onset of brain 
death and subsequent hypotension) may be held responsible for the up-regulation of heat 
shock proteins, as well as the induction of an inflammatory endothelial reaction. These 
changes probably cause an amount of endothelial shear stress followed by a period of vaso-
constriction, leading to temporary ischemia of the abdominal organs. In addition, these same 
factors, shear stress as well as ischemia, are known to activate the endothelium and cause an 
inflammatory response (24).
On the other hand, brain damage itself may cause a release of some yet (un)known factors, 
which trigger a response on the level of the organ itself. Possible candidates for these factors 
are cytokines, soluble adhesion molecules, or vasoactive substances such as endothelin-1. In 
earlier studies, elevated serum levels of several cytokines and their soluble receptors could be 
detected in brain death, most notably soluble IL2 receptor, IL-6, and IL-8 (2,12). In acute 
ischemic stroke, a rise in both systemic soluble proinflammatory cytokines and soluble adhe-
sion molecules could be detected (25,26), whereas subarachnoid hemorrhage is known to 
cause a release of endothelin-1 in serum (27,28).
Because ischemia might be partly held responsible for an inflammatory response and pro-
duction of heat shock proteins in BD, we also studied gene expression of iNOS. This protein 
catalyzes the production of NO during many inflammatory responses (29). NO inhibits 
oxidative stress in the microvasculature by neutralizing superoxide and seems to decrease 43
leukocyte adhesion to the endothelium (29). On the other hand, NO is a very reactive
  molecule and can also cause oxidative injury, either on its own or by interacting with super-
oxide by forming the cytotoxic peroxynitrite radical. So far, we have found no differences in 
gene expression of iNOS between BD and living donor kidneys, but elevated iNOS expres-
sion levels in kidneys from both BD and living donors show a strongly negative effect on 
recipient serum creatinine levels for as long as 3 years after transplantation.
- Conclusion -
This clinical study shows that brain death induces an inflammatory response with poten-
tial detrimental sequelae as well as an up-regulation of heat shock protein gene expression 
in human donor kidneys. Brain death clearly seems to be a stress factor to potential donor 
kidneys. Thus, the results of this study could explain in part the inferior outcomes after 
cadaveric kidney transplantation compared with the outcomes in living (un)related kidney 
transplantation. The mechanism(s), however, by which brain death leads to these processes 
remain unclear. No data currently exist on the balance of injury and repair in the donor, and 
its correlation with time of procurement and outcome after transplantation.
- Acknowledgements -
The authors thank Dr. G. Molema from the Department of Pathology and Laboratory
Medicine, Medical Biology Section, University Hospital Groningen for her advice and 
discussion about the immunohistochemical analyses and R. Nap from the Department of 
Surgery for his valuable statistical advice.
4243 42
References
1.  Terasaki PI, Cecka JM, Gjertson DW, et al. High survival rates of kidney transplants from spousal and living
  unrelated donors. N Engl J Med 1995; 333: 333–336. 
2.   Lopau K, Mark J, Schramm L, et al. Hormonal changes in brain death and immune activation in the donor.
  Transpl Int 2000; 13(suppl 1): S282–S285. 
3.   Mertes PM. Physiology of brain death. In: Tilney NL, Strom TB, Paul LC, eds. Transplantation biology: cellular and  
  molecular aspects. Philadelphia, Lippincott-Raven Publishers 1996, pp 275–289. 
4.   Pratschke J, Wilhelm MJ, Kusaka M, et al. Accelerated rejection of renal allografts from brain-dead donors. Ann Surg  
  2000; 232: 263–271. 
5.   Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral    
  organs in the rat. Transplantation 1998; 65: 1533–1542. 
6.   Van der Hoeven JA, Ploeg RJ, Postema F, et al. Induction of organ dysfunction and up-regulation of inflammatory   
  markers in the liver and kidneys of hypotensive brain dead rats: a model to study marginal organ donors.
  Transplantation 1999; 68: 1884–1890. 
7.   Van der Hoeven JA, Ter Horst GJ, Molema G, et al. Effects of brain death and hemodynamic status on function and  
  immunologic activation of the potential donor liver in the rat. Ann Surg 2000; 232: 804–813. 
8.   Van der Hoeven JA, Lindell S, van Schilfgaarde R, et al. Donor brain death reduces survival after transplantation in  
  rat livers preserved for 20 hr. Transplantation 2001; 72: 1632–1636. 
9.   Koo DD, Welsh KI, McLaren AJ, et al. Cadaver versus living donor kidneys: impact of donor factors on antigen    
  induction before transplantation. Kidney Int 1999; 56: 1551–1559. 
10.  Koo DD, Welsh KI, Roake JA, et al. Ischemia/reperfusion injury in human kidney transplantation: an immunohisto 
  chemical analysis of changes after reperfusion. Am J Pathol 1998; 153: 557–566. 
11.  Kusaka M, Pratschke J, Wilhelm MJ, et al. Activation of inflammatory mediators in rat renal isografts by donor brain  
  death. Transplantation 2000; 69: 405–410. 
12.  Stangl M, Zerkaulen T, Theodorakis J, et al. Influence of brain death on cytokine release in organ donors and renal   
  transplants. Transplant Proc 2001; 33: 1284–1285. 
13.  Amado JA, Lopez-Espadas F, Vazquez-Barquero A, et al. Blood levels of cytokines in brain-dead patients:
  relationship with circulating hormones and acute-phase reactants. Metabolism 1995; 44: 812–816. 
14.  Gao JJ, Xue Q, Papasian CJ, et al. Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha  
  through a post-transcriptional mechanism. J Immunol 2001; 166: 6855–6860. 
15.  McWhinnie DL, Thompson JF, Taylor HM, et al. Morphometric analysis of cellular infiltration assessed by
  monoclonal antibody labeling in sequential human renal allograft biopsies. Transplantation 1986; 42: 352–358. 
16.  Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of monocyte chemoattractant protein 1 in
  macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991; 88: 5252–5256. 
17.  Kregel KC. Invited review. Heat shock proteins: modifying factors in physiological stress responses and acquired    
  thermotolerance. J Appl Physiol 2002; 92: 2177–2186. 
18.  Moseley PL. Heat shock proteins and the inflammatory response. Ann N Y Acad Sci 1998; 856: 206–213. 
19.  Katori M, Tamaki T, Takahashi T, et al. Prior induction of heat shock proteins by a nitric oxide donor attenuates    
  cardiac ischemia/reperfusion injury in the rat. Transplantation 2000; 69: 2530–2537. 44
20.  Redaelli CA, Wagner M, Kulli C, et al. Hyperthermia-induced HSP expression correlates with improved rat renal   
  isograft viability and survival in kidneys harvested from non-heart-beating donors. Transpl Int 2001; 14: 351–360. 
21.  Shimizu H, Takahashi T, Suzuki T, et al. Protective effect of heme oxygenase induction in ischemic acute renal failure.  
  Crit Care Med 2000; 28: 809–817. 
22.  Dennery PA. Regulation and role of heme oxygenase in oxidative injury. Curr Top Cell Regul 2000; 36: 181–199. 
23.  Kunzendorf U, Hohenstein B, Oberbarnscheid M, et al. Duration of donor brain death and its influence on kidney  
  graft function. Am J Transplant 2002; 2: 292–294. 
24.  Topper JN, Gimbrone MA Jr. Blood flow and vascular gene expression: fluid shear stress as a modulator of 
  endothelial phenotype. Mol Med Today 1999; 5: 40–46. 
25.  Fassbender K, Rossol S, Kammer T, et al. Proinflammatory cytokines in serum of patients with acute cerebral    
  ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 1994;  
  122: 135–139. 
26.  Fassbender K, Mossner R, Motsch L, et al. Circulating selectin- and immunoglobulin-type adhesion molecules in    
  acute ischemic stroke. Stroke 1995; 26: 1361–1364. 
27.  Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 2000;
  92: 390–400. 
28.  Fassbender K, Hodapp B, Rossol S, et al. Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant
  produced by cerebrospinal fluid leukocytes. Stroke 2000; 31: 2971–2975. 
29.  Hickey MJ, Granger DN, Kubes P. Inducible nitric oxide synthase (iNOS) and regulation of leucocyte/endothelial  
  cell interactions: studies in iNOS-deficient mice. Acta Physiol Scand 2001; 173: 119–126.
4544
chapter
1 4  23 
Inflammatory Angiopoietin Response
in Deceased Brain Dead Donors 
Lyan G. Koudstaal, Willemijn N. Nijboer, Johannes G. Burgerhof, Jaap J. Homan van der Heide,
Vincent B. Nieuwenhuijs, Maarten W. Nijsten, Harry van Goor, Rutger J. Ploeg, Henri G.D. Leuvenink
4546 47
- Abstract -
Background:
Kidneys retrieved from deceased brain dead (DBD) donors show inferior function com-
pared to living donors. Bacterial translocation and endotoxemia as well as inflammation are 
frequent in DBD donors. Recently it was shown that in endotoxic patients the angiopoietin 
levels are influenced. We hypothesized that the anti-inflammatory protein angiopoietin-1 
(Ang-1) and the pro-inflammatory Angiopoietin 2 (Ang-2) are shifted towards inflamma-
tion in DBD donors compared to living donors. Therefore, we studied serum vascular endo-
thelial growth factor (VEGF), Ang-1 and Ang-2 in DBD donors using living kidney donors 
as controls. Lipopolysaccharide Binding Protein (LBP) was used to quantify endotoxemia.
Methods:
Serum was collected just after confirmation of brain death diagnosis (T0) and immediately 
prior to organ recovery (T1) from 30 consecutive DBD donors. Twenty living donors were 
asked informed consent for two blood samples, obtained at the beginning of the operation 
and immediately prior to retrieval of the donor kidney.
Results:
DBD donors had higher median serum LBP, VEGF and Ang-2 levels compared to living
donors. Higher Ang-1 levels were observed just after brain death diagnosis compared to
living donors. Serum levels of LBP and Ang-2 were correlated with a Spearman’s ρ of 0.6. 
Importantly, serum Ang-2 levels in the DBD donor predicted the chance on rejection in 
the first year after kidney transplantation with an odds ratio at T0 1.38 and at T1 1.50 
(P<0.05).
Conclusions:
The angiopoietin balance in brain dead donors is modulated progressively towards inflam-
mation during the period of brain death prior to organ recovery.46 47
- Introduction -
Organs recovered from heart beating deceased brain dead (DBD) donors show inferior 
organ function and a higher rate of acute rejection compared to those obtained from living 
donors (1-4). Both in humans and in experimental models, brain death induces a progressive
inflammatory response in potential donor organs such as kidney, liver and intestine (5-7).
This response coincides with systemic higher levels of circulating cytokines including 
interleukin (IL)-1, IL-6, tumor necrosis factor alpha, vascular endothelial growth factor, 
and macrophage chemoattractant protein-1 (8-10). The exact mechanism responsible for 
these pro-inflammatory changes and their detrimental effect on transplant outcome are yet 
unknown.
The intestine is considered to be a crucial player in the development of distant organ injury.
In several conditions, such as severe burns, brain injury, acute pancreatitis and Acute Res-
piratory Distress Syndrome (ARDS), enhanced intestinal permeability is associated with 
distant organ injury (11-15). Several human studies have provided evidence that DBD 
donors have a higher endotoxin load. Bacterial translocation and elevated endotoxin levels 
are also frequent in DBD donors (16). Almost half of the donors have positive cultures of 
the ileocoecal lymph node (17). 
Recently, a link between endotoxemia and Angiopoietin 1 (Ang-1) and Angiopoietin 2
(Ang-2) has been established. In humans, LPS is a triggering factor for Ang-2 release (18). 
Ang-1 and Ang-2 both are regulatory proteins which play an important role in vascular 
inflammation. The angiopoietin–Tie ligand-receptor system is crucial in regulating vascular
integrity and quiescence (19). Ang-1 dampens the inflammatory response while Ang-2 
boosts it (20).
Ang-1 has the ability to seal the vasculature, act as an anti-inflammatory agent, protect 
against cardiac allograft arteriosclerosis and renal fibrosis, and promote wound healing (21-24). 
Ang-2 is associated with an increased morbidity and mortality during sepsis. A model has 
been reported which indicates that a balanced Ang-1/Ang-2 ratio determines the functional 
status of the vasculature (25). It has also been shown that in vivo endotoxemia triggers
functional inhibition of the angiopoietin pathway by reducing Ang-1 expression and
inducing Ang-2 levels and that this response may contribute to enhanced vascular leakage 
during sepsis (26).
We hypothesized that in heart beating brain dead donors the inflammatory proteins Ang-1 
and Ang-2 are shifted towards inflammation. Living kidney donors were used for comparison 
as controls. Further, we questioned whether the Ang-1 and Ang-2 status in the DBD donor 
can be used as a prognostic tool to predict renal function after transplantation including de-
layed graft function (DGF) and rejection. Therefore, we studied serum Ang-1 and Ang-2 in 
30 DBD donors and 20 living kidney donors and linked the results to clinical kidney trans- 
plant outcome. We studied serum lipopolysaccharide Binding Protein (LBP) as a quantifi-
cation of endotoxemia in kidney donors serum and vascular endothelial growth factor (VEGF), 
because it has been shown Ang-2 primes the endothelium to respond to VEGF (27-33).48 49
-Methods -
Patients and serum samples
Serum samples were prospectively, consecutively collected during organ procurement proce-
dures from a series of heart beating DBD donors, from 2004 through 2007. Selection
criteria were donor age <65y and a cold ischemia time <30h. All donors were declared brain 
dead on the intensive care. All samples were collected after declaration of brain death,
according to the Dutch Transplantation Law. Baseline samples were collected just after brain 
death diagnosis (T0). A second sample (T1) was obtained prior to organ recovery just be-
fore wash-out and preservation. Due to logistic reasons, at T0 in four DBD donors no serum 
could be obtained. Twenty living kidney donors were asked informed consent for two blood 
samples: a baseline sample (T0) just before the donor operation (T0) and a second sample 
(T1) at the time of kidney recovery during the donor operation just prior to retrieval. All 
samples were kept on ice, centrifuged for 20 minutes at 1500 x g and stored at -80˚C until 
analysis. Clinical donor variables were recorded and one year-follow up of kidney function 
after transplantation was received from recipient hospitals. As the end points for clinical out-
come were used: Delayed graft function (DGF), defined as the need for dialysis in the first 
week after transplantation; rejection, defined as biopsy proven rejection in the first year and 
serum creatinine in the recipient on day 14 after transplantation. All grades of interstitial and 
vascular rejection were included. Borderline rejection was excluded. Biopsies were scored du-
ring routine clinical practice by a blinded pathologist according to the BANFF classification.
Serum Lipopolysaccharide Binding Protein (LBP)
To evaluate LBP in serum samples from all patients included in the study an enzyme-linked 
immunosorbent assay (ELISA) test kit (HyCult Biotechnology, Uden, The Netherlands) 
for Human Lipopolysaccharide Binding Protein (LBP) was used, according to the manufac-
turer’s instructions, with an upper reference value for healthy individuals of 10 μg/ml. All 
samples were tested in duplicate and read at 450 nm, in a microplate reader (Victor3, 1420 
multilabel counter, Perkin Elmer).
Serum Vascular endothelial growth factor (VEGF)
To determine VEGF levels, serum samples were measured using a multiplex bead sandwich 
immunoassay (Biosource, Invitrogen, Carlsbad, CA) which was analyzed using a Luminex 
100 instrument (Luminex, Austin, TX).
Serum angiopoietin 1 and 2
Human Ang-1 and Ang-2 enzyme-linked immunoassay (ELISA) test kits (R&D systems, 
Minneapolis, USA) were used according to the manufacturer’s instructions, to evaluate
Ang-1 and Ang-2 in serum samples from all patients included in this study. The upper 
reference value in healthy individuals for ang-1 is 6 ng/ml and ang-2 is 2.5 ng/ml (34). All 
samples were tested in duplicate and read at 450 nm using a microplate reader (Victor3, 
1420 multi-label counter, Perkin Elmer).48 49
Statistical methods
Statistical analysis was performed using the computer program SPSS version 16.0 (SPSS 
Inc., Chicago, IL, USA). Results are expressed as median and 25 and 75 percentiles. Statisti-
cal comparisons between groups were performed using a T-test if data had a normal distri-
bution; otherwise groups were compared using the Mann-Whitney U test. Dichotomous 
variables were compared using Fisher’s test. The association between LBP, VEGF, ang-1 and 
ang-2 was tested with Spearman’s rho. For linear regression a normal distribution of the resi-
dues was checked using a normal probability plot. Multivariate stepwise logistic regression 
with the log likelihood test was used for the dichotomous variables, DGF and rejection. For 
serum creatinine in the recipient on day 14 after transplantation multivariate linear regres-
sion was used. In all models as covariates As covariates donor age, HLA-mismatches, sex, 
cold ischemia time were tested. All differences were considered to be significant at P<0.05.
 -Results -
In this study 30 DBD donors and 20 living renal donors were included; all kidneys obtained 
from these donors were transplanted. The median time between T0, declaration of brain 
death and T1, at the time of kidney recovery was 11 hours (10-13). The cause of death 
was a cerebrovascular accident (CVA) in 19 donors and 11 donors with a trauma capitis or 
other cause. The occurrence of DGF and serum creatinine after 14 days was recorded for all 
patients; however occurrence of rejection in the first year was analyzed in 48 patients. Ten 
DBD donors experienced DGF compared to one in the living donors and six DBD donors 
experienced rejection compared to three living donors (P<0.05). One patient experienced 
graft loss four weeks post-transplant due to mycotic aneurysm, two patients died with a 
functioning graft and two patients were referred to non-participating hospitals. Donor char-
acteristics are shown in Table 1.50 51
Gender (M:F)c
Age (years) b
Cause of death
    CVA 
    Trauma/Other
Serum creatinine T0 (μmol/L)a
Serum creatinine T1 (μmol/L)a
Post-transplant Parameters
Cold Ischemia Time (hours)a
HLA mismatcha 
First transplanta
Serum Creatinine day 14
(μmol/L)a
    Delayed Graft Functionc
    Rejectionc   
Immunosuppressive Treatment
Prednisolon/Mycophenolate    
mofetil/Cyclosporine
Prednisolon/Mycophenolate 
mofetil/Tacrolimus
Prednisolon/Cyclosporine/ FTY720
Prednisolon/Mycophenolate 
mofetil/Rapamycin   
Antithymocyte globulin
Daclizumab
Basiliximab 
Unknown
DBD Donors 
10:20
49 (42-57)
19
11
60 (49-87)
57 (48-72)
198 (15-23)
2 (2-3)
28/30
166 (114-556)
10
6
24
2
1
1
2
4
3
2
Living donors
7:13
50 (44-58)
64 (60-70)
55-68)
3 (2-3)
3 (2-4)
20/20
133 (116-185)
1
3 
20
0
0
0
2
9
2
0
P-value
0.903
0.246
0.782
0.357
0.001
0.01
0.0001
0.111
0.033
0.716
Table 1   Characteristics of DBD and Living Donors and Kidney Recipients
Mann Whitney U test a; Student’s T-test b; Fisher’s test c; Results of age and serum
creatinine are expressed as median and 25 and 75 percentiles.50 51
In the serum of DBD donors we found significantly higher LBP, VEGF, Ang-1 and Ang-2 
levels at T0 (P<0.001) and higher LBP, VEGF and Ang-2 levels at T1 (P<0.001). Inter-
estingly, the Ang-1 levels decreased significantly during the brain death period (P<0.001). 
In DBD donors at T1 the Ang-1/Ang-2 ratio was decreased compared to living donors 
(P<0.001). In DBD donors the Ang-1/Ang-2 ratio decreased from T0 to T1 (Figure 1) 
(P<0.001).
Figure 1
Dot plots of Lipopolysaccharide Binding Protein a, Vascular Endothelial Growth Factor 
b, Angiopoietin-1 c, Angiopoietin-2 d and ratio Ang1/Ang2. Medians are shown. Baseline 
samples were collected just after brain death diagnosis (T0).
A second sample (T1) was obtained during organ recovery just prior to wash-out and
preservation. In DBD donors we observed high Ang-1 levels at T0 in all donors who died from a stroke 
(n=19). At T0 median Ang-1 levels were 24 (17-31) ng/ml in donors who died from a CVA 
compared to 9 (6-14) ng/ml in donors with another cause of death (P<0.05). These medians 
did not differ anymore during organ recovery. In donors respectively a CVA or with another 
cause of death, Ang-1 levels were at T1 6(3-8) ng/ml vs. 8 (5-10) ng/ml (NS).
We also studied the association between Ang-1 and LBP and the association between Ang-2 
and LBP. We found an association at T0 of LBP with Ang-2 with a Spearmans ρ of 0.622 
(P<0.001) and at T1 of 0.603 (P<0.001) (Figure 2).
52 53
Figure 2
Dot plots correlation between Serum Lipopolysaccharide Binding Protein and Serum 
angiopoietin 2 in deceased brain dead donors (DBD) at T0, baseline just after brain death 
diagnosis (a) and T1 during organ recovery just prior to wash-out and preservation (b).52
To evaluate whether levels of Ang-1, Ang-2 or the Ang-1/Ang-2 ratio in the DBD donor
group had an independent effect on outcome after transplantation linear and logistic step-
wise multivariate regression models were built. DGF, rejection and serum creatinine on 
day 14 following transplantation were studied. As covariates donor age, HLA-mismatches, 
sex, cold ischemia time were tested. Only donor age did predict DGF, with an OR of 1.1 
(P<0.05). Elevated Ang-2 levels were associated with an increased risk of rejection with an 
odds ratio at T0 1.377 and at T1 1.499 (P<0.05). In contrast, donor serum creatinine did 
not predict kidney outcome after transplantation. DGF and serum creatinine on day 14 
were not predicted by LBP, VEGF, Ang-1, Ang-2, or the Ang-1/Ang-2 ratio. ROC analy-
ses are presented in Figure 3 to evaluate the prognostic effect of serum Ang-2 on rejection 
in the first year after transplantation. The area under the curve for both time point was 0.8 
(P<0.05). With an angiopoietin value of 4.5 ng/ml, the sensitivity is 0.8 with a false negative 
rate of 0.2.
53
Figure 3
ROC analyses of angiopoietin-2 to predict rejection in the first year after transplantation.54 55
-Discussion -
The cardinal finding of this study is the modulated angiopoietin balance in brain dead 
donors towards pro-inflammatory activation. Just after the diagnosis of brain death and 
prior to organ recovery, we found higher serum Ang-2 levels compared with living donors. 
Interestingly, we also observed higher Ang-1 levels just after brain death diagnosis compared 
to living donors. These Ang-1 levels decreased during the period of brain death until the mo-
ment of organ recovery to levels comparable with living donors. Similarly, during the brain 
dead period the ratio of Ang-1/Ang-2 decreased significantly, shifting to pro-inflammatory 
activation. In addition, serum Ang-2 levels in the DBD donor predicted the chance of rejec-
tion in the recipient. The area under the curve of the ROC analysis, was 0.8, showing a good 
discriminating potential of Ang-2. Therefore, among the other prognostic factors, Ang-2 can 
add relevant information for clinical decision-making to determine whether a kidney will 
be suitable for transplantation. Based only on this study, it is too premature to draw definite 
conclusion. Further research is needed to evaluate Ang-2 prognostic value.
In this study we observed an enhanced endotoxin load as evidenced by the elevated serum 
LBP levels in DBD organ donors in contrast with living organ donors. This is in accordance 
with the observation that bacterial translocation is common in organ donors (35;36). LBP 
was shown to be a sensitive marker of prolonged endotoxin exposure (37), and our analysis 
revealed that prolonged exposure to endotoxins was present in the majority of heart beating 
DBD donors.
Serum Ang-2 and VEGF are markedly elevated in several conditions such as sepsis and 
trauma (38;39). Angiopoietins play also a role in various kidney diseases (40). In trauma 
patients with severe injury and systemic hypoperfusion, Ang-2 is released within 30 minutes 
after trauma and high levels of Ang-2 were associated with an activated endothelium, coagu-
lation abnormalities, complement activation, and worse clinical outcome (41). In addition, in 
patients with acute lung injury (ALI) and ARDS high levels of circulating Ang-2 are associ-
ated with pulmonary permeability oedema, occurrence and the severity of ALI/ARDS as 
well as with mortality (42;43). Furthermore, kidney grafts from living unrelated donors have 
high survival rates, despite a higher degree of HLA mismatching than is found in deceased 
grafts (44). The inferior survival of deceased donation cannot be attributed to differences in 
immunogenicity alone. Even when corrected for donor variables such as donor age, gender, 
race, terminal serum creatinine, shorter cold-ischemia times, cerebrovascular accident as the 
cause of death, and history of hypertension organs recovered from deceased donors show 
inferior outcome (45;46). The observed systemic inflammatory state and extend of injury 
in DBD donors is thought to induce worse outcome (47-51). The modulated inflammatory 
Angiopoietin response is in line with these observations.
In DBD donors the Ang-1/Ang-2 ratio is decreased and progressively shifted towards pro-
inflammatory activation. Intervening in the Ang-1/Ang-2 balance may therefore be of thera-
peutical value to improve outcome after transplantation when kidneys from heart beating 
DBD donors are used. Ang-2 neutralizing reagents have been developed as anti-angiogenic 54 55
tumor drugs (52) and could also be used to decrease the pro-inflammatory status of the 
donor. Increasing the Ang-1 concentration to restore the balance has a potent anti-inflamma-
tory potential in animal models, although Ang-1 therapies have also shown side effects like 
pulmonary hypertension (53;54).
Interestingly, hypertensive patients have higher levels of Ang-1, even without target organ 
damage (55). In DBD donors we observed high Ang-1 levels at T0 in all donors who died 
from a stroke (n=19). The elevated levels of Ang-1 in donors who died from a stroke direct 
after declaration of brain dead, but not just before organ recovery, may reflects a protective 
response or reflects chronic vascular dysfunction in stroke patients.
We also found a strong association between LBP and Ang-2 levels at both time points. The 
higher Ang-2 levels, combined with the lower Ang-1 levels just before organ recovery, are 
in accordance with triggering of Ang-2 by administration of LPS to healthy volunteers and 
with the observation in mice, that endotoxemia triggers functional inhibition of the Ang-1 
pathway in vivo by reducing vng-1 expression and inducing Ang-2 (56;57).
We conclude that the angiopoietin balance in brain dead donors is modulated progressively 
towards pro-inflammatory activation. Angiopoietin-2 could be a valuable marker to predict 
the quality of the renal graft as early as in the donor.56 57
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 - Abstract -
Main problem:
In kidney transplantation, graft survival using grafts from donation after brain death (DBD) 
donors is inferior to results after living donation. However, little is known about the effect of 
the duration of brain death (BDdur) on outcome after transplantation.
Methods:
Retrospective OPTN analysis using kidney donor and recipient data from 1994-2006. 
BDdur was calculated as the period between brain death declaration and aortic cross clamp. 
Effects of BDdur on delayed graft function (DGF), acute rejection and graft failure were 
calculated using binary logistic regression and Cox regression models.
Results: Median BDdur was 23.8h. Longer BDdur decreased the risk for DGF and 1- and 
3-year graft failure slightly, but not for acute rejection. In multivariate analysis, donor age 
and acute rejection were confounders. Yet, in a multivariate subgroup analysis of donors 
≤55 years BDdur independently predicted DGF; each hour of BDdur decreasing the risk of 
DGF with 0.4% (P=0.008). 
Conclusion:
Longer BDdur is not detrimental and in fact slightly beneficial in DBD donors ≤55 years, 
reducing the chance of DGF in the recipient. This finding may have impact on organ
retrieval procedures, as no rush but rather an improved donor management prior to retrieval 
will benefit donor kidney viability.60 61
- Introduction -
To date, due to the persistent donor organ shortage, increasing numbers of living donors 
(LD) and donors after cardiac death (DCD) are used in kidney transplantation. The 
majority of donor organs, however, is still retrieved from heart beating donation after brain 
death (DBD). Living (un)related grafts are associated with better survival and lower rates 
of delayed graft function (DGF) than kidneys retrieved from DBD (1;2). This difference in 
success can be attributed to pathophysiological changes which take place during the phase 
of brain death in the donor and the injury related to other factors such as warm and cold 
ischemia times or HLA mismatches (3;4). The combination of risk factors including brain 
death may result in an increased risk for (vascular) rejection and lower graft survival (5). 
A number of studies has analyzed the detrimental effects of brain death on potential grafts, 
but only few studies have evaluated the impact of the duration of the brain death process 
on the outcome after kidney transplantation. In an animal model, our group has shown that 
prolonged duration of brain death leads to progressive organ dysfunction, and that the pro-
inflammatory and pro-coagulatory responses which underly this effect are more pronounced 
in the presence of hemodynamic instability (6). Thus, longer duration of brain death might 
lead to more extensive damage, as organs are longer exposed to the detrimental influences of 
cerebral injury and the subsequent hemodynamic consequences. 
On the other hand, we and others have found that longer duration of brain death will also 
allow organs to recover and initiate reparative processes after the initial event that caused the 
cerebral injury (7). Avlonitis and colleagues demonstrated a decreased pulmonary vascular 
resistance after a prolonged period of brain death, which according to their explanation may 
have been triggered by the recovery of the lung from hemodynamic injury sustained during 
induction of brain death (8).
Studies adressing the issue of the importance of the duration of brain death in human organ 
donation are rare, which is remarkable as their outcome could have a major impact on dona-
tion logistics. Kunzendorf and co-workers suggested in their analysis of 1,106 DBD kidney 
transplants that grafts retrieved from donors with a long duration of brain death (BDdur): > 
470 min had a lower incidence of DGF and a better graft survival rate compared to kidneys 
retrieved after a BDdur < 470 min. Unfortunately, their validation study remained inconclu-
sive and no multivariate analyses were performed to determine whether (longer) BDdur was 
an independent predictor for successful transplantation, or that this effect was influenced by 
some confounding factor (9).  
Thus, the question whether the length of the period of brain death is a risk factor for out-
come after kidney transplantation, is still unsolved yet. This situation has lead to a difference 
in approach between European countries and the U.S.: while in Europe we try to recover 62 63
donor organs as fast as possible, in the U.S. donors have often longer periods of brain death, 
and recovery procedures are typically performed during office hours. The outcome of a prop-
er analysis regarding transplantation success after a certain duration of brain death could 
have significant consequences for donor management and logistics affecting the decision to 
either ‘rush and retrieve’ or ‘relax and repair’. We have therefore studied the effect of BDdur 
on the incidence of DGF, acute rejection, and one- and three-year graft survival after kidney 
transplantation using the large transplantation database of the U.S. Organ Procurement and 
Transplant Network (OPTN) for this comparison.
  
- Patients and methods -
Dataset
A June 2007 extract of the OPTN database was used. The study population consisted of 
DBD single-kidney recipients who were transplanted between 1 April 1994 and 11 June 
2007. We chose 1994 as the lower limit of this cohort, as several important donor variables 
had not been collected before this year. Consecutive donor-recipient combinations were 
included when the following variables were known: date and time of brain death declaration, 
date and time of cross clamping, and data about the occurrence of DGF, rejection in the first 
year after transplantation and graft survival one and three years after transplantation. 
Endpoints
The endpoint for short-term outcome after kidney transplantation was delayed graft func-
tion (DGF), defined as any dialysis requirement in the first week after transplantation. To 
assess the incidence of acute rejection, any treatment for rejection in the first year after trans-
plantation was scored. Graft survival (GS) at one and three years posttransplant served as 
long-term outcome measures. Graft failure was defined as permanent return to maintenance 
dialysis and was censored upon death with a functioning graft.
Statistical analysis
Donor and recipient demographics as well as graft related factors were calculated for the 
study cohort. BDdur was defined as the interval between declaration of brain death and 
the time point of aortic clamping just prior to the start of systemic perfusion during organ 
retrieval (9). In several cases, brain death declaration time was recorded, but brain death 
declaration date was unknown. If, in these cases, the date of donor admission to the hospital 
was identical to the date of cross clamping, the date of hospital admission was used to cal-
culate BDdur. Outcomes are expressed as median (range). Differences between groups were 
analyzed using Student’s T-test.62 63
Binary logistic regression models including pertinent donor-, preservation-, and recipient-
related risk factors were employed to identify whether BDdur was an independent risk factor 
for DGF and acute rejection. 
Cox regression models were constructed with relevant donor-, preservation-, and recipient-
related risk factors as covariates to examine whether BDdur significantly contributed to the 
risk of graft failure at one and three years posttransplant. Statistical analyses were conducted 
using SPSS software, version 14 (SPSS Inc., Chicago, IL). Two-sided P-values of less then 
0.05 were considered to indicate statistical significance.64 65
- Results -
Demographics and data management
Between April 1, 1994 and June 11, 2007 20,773 deceased heart beating donor (DBD) 
single-kidney transplants were performed in the USA with recorded data of BDdur in the 
donor and available recipient outcome data. Table 1 shows the basic demographic characteri-
sation for the study population. In this dataset, the median time interval between declaration 
of brain death and aortic cross clamp was 23.8h (1.0-189.9). In 95.5% BDdur was less than 
48h. Figure 1 shows the number of kidney transplant recipients according to distribution of 
donor BDdur.
Table 1   Donor, recipient, and graft related factors for the study cohort
Donor demographics (N = 20,773)
Donor agea (y)  40 (0-82)
Female donor (%)  40.7
ECD donor (%)  18.3
Traumatic cause of death (%)  43.1
Donor history of hypertension (%)  26.1
Donor history of diabetes mellitus (%)  6.5
Recipient demographics
 
Recipient agea (y)  52 (0-86)
Female recipient (%)  39.4
Total time spent on the wait lista (yr)  1.6 (0-17.8)
Previous transplants (% ≥1)  11.6
DGF (%)  21.9
Rejection treatment (<1 y post Tx) (%)  12
Graft survival at 1 year (%)  92.7
Graft survival at 3 years (%)  90.6
Graft related factors
HLA mismatches  4 (1-6)
Cold ischemic timea (h)  18 (0-99)
a) Median (range).64 65
Differences in BDdur between groups
Recipients who suffered from DGF had donors with a mean BDdur of 25.0h, while grafts 
transplanted into recipients with immediate graft function had sustained a mean BDdur of 
25.7h (P = 0.001). No statistical difference in donor BDdur was found between recipients 
who needed treatment for rejection within one year after transplantation and rejection-free 
recipients. Recipients with functioning grafts at one year after transplantation (92.7%) had 
kidneys from donors with a mean BDdur of 25.7h, while recipients with graft failure at one 
year had donors with a mean BDdur of 24.2h (P < 0.001). Similarly, at three years after 
transplantation, mean BDdur of functioning grafts (90.6%) was 25.8h as compared to 23.7h 
for failed grafts (P < 0.001)
 
BDdur and risk of delayed graft function
In a univariate binary logistic regression model, BDdur decreased the risk of DGF with an 
odds ratio (OR) of 0.995. This indicates that for each hour increase of BDdur, the odds for 
DGF in the recipient decreased by 0.5% (95% confidence interval (CI) 0.992-0.998,
P = 0.001). In a multivariate regression analysis, which included several donor-,  graft- , 
preservation- and recipient related covariates which are known to influence the risk of DGF, 
BDdur was not an independent risk factor for DGF (P = 0.14). Table 2 shows the covariates 
included in the multivariate analysis. 
Figure 1  Distribution of donor BDdur in hours66 67
After entering each covariate separately into the regression model, we found donor age to be 
the only factor that significantly influences BDdur. We then tested the correlation between 
donor age and BDdur. These variables were correlated with a Pearson’s coefficient of -0.118 
(P < 0.001), indicating that older donors had a shorter BDdur. We performed a post-hoc 
subgroup analysis to study the effect of BDdur on ‘young donors’, defined as donors ≤ 55 
years (10;11). In our study cohort, this group concerned 81.4% of the total population. In a 
multivariate regression analysis for this subgroup, BDdur did significantly decrease the risk 
of DGF with an adjusted OR of 0.996 (95% CI 0.992-0.999, P = 0.008).
Since Kunzendorf and colleagues (9) showed a difference in DGF and graft survival after 
dividing their study population into donors with ‘short BDdur’ (the lower half of BDdur 
values in his dataset, with BDdur <470 min) and donors with ‘long BDdur’ (>470 min), 
we decided to do the same with our data. Following this method, we found in both univari-
ate and multivariate analyses ‘short BDdur’ to be an independent risk factor for DGF, not 
influenced by donor age (adjusted OR 1.313, 95%CI 1.084-1.590, P = 0.005). In our study 
cohort, donors with ‘short BDdur’ concerned 2.8% of the total population.
Table 2   Multivariate risk analysis for delayed graft function
Delayed graft function: variable  Odds ratio (95% CI)  P-value
Duration of brain death (h)  0.998 (0.995-1.001)  0.111
Donor age (y)  1.013 (1.010-1.016)  <0.0005
Donor ethnicity: African-American  1.046 (0.945-1.156)  0.386
ECD donor vs. non-ECD donor  0.737 (0.658-0.826)  <0.0005
Donor cause of death: CVA  0.970 (0.875-1.076)  0.566
Donor cause of death: trauma  0.735 (0.665-0.813)  <0.0005
Donor history of hypertension  1.444 (1.321-1.579)  <0.0005
Donor history of diabetes mellitus  1.063 (0.931-1.213)  0.367
Cold ischemic time (h)  1.035 (1.031-1.039)  <0.0005
Number of HLA mismatches  1.056 (1.035-1.077)  <0.0005
Recipient age (y)  1.002 (1.000-1.005)  0.075
Total time spent on the wait list (y)  1.116 (1.096-1.136)  <0.0005
Number of previous kidney transplants  1.151 (1.048-1.264)  0.00366 67
BDdur and risk of rejection in the first year posttransplant
In a multivariate logistic regression analysis, BDdur had no effect on the incidence of anti-
rejection treatment in the first year after transplantation (P = 0.112).
BDdur and graft survival 
Using Cox proportional hazards analysis, the influence of BDdur on one- and three-year 
graft survival was determined. In a univariate analysis, BDdur significantly lowered the risk 
of graft failure at one year with a hazard ratio (HR) of 0.995 (P = 0.018). In a multivariate 
Cox model, BDdur was not an independent risk factor for graft failure at one year
(P = 0.50). Confounding factors for this effect were donor age and recipient treatment for 
rejection in the first year after transplantation. Division of BDdur into a ‘short BDdur’ group 
with BDdur < 470min and a ‘long BDdur’ group with BDdur > 470min did not alter these 
outcomes; neither did a subgroup analysis including only donors ≤ 55 years.
For three-year graft survival, similar results were found. In a univariate Cox model, BDdur  
significantly lowered the risk of graft failure three years after transplantation with a HR of 
0.996 (P = 0.034), but in the multivariate model BDdur was not an independent risk factor 
for graft failure (P = 0.12). Confounding factors were again donor age and recipient treat-
ment for rejection in the first year. Also, in a subgroup analysis for donors ≤ 55 years, BDdur 
was no independent predictor of graft loss. Table 3 shows results for all covariates entered 
into the multivariate models.
Table 3  Multivariate risk analysis for graft failure at one and three years
  after transplantation.
Graft failure: variablea  Hazard ratio (95% CI)
    1 year  P-value  3 years  P-value
Duration of donor brain death (h)  1.004 (0.993-1.016)  0.486  1.006 (0.998-1.014)  0.132
Donor age (y)  1.011 (0.999-1.024)  0.063  1.012 (1.004-1.020)  0.002
Donor ethnicity: African-American  1.233 (0.851-1.786)  0.269  1.541 (1.229-1.933)  <0.0005
Donor cause of death: CVA  1.246 (0.802-1.936)  0.328  1.085 (0.825-1.427)  0.558
Donor cause of death: trauma  1.142 (0.742-1.757)  0.547  0.978 (0.747-1.280)  0.869
Donor history of hypertension  1.137 (0.802-1.613)  0.471  1.111 (0.892-1.385)  0.348
Donor history of diabetes mellitus  1.599 (1.008-2.535)  0.046  1.707 (1.269-2.295)  <0.0005
Cold ischemic time (h)  1.001 (0.985-1.018)  0.868  0.996 (0.985-1.007)  0.476
Number of HLA mismatches  1.069 (0.985-1.160)  0.113  1.075 (1.020-1.133)  0.007
Recipient age (y)  0.996 (0.987-1.006)  0.449  0.999 (0.993-1.005)  0.727
Total time spent on the wait list (y)  0.918 (0.847-0.995)  0.037  0.958 (0.912-1.007)  0.092
Rejection treatment (<1 y post Tx)(%)   2.927 (2.185-3.919)  <0.0005  2.687 (2.225-3.246)  <0.0005
Number of previous kidney transplants  1.159 (0.812-1.653)  0.417  1.168 (0.925-1.475)  0.193
DGF in recipient  2.621 (1.980-3.469)  <0.0005  1.778 (1.479-2.138)  <0.0005
a) Censored upon death with a functioning graft.69
- Discussion -
In this retrospective OPTN database analysis, we have shown for a large group of donor-re-
cipient combinations that longer duration of brain death (BDdur) in the donor after cerebral 
injury is not detrimental and as a matter of fact may have a positive effect on outcome after 
kidney transplantation. In univariate analyses, a longer BDdur yielded lower odds for the 
development of DGF, and it improved one-and three-year graft survival. In addition, we per-
formed a multivariate analysis including several donor-, preservation-, graft- and recipient-
related factors that have all been shown in previous studies to have an independent effect on 
outcome after kidney transplantation (12-18) and which had a significant prevalence in the 
database. Of course, there are more factors known to have an effect on outcome after kidney 
transplantation, e.g. machine perfusion of the kidney after retrieval (19;20), but these data 
either had a very low prevalence in the studied cohort or are not related to BDdur. Also, in 
the timeframe of this study, there were no major differences in organ preservation methods 
or immunosuppressive regimens, which might have otherwise affected the outcomes of this 
study. In this multivariate analysis, the positive effect of BDdur on lower DGF incidence was 
not an independent effect, but could be explained by donor age. Likewise, the positive effect 
of BDdur on graft survival could be explained by donor age and chance of anti-rejection 
therapy in the first year after transplantation.  
In the subgroup of donors ≤ 55 years, however, BDdur did have an independent negative 
effect on the odds for developing DGF. Although the odds ratio seems rather close to 1.0 at 
first sight (0.996), it should be noted that BDdur was included in the model as a continu-
ous variable, in contrast to the previously published study of Kunzendorf et al (9) in which 
BDdur was a binary variable classified as ‘long BDdur’ or ‘short BDdur’. Our model shows 
that for all DBD donors aged ≤ 55 years, each hour increase of BDdur in the donor reduces 
the odds of developing DGF in the recipient by 0.4%. Therefore, based on this study we 
would carefully recommend not to rush with organ recovery procedures in DBD donors
≤ 55 years of age. 
To our surprise the median BDdur in this U.S. cohort was 23.8h. In Kunzendorf’s Euro-
pean study, the median BDdur was 470 min, or 7.8h. When we simulated his analysis in our 
OPTN dataset, dividing the population into donors with BDdur <470 min and donors with 
BDdur >470min, we could reproduce his findings with respect to DGF, but not for graft 
survival. However, in our study population donors with BDdur <470 min comprised only 
582 donors (2.8%) of the total population. We could not find a satisfactory explanation for 
this difference between American OPTN data and European data. We therefore checked 
Kunzendorf’s BDdur calculations by looking at donor BDdur times from kidneys allocated 
to our transplant center in Groningen, The Netherlands, which is part of the same organ 
sharing network as Kunzendorf’s center (Eurotransplant), and we found a median BDdur of 
10.5h. This value lies in the same order of magnitude as Kunzendorf’s. 
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Personal communication with U.S. procurement coordinators learned that the difference can 
be explained by two factors. First, in the U.S. more time is spent with the donor’s relatives to 
obtain consent for donation, thus lengthening the period between declaration of brain death 
and the preparations for organ retrieval. Second, the donor operation is usually scheduled to 
take place during office hours, whereas in Europe, the donor operation is often performed as 
soon as possible, and even in the middle of the night. As organs are recovered early, recipients 
also have to be found as quickly as possible. This may lead to more complicated logistics, 
with transplant centers under higher pressure to accept an organ offer.
As BDdur is much longer in our study population when compared to Kunzendorf’s series, a 
pitfall in our analysis could be a ‘stable donor’ selection bias: Donors with longer BDdur have 
a prolonged ICU stay, which increases the risk of hemodynamical instability. This may lead 
to higher numbers of organs that are not retrieved and more organs that are discarded after 
recovery. As a result, a selection bias could be present in our study cohort, as we have only 
investigated donors of kidneys that have actually been transplanted. On the other hand, early 
organ recovery as it is currently practised in Europe could lead both to a lower donor non-
utilization rate and to a higher kidney discard rate, as accepting transplant centers are under 
high pressure to either accept or decline an organ offer.   
To evaluate this, we compared American and German kidney donor non-utilization as well 
as kidney discard rates. Donor non-utilization rate was defined as the number of reported 
organ donors from whom organs were not removed because of a medical contraindica-
tion after consent for donation had been obtained. Kidney discard rate was defined as the 
number of kidneys that were recovered and subsequently found to be unsuitable for trans-
plantation. Data were obtained from the OPTN/SRTR Annual Report, Tables 2.2, 3.2 and 
3.3 1996-2005 for American figures, and from the Kidney balance statistics for 1999-2000 
from the Eurotransplant website for German figures. In the U.S., donor non-utilization rate 
was 7.8% and kidney discard rate was 11.8%. For Germany, these numbers were 6.1% and 
9.7%, respectively, which lies in the same order of magnitude. Thus, we suggest that a longer 
average BDdur of 23.8h neither leads to more donor non-utilization, nor to a higher kidney 
discard rate. These data, also, seem to justify the American approach, where more time is 
taken to communicate with the donor family and standard hospital logistics are left relatively 
unaffected by a donor procedure due to the fact that organ retrieval is not performed with 
high urgency. 
The positive effect of longer BDdur on outcome after kidney transplantation seems some-
what counter-intuitive. However, it should be considered that a prolonged period of appro-
priate donor resuscitation and appropriate management in the ICU may have positive effects 
on organ function and recovery. Giral et al have demonstrated that a long stay in intensive 
care and colloid transfusion of > 1250 mL correlate with a lower risk of DGF in the recipi-
ent (21). These effects may originate from the cellular processes observed during brain death. 70
Experimental animal models, as well as human studies not only show an activation of inflam-
matory processes during brain death but also a time dependent effect of brain death on gene 
expression and protein production of several protective proteins in the graft (22;23). Due 
to brain death, several heat shock proteins as well as other chaperone molecules are upregu-
lated, which can help organs to protect themselves during prolonged periods of cellular stress 
(7). In addition, ICU treatment modalities may have a direct (innate) immunological effect 
on the future graft (24). Hoeger showed that treatment with dopamine causes a reduction of 
monocyte infiltration of the kidney, a reduction of several pro-inflammatory molecules and 
an increase of the heat shock protein heme oxygenase-1 (25). In human kidney donation, 
dopamine treatment of the donor has been reported to result in superior graft survival in the 
recipient (26).
An interesting observation of our study is the negative correlation between BDdur and 
donor age. This can be explained by an increased hemodynamic instability in older donors, as 
older donors have been exposed to more concomitant morbidity than their younger coun-
terparts (27). Organ retrieval should be initiated earlier in such unstable donors, to prevent 
organ discard due to unfavourable hemodynamic incidents during their ICU stay. Although 
it is not easy to test this theory in detail in a large database as used for this study, we took 
the need for inotropic medication as a surrogate marker for hemodynamic instability. When 
this factor was added as a covariate into the model, however, we found no effect on BDdur. 
An explanation might be that it takes less time for a procurement coordinator to evaluate 
older donors and allocate organs, as with increasing donor age the kidneys are more often 
the only organs offered for donation and transplantation. We then calculated the deceased 
donor kidney recovery rate as a percentage of the total organ recovery rate for the period 
1994-2007 using the OPTN data. In this period, kidney recovery constituted 44.1% of total 
organ recovery in donors aged 18-34 years. For the donor age group of 35-49 years, this 
increased to 51.2%. For the age group 50-64 years it was 60.9%, and for 65+ donors kidney 
recovery comprised 63.1% of the total organ recovery. Hence, the phenomenon of shorter 
donor workup times in older donors may explain the correlation between BDdur and donor 
age, as well as it explains why donor age is a confounding factor for the effect of BDdur in 
our multivariate analyses. 
In conclusion, our results show that longer BDdur has a modest beneficial effect on the odds 
for immediate graft function and one- and three-year graft survival after kidney transplan-
tation. BDdur has no influence on acute rejection in the first year after transplantation. In 
multivariate analyses, the positive effect of BDdur on outcome can be attributed to the effect 
of donor age and the occurrence of acute rejection in the recipient. However, for donors ≤ 55 
years, BDdur is an independent predictor of DGF in the recipient, and the odds for develop-
ing DGF decrease by 0.4% for each additional hour of brain death. The patho-physiological 
mechanisms underlying this effect are currently unknown and will need further study. Long-
er BDdur, as seen in the U.S. when compared to Europe, does not lead to increased numbers 
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of donor non-utilization or kidney discard and longer BDdur has no detrimental influence 
on kidney graft quality. Based on these data we recommend a meticulous, but unhurried and 
high quality ICU donor management before DBD organ retrieval as there is no need to ‘rush 
and retrieve’, but rather time to ‘relax and repair’.
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- Abstract -
Early non-invasive determination of urinary biomarkers around kidney transplantation 
may help to evaluate graft quality and predict outcome after transplantation. We evaluated 
urinary levels of lactate dehydrogenase (LDH), kidney injury molecule-1 (KIM-1), heart-
type fatty acid binding protein (H-FABP), alanine aminopeptidase (AAP), malondialdehyde 
(MDA), N-acetyl-ß-D-glucosaminidase (NAG) and interleukin-18 (IL-18) as biomark-
ers for the detection of kidney injury and compared them to classic parameters of kidney 
function. Urine samples were collected from 40 kidney donors during donation, and from 
29 transplant recipients during the first 10 days after kidney transplantation. Biomarker 
levels were related to delayed graft function, acute rejection and kidney function up to one 
year after transplantation using regression analysis. Most biomarkers were elevated in urine 
samples from deceased donor kidneys. In the Donor study, AAP predicted short-term kidney 
function, and H-FABP and KIM-1 predicted 3-month’s function independently. Further, 
DGF was predicted by LDH in donor urine. In the Recipient study, urinary creatinine, LDH 
and NAG predicted kidney function at 3 months and one year after transplantation. Our 
study suggests that determination of urinary biomarkers around kidney transplantation may 
be useful for early evaluation of kidney grafts, especially when measured in the donor.  76 77
- Introduction -
Despite many achievements in kidney transplantation, especially in the field of immuno-
suppression, organ shortage has persisted and as a result the acceptance of older and more 
marginal donor kidneys has increased. Currently used organs from deceased donors bear a 
high risk for delayed graft function (DGF) and reduced early as well as long term survival.
Effort should therefore be directed towards identification and better insight in biomarkers 
and their validity that are able to predict an increased risk for the grafts-to-be during brain 
death and subsequent ischemia/reperfusion injury.
In the past years a number of diagnostic blood, urine and kidney tests in the donor such as 
urinary protein, Cystatin C, and microarrays have been reported to predict successful trans-
plantation, but none of these have become pertinent and reliable predictors of transplanta-
tion outcome [2;6;9;12]. Other tests, such as GFR assessment with (125)I-iothalamate, are 
complex and not feasible in deceased donors. Also, medical history from deceased donors 
is often incomplete and additional markers to assess renal function and the quality of the 
donor organ immediately prior to explantation or just after implantation would be extremely 
helpful.  
Recently, a number of authors has published the use of novel urinary biomarkers in kidney 
disease [1;10;14;19]. Urinary biomarkers are attractive also in kidney transplantation, as 
specimen collection is not invasive and some of these biomarkers appear to specifically reflect 
the condition of the kidney.  
In this study we have investigated several novel urinary biomarkers in the early phase of 
kidney transplantation and compared their predictive value to so called “classic” markers of 
kidney function. We have studied two different patient groups at two different early stages in 
transplantation: In the first study – the Donor study - we have looked at biomarkers in urine 
sampled from the donor, and in the second study – the Recipient study - we have analyzed 
biomarkers in urine sampled from transplanted kidneys during the first ten days after trans-
plantation. We have also evaluated the value of these biomarkers in living donation as the 
gold standard for optimal condition in kidney donation and transplantation. The comparison 
of these results to those obtained after deceased donation could be helpful to assess which 
biomarker is especially suitable to predict future complications in kidneys from deceased 
donors. 78 79
- Methods -
Patient selection and urine collection
Donor study
Urine samples were obtained from 2004 through 2006 during organ retrieval procedures 
from a consecutive series of 20 DBD donors. Inclusion criteria were age <65y and cold 
ischemia times <30h. All samples were collected after declaration of brain death, according 
to Dutch Transplantation Law. Urine samples were collected at two different time points: 
Baseline samples were collected just after brain death diagnosis (T0), and a second sample 
(T1) was obtained during organ retrieval with intact circulation and prior to wash-out and 
preservation. As a control group, informed consent was obtained from 20 living kidney 
donors for two urine samples: A baseline sample just before the donor operation (T0) and 
a second sample just prior to kidney retrieval during the donor operation (T1). One tablet 
Protease Inhibitor Cocktail (Roche) was added to all samples immediately in order to pre-
vent protein degradation in the sample; samples were kept on ice, centrifuged for five minutes 
at 400 x g and stored at -80˚C until analysis. Clinical donor and subsequent recipient vari-
ables were recorded including the follow up of kidney function after transplantation. Data 
were obtained from our transplantation database or from other recipient transplant centres. 
To assess the predictive value of urinary markers the following clinical outcome parameters 
were used: Delayed graft function - defined as the need for dialysis in the first week after 
transplantation; rejection - defined as biopsy proven rejection in the first year; kidney func-
tion as expressed by serum creatinine in the recipient at day 14 (short-term), at 3 months 
(mid-term) and at 1 year after transplantation (long-term). All grades of interstitial and 
vascular rejection were included. Borderline rejection was excluded. All biopsies were scored 
during routine clinical practice by a blinded pathologist according to the Banff classification. 
Recipient study
During three months in 2006, urine samples were collected from a consecutive series of 27 
kidney recipients transplanted at our hospital. All samples were collected after informed con-
sent. The immunosuppressive therapy was similar for all patients, consisting of cyclosporine 
or tacrolimus with prednison and mycophenolate mofetil. All kidneys were transplanted 
using the Lich-Gregoir ureterovesical reimplantation technique after insertion of an eight 
Gauge ureteral splint connected to a suprapubic catheter. All urine samples were collected 
directly from the splint urine at five different time points: At one, three, five, seven and 10 
days after kidney transplantation. Samples were stored and clinical outcome parameters were 
recorded as described for the donor study.
Biochemical determinations
Three blinded investigators (P.J.O., O.V., and V.S.V.) who were unaware of the patients’
clinical characteristics performed all measurements.78 79
Creatinine
Creatinine was measured in urine using the Jaffé method in order to evaluate glomerular 
filtration. In this assay, creatinine and picric acid form a yellow complex in an alkaline
environment which can be quantitatively measured colorimetrically. Results are expressed
as mMol/L.
Total urinary protein
Total urinary protein was measured using the Lowry method. In this assay, proteins and 
alkaline copper tartrate form a complex which turns blue after adding Folin reagent.
Lactate dehydrogenase (LDH)
Activity of the cytoplasmic enzyme LDH was measured in urine to evaluate the amount
of general cellular breakdown. The assay was performed at the Laboratory Center of the 
University Medical Center Groningen (Mega, Merck, Amsterdam, The Netherlands) and 
based on the conversion rate of lactate to pyruvate, which is enabled by LDH. Levels were 
normalized using urine creatinine values and the results are expressed as μg/mmol UCr.
Kidney Injury Molecule (KIM-1)
For the quantification of human KIM-1 protein in urine, a sandwich ELISA was used as 
described previously [3]. Levels were normalized using urine creatinine values and the results 
are expressed as μg/mmol UCr.
Heart fatty acid binding protein (H-FABP)
H-FABP was measured using a human H-FABP ELISA kit (Hycult Biotechnology, Uden, 
The Netherlands) following the manufacturer’s instructions. Levels were normalized using 
urine creatinine values and the results are expressed as μg/mmol UCr.
Alanine aminopeptidase (AAP)
Activity of the brush border enzyme AAP was measured using a method based on hydroly-
sis of L-alanine-p-nitroanilide into p-nitroaniline. Briefly, a 10 μl urine sample was incubated 
with 10 μl activation buffer containing 1 mM CoCl2 and 190 μl substrate solution with 1.66 
mM L-alanine-p-nitroanilide (Sigma) at 37°C for 30 minutes. Samples were analyzed for 
the amount of formed product photometrically at 405 nm. Enzyme activity was expressed 
as the amount of enzyme required to release 1 μmol of product per minute and normalized 
using urine creatinine values and the results are expressed as U/mmol UCr.
Malondialdehyde (MDA)
MDA was quantified by measuring the amount of thiobarbituric acid-reactive substances 
(TBARS) in urine using a method based on the reaction with thiobarbituric acid (TBA) at 
92–97°C, producing a pink pigment having an absorption maximum at 530 nm. Briefly, 20 
μl of urine sample was mixed with 90 μl of a 3% sodiumdodecylsulfate solution and 10 μl of 80 81
0.05M bytylhydroxytoluene. After setting the pH level to 2-3, 200 μl 0.7% TBA was added 
and samples were heated to 95°C for 30 min. The reaction product was precipitated with 
butanol and absorbance was read at 530 nm. Levels were normalized using urine creatinine 
values and the results were expressed as μmol/mmol UCr.
N-acetyl-ß-D-glucosaminidase (NAG) 
NAG activity was measured using a method based on enzymatic hydrolysis of p-Nitrophe-
nyl N-Acetyl-ß-D-Glucosaminide to p-Nitrophenol and N-Acetyl-β-D-Glucosamine at a 
pH of 4.25 at 37°C for 60 minutes. Enzyme activity was expressed as the amount of enzyme 
required to release 1 μmol of product per minute. NAG levels were normalized using urine 
creatinine values and are expressed as U/mmol UCr.
Interleukin-18 (IL-18)
IL-18 levels were measured using a human IL-18 sandwich ELISA kit (Medical and
Biological Laboratories, Nagoya, Japan) following the manufacturer’s instructions. Levels 
were normalized using urine creatinine values and are expressed as μg/mmol UCr.
Statistical methods
Statistical analysis was performed using the computer program SPSS version 14.0 (SPSS 
Inc., Chicago, IL, USA). Results are expressed as median and 25 and 75 percentiles. Statisti-
cal comparisons between groups were performed using Student’s T-test if the data had a nor-
mal distribution; otherwise groups were compared using Fisher’s exact test for dichotomous 
variables and Mann-Whitney U test for continuous variables. For paired observations the 
Wilcoxon matched pairs signed rank sum test was used. Both univariate regression analyses 
and stepwise regression analyses were used as exploratory measures for marker predicta-
bility of kidney function after transplantation. Next, a selection of markers was made using 
markers with α < 0.10 in univariate analysis. These markers were subsequently entered into 
stepwise multivariate analysis, using a probability of F to enter ≤ 0.05 and a probability of F 
to remove ≥ 0.10. Linear regression was used for continuous outcome variables, and logistic 
regression was used for dichotome variables. For linear regression normal distribution of the 
residuals was tested using normal probability plots. To achieve a normal distribution, trans-
plant outcome levels of serum creatinine after transplantation were transformed to μmol/L-
1x105. In the donor study, both sample time points (T0 and T1) were assessed separately. In 
the recipient study, changes in urinary biomarker excretion were assessed using the calculated 
delta over the study period for each recipient, defined as the difference between the first day 
and the 10th day after transplantation, corrected for baseline level on the first day. All uri-
nary biomarkers were compared to urinary protein and serum creatinine as commonly used 
markers for kidney function. We did not adjust for multiple comparison tests because our 
study had an exploratory character. All differences were considered significant at P<0.05.80 81
- Results -
Donor study
Patient characteristics
Clinical characteristics of all donors from whom urine was obtained to determine urinary 
biomarkers are reported in Table 1. In this study 20 deceased brain dead (DBD) donors 
and 20 living donors were included. All kidneys were transplanted. Donor age was slightly 
lower in the DBD donor group. No other differences in donor characteristics were observed 
between groups. One recipient experienced graft loss four weeks after transplantation and 
two recipients were referred to non-participating hospitals and lost to follow-up. In this 
small cohort, kidney function at three months and one year after transplantation was better 
for kidneys retrieved from DBD donors compared with those retrieved from living donors, 
possibly due to the lower donor age of DBD donors.   
Table 1   Characteristics of DBD and Living Donation in the Donor Study and Outcome  
    after Kidney Transplantation
Donor Study  DBD donation   Living donation  P-value
    (N=20)   (N=20)
Gender (N)  6 ♂ / 14 ♀  7 ♂ / 13 ♀  1.000
Age (years)*  46 (37-51)  50 (45-58)  0.033
Cause of death
  CVA   (N)  11  NA
  Trauma/Other   (N)  9  NA
Serum creatinine T0 (μmol/L)*  71 (46-99)   64 (60-70)  0.297
Serum creatinine T1 (μmol/L)*  52 (45-74)    64 (55-68)  0.762
Post-transplant outcome:
  Delayed Graft Function N (%)  4 (20%)  2 (10%)  0.661
  Rejection episodes 1st year N (%)  6 (30%)  4 (20%)  0.716
  Se-Creat. day 14 (μmol/L)*  134 (109-247)    133 (116-189)   0.776
  Se-Creat. 3 months (μmol/L)*  111 (95-134)  147 (127-159)   0.011
  Se-Creat. 1 year (μmol/L)*  106 (93-138)  139 (112-185)   0.018
DBD, brain death donation (heart beating); CVA, CerebroVascular Accident; Se-Creat,
Serum creatinine; T0, baseline sample just after brain death diagnosis (DBD) or just before 
the donor operation (Living), T1, sample at the time of kidney retrieval during the donor 
operation.  Differences between groups were tested using Fisher’s exact test or the Mann-
Whitney test. P<0.05 was considered to be significant.
*) Values are expressed as medians (25-75 percentile).82 83
Quantitation of urinary biomarkers
T0 was sampled just after declaration of brain death in DBD donors, or at the start of the 
donor laparoscopic nephrectomy in living kidney donors. T1 was sampled during the donor 
operation just prior to the moment of kidney retrieval. Compared to living donors, DBD 
donors had higher levels of NAG, AAP, IL-18, LDH and H-FABP at both time points (T0 
and T1 P<0.01; for LDH at T1 P=0.014). For MDA and KIM-1, no significant differ-
ences were found at T0, but differences at T1 were significant (MDA: P<0.001; KIM-1: 
P=0.012). Urinary creatinine was significantly higher in living donors at T0 (P<0.01) but 
not at T1. No statistically significant differences between DBD donors and living donors 
were found for total urinary protein and serum creatinine. When both time points were 
compared for the whole donor group, the markers H-FABP, MDA and IL-18 showed 
significant rises over time (P<0.05). Both, urinary creatinine and serum creatinine decreased 
over time (P<0.05), while NAG, AAP, total urinary protein, KIM-1 and LDH did not differ 
significantly between time points. Normalized levels of urinary markers tested are shown in 
dot plot graphs in Figure 1.82 83
Figure 1   Comparison of Urinary Biomarkers in the Donor Study. DBD: Deceased Brain  
  dead heart-beating Donation; Ucr: Urinary creatinine. -■- grafts from DD, 
  -○- grafts from living donor, * P<0.05 (Mann-Whitney)84 85
Regression analyses
The predictive value of urinary biomarkers on outcome after transplantation was assessed 
using univariate regression analysis. Significant findings up to α<0.1 are listed in Table 2. All 
other markers were not significant predictors for the outcome measures investigated. Next, 
biomarkers listed in Table 2 were entered into a multivariate stepwise regression analysis, 
with a probability of F to enter ≤ 0.05 and a probability of F to remove ≥ 0.10. As donor 
type (DBD vs living donor) and donor age might influence the predictive quality of the
model, both donor type and donor age were entered as separate variables into each model. 
For short-term kidney function, this resulted in a model including only the single variable 
AAP at T0 as an independent significant predictor [R2=0.171, P=0.017]. For mid-term 
kidney function defined as SeCreat-1 three months after transplantation, KIM-1 at T0, 
H-FABP at T0 and donor age were found to be independent predictors (R2=0.535, 
P<0.03). For long-term kidney function defined as SeCreat-1 one year after transplantation, 
no early biomarker turned out to be an independent predictor, leaving donor age as the sole 
independent risk factor (R2=0.264, P=0.003). For DGF, a forward stepwise logistic regres-
sion model resulted in LDH at T0 as the single predictive variable (Nagelkerke’s R2= 0.206, 
P=0.042). No donor related predictors were found in a multivariate model for rejection 
episodes in the first year after kidney transplantation.
Table 2   Donor Study: Univariate Regression Analyses
Donor Study  Independent variables  B (Std.Error)   P-value R2
Post-transplant   AAP T0   -59.514 (21.957)  0.011  0.182
Se-Creat-1 14 days:  NAG T0  -1.656 (0.855)  0.061  0.102
Post-transplant   HFABP T0  0.022 (0.008)  0.008  0.210
Se-Creat-1 3 months:  MDA T1  0.332 (0.138)  0.022  0.142
    KIM-1 T0  0.045 (0.020)  0.031  0.146
    IL-18 T0  0.015 (0.007)  0.046  0.122
Post-transplant   HFABP T0   0.021 (0.009)  0.020  0.172
Se-Creat-1 1 year:  MDA T1  0.326 (0.152)  0.039  0.119
    IL-18 T0  0.015 (0.008)  0.068  0.110
    Independent variables  B (Std.Error)  P-value
    Exp(B)
Post-transplant   AAP T0  5.597 (2.584)  0.030  269.550        
DGF:     LDH T0  0.003 (0.002)  0.042  1.003
    Urinary creatinine T0  -0.621 (0.322)  0.054  0.538 
Post-transplant   Urinary creatinine T1  -0.811 (0.398)  0.041  0.444
rejection 1st year:   LDH T1  0.005 (0.002)  0.046  1.00584 85
Recipient study
Patient characteristics
Clinical characteristics of all patients from whom urine was obtained to determine urinary 
biomarkers are reported in Table 3. In this study 17 patients received a kidney from a 
deceased donor (DD; DBD or non-heart beating donor after cardiac death (DCD)) and 12 
patients received a kidney from a living donor (LD, eight genetically related donors and four 
unrelated donors). Recipient age was lower in patients who received a kidney from a living 
donor. As expected, cold ischemia time was shorter in patients who received a kidney from a 
living donor. No other differences in patient characteristics were observed between groups. 
Three recipients died during the first year after transplantation due to Pneumocystis Carinii 
sepsis, cardiac arrhythmia and Post-Transplant Lymphoproliferative Disease (PTLD). In the 
remaining recipients, no graft losses occurred within the first year after transplantation. 
Table 3   Characteristics of Patients from the Recipient Study
Recipient Study   Kidney from DD  Kidney from LD   P-value
    (N=17)  (N=12)
Gender (N)  10 ♂ / 7 ♀  7 ♂/ 5♀  1.000
Recipient Age (years)*  62 (50-66)  38 (28-49)  0.006
Donor type (DBD / DCD NHB III)  8 / 9  NA    
Donor age (years)*  49 (33-60)  52 (48-62)   0.263
Cold ischemia time (minutes)*  1047 (761-1337)  171 (136-191)   <0.001
Number of HLA mismatches*  3 (1.5-3.0)  3 (2.0-3.75)   0.325
Delayed Graft Function (N)  8   0   0.009
Rejection episodes 1st year  4  3   1.000
Se-Creat. day 14 (μmol/L)*  303 (165-655)  146 (113-189)   0.002
Se-Creat. 3 months (μmol/L)*  109 (90-129)  130 (91-159)   0.371
Se-Creat. 1 year (μmol/L)*  120 (96-147)  122 (100-164)   0.807
DD, deceased donor (DBD and DCD NHB III donors); LD, living donor; Se-Creat, serum 
creatinine; NA, not applicable. Differences between the groups were tested using Fisher’s 
exact test or the Mann-Whitney test. P<0.05 was considered to be significant.
*)Values are expressed as medians (25-75 percentile).86 87
Quantitation of serial urinary biomarkers
Samples were taken on days one, three, five, seven and 10 after kidney transplantation. Most 
biomarkers had higher values in the urine from kidneys retrieved from DBD donors, but the 
differences did not reach statistical significance, due to the large standard deviation found 
in this group. Due to anuria of the recipients no urine could be collected in 16% of the time 
points. This occurred in the recipient group with DD kidneys (in 23% of cases; 17% of those 
missing samples were from DCD kidneys); in the recipient group with LD kidneys, 6% of 
the samples could not be collected. Normalized levels of urinary markers tested are shown in 
Figure 2.
Regression analyses
The predicting value of urinary biomarkers on kidney function after transplantation was as-
sessed using linear regression analysis. Significant findings up to α<0.1 are listed in Table 4. 
All other markers were not significant predictors for the outcome measures investigated.
Table 4   Recipient Study univariate regression analyses
Recipient Study  Independent variables  B (Std.Error)  P-value  R2
Post-transplant   delta Se-Creat.  -0.074 (0.029)  0.017  0.630
Se-Creat-1 14 days:           
 
Post-transplant   delta Se-Creat.  0.087 (0.035)  0.020  0.212
Se-Creat-1 3 months:  delta Urinary creatinine  -4.737 (1.134)  <0.001  0.627
    delta LDH  -0.008 (0.002)  0.003  0.494
    delta NAG  1.115 (0.625)  0.090  0.513
Post-transplant   delta Urinary creatinine   -3.092 (1.056)  0.009  0.420
Se-Creat-1 1 year:  delta LDH   -0.004 (0.002)  0.070  0.193
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Figure 2   Comparison of Urinary Biomarkers in the Recipient Study. Values are medians  
  (25-75 percentile). DD: Deceased donor; Ucr: Urinary creatinine. 88
- Discussion -
To our knowledge, our study is the first prospective analysis to demonstrate the clinical use 
of novel urinary biomarkers not only posttransplant, but also in the donor as a potential 
tool to predict outcome after kidney transplantation. Early detection of kidney injury prior 
to transplantation is important, as this early injury may result in DGF and/or acute rejec-
tion and lead to a higher risk of chronic transplant dysfunction and graft loss [7;13]. Urine 
produced and excreted by the donor kidney has the potential to reflect injury of renal paren-
chyma by containing highly specific biomarkers for the kidney [4]. 
In our donor study, we found the use of novel urinary biomarkers already prior to transplan-
tation very promising. Urine specimens were collected as early as during donor ICU stay 
and during the organ retrieval operation. Specimen collection was always possible, as kidney 
donors without any diuresis are not accepted. Our study shows a significant independent 
predicting effect of alanine aminopeptidase (AAP) activity on short-term kidney function 
after transplantation, and an effect of both Kidney Injury Molecule-1 (KIM-1) and Heart-
type Fatty Acid Binding Protein (H-FABP) on mid-term kidney function. In addition, 
lactate dehydrogenase (LDH) levels in donor urine independently predicted the incidence 
of delayed graft function after transplantation. Although most biomarkers were significantly 
higher in DBD donors compared with our control group of selected ‘ideal’ living donors, this 
did not influence our model.
If found to be predictive for success after transplantation, urinary biomarkers in the donor 
can be employed to monitor the effect of specific interventions in the donor to improve 
organ quality before organ retrieval and after preservation. Thus they will lead to decreased 
rates of DGF and acute rejection after transplantation. Pratschke et al showed in an animal 
model that treatment of the donor during brain death with steroids or soluble P-selectin 
glycoprotein ligand, did reduce the intensity of ischemia-reperfusion injury and risk for acute 
rejection, leading to better recipient survival after kidney transplantation [16]. This was 
confirmed in a clinical setting for outcome after human liver transplantation by Kotsch et al, 
who treated DBD donors with methylprednisolone [8]. In this respect, the development of 
easy-to-use bedside tests, such as the new KIM-1 dipstick test that was described recently 
and the H-FABP dipstick which is already commercially available (CardioDetect, Clindia 
Benelux BV, Leusden, The Netherlands) could be very helpful to monitor the effect of donor 
treatment [17].
While evaluation of urinary biomarkers offers additional useful monitoring of treatment 
effect in heartbeating DBD procedures, application may be restricted in non heart beating 
donors after cardiac death (DCD). In the Netherlands, the majority of DCD donors are 
Maastricht category III donors after a controlled ventilator switch-off procedure. Most of 
the injury in those donors will be due to warm ischemia and reperfusion injury, which occurs 
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after cessation of the circulation leading to an arrest of urine production. Therefore, DCD 
donors were not included in our donor study. 
In contrast to the use of urinary biomarkers in the donor, the use of serum biomarkers in the 
donor is less promising. Palambo et al described measurements of several cytokines in portal 
and caval blood samples collected just before organ retrieval in liver donors. Cytokine levels 
were elevated in DBD donors, but did not predict early allograft function after transplanta-
tion or transplant outcome [15]. Venkateswaran et al measured cytokine levels in serum of 
heart and lung donors. Of several tested cytokines, only procalcitonin, a marker of bacterial 
infection that is not organ specific, appeared to be associated with transplantation success [18].
Following the evaluation of donor urinary biomarkers we then performed a recipient study 
to investigate the expression of urinary biomarkers produced by the transplanted kidney in 
the early phase after transplantation. Urine was collected from the ureter splint of trans-
planted kidneys during the first ten days after transplantation. We found that changes in 
urinary creatinine, LDH and N-acetyl-β-D-glucosaminidase were significant predictive 
factors for kidney function at three months and one year. For short-term kidney function, 
decrease of serum creatinine in the recipient was the only predictor in our cohort. This result 
may have been caused by missing data in our recipient cohort, as many patients who suffered 
from DGF were anuric or oliguric. Therefore, remaining data for short term function of the 
group are probably biased as they originate from relatively well-performing kidneys. The 
same problem was also described in the study of Manfro, where urine samples from patients 
with DGF could not always be collected [11]. Nevertheless, the biomarker concentrations 
calculated in our recipient study do reflect the condition of the transplanted kidney accurately, 
as all urine was obtained from a splint inserted in the ureter of the transplanted kidney only.
The search for apropriate biomarkers in urine to detect kidney injury in kidney transplanta-
tion has been described before. However, in several recently published studies patients were 
only eligible for enrollment if they had a clinical indication for a diagnostic biopsy (e.g. a rise 
in serum creatinine). This was the case for the study of Hu et al, who used a multiplex assay 
of soluble cytokines and chemokines on urine samples from kidney transplant recipients.
A combination of four markers was found to discriminate acute from chronic renal allograft 
injury, although the various causes of acute graft dysfunction could not be differentiated [5]. 
Also, the study of Manfro et al reported Tim-3 messenger RNA expression in urine to detect 
acute rejection in kidney transplant recipients. Patients, however, were selected based on a 
clinical indication for a biopsy [11]. In our study, samples were obtained prospectively from 
consecutive series of donors and recipients without any clinical pre-selection bias. Also, we 
are not aware of a previous study that describes the potential of urinary biomarkers to predict 
early kidney injury and relates this to the outcome after transplantation when measured in 
the donor. We feel that our results present a tool to facilitate early intervention and better 
organ allocation algorhythm.91 90
Despite our positive findings with urinary biomarker evaluation in the donor, one comment 
should be made concerning the urine sample collection in our donor study. Most predictive 
markers in our donor study were found in urine sampled at T0. In DBD donors, this sample 
is collected immediately after declaration of brain death. Markers from urine sampled at T1 
at the moment of organ retrieval had less predictive value although our previous work dem-
onstrates a progression of injury during brain death. We think that this is due to a dilution 
effect in the donor related to aggressive fluid resuscitation. Due to pituitary gland dysfunc-
tion resulting from brain death, DBD donors often suffer from diabetes insipidus, which 
results in large amounts of highly diluted urine and an increased demand for intravenous 
fluids. Also, during laparoscopic living donor nephrectomy we use a protocol that prescribes 
high amounts of intravenous fluids aiming at a diuresis of 1mL/kg bodyweight/hour to 
reduce the chance of hypoperfusion and DGF after transplantation. Therefore, we have tried 
to compensate for these dilution effects by normalizing biomarker concentration to urine 
creatinine concentration. 
In summary, our study shows that early urinary biomarker screening in the donor and in the 
recipient is able to detect kidney injury at a very early stage, and is associated with outcome 
after kidney transplantation. Early detection of organ specific injury increases the possibili-
ties for early intervention, not only in the recipient, but also in the donor before transplan-
tation. In this respect, the evaluation of kidney quality already in the donor seems to be 
especially promising. References
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- Abstract -
With more marginal deceased donors affecting graft viability there is a need for specific 
parameters to assess kidney graft quality at the time of organ procurement in the deceased 
donor. Recently, Kidney Injury Molecule-1 (Kim-1) was described as an early biomarker 
of renal proximal tubular damage. We assessed Kim-1 in a small animal brain death model 
as an early and non-invasive marker for donor derived injury related to brain death and its 
sequelae, with subsequent confirmation in human donors.
In rat kidney, real-time PCR revealed a 46-fold Kim-1 gene upregulation after 4h of brain 
death. In situ hybridisation showed proximal tubular Kim-1 localization, which was con-
firmed by immunohistochemistry. Also, Luminex assay showed a 6.6-fold Kim-1 rise in 
urine after 4h of brain death. In human donors, 2.5-fold KIM-1 gene upregulation and 
two-fold higher urine levels were found in DBD donors compared to living kidney donors. 
Multiple regression analysis showed that urinary KIM-1 at brain death diagnosis was a 
positive predictor of recipient serum creatinine 14 days (P<0.001) and 1 year (P<0.05) after 
kidney transplantation.
In conclusion, we think that Kim-1 is a promising novel marker for the early, organ specific 
and non-invasive detection of brain death-induced donor kidney damage.   94 95
 - Introduction -
 
Kidney transplantation has become the therapy of choice in the treatment of end-stage renal 
failure. Nowadays, due to the persistent donor shortage more organs from living donors are 
used in transplantation. However, the majority of donor organs is still retrieved from heart 
beating donation after brain death donors (DBD donors). Living (un)related grafts are as-
sociated with better survival and lower rates of delayed graft function compared to kidneys 
retrieved from DBD (1;2). Also, brain death in the donor has been reported as a probable 
risk factor for developing vascular rejection (3). 
In the past years it has become clear that this difference in success can largely be attributed to 
pathophysiological changes during the brain death process in the donor in addition to other 
factors as are, warm and cold ischemia times or HLA mismatches (4;5). Experimental and 
clinical studies have shown that brain death negatively affects hemodynamic stability and 
hormone regulation in the donor (6;7). Our group, as well as others, have demonstrated that 
brain death induces pro-inflammatory and pro-coagulatory responses in potential donor 
organs, enhancing the immunogenicity of the graft-to-be and affecting the allograft response 
in the recipient (8-10). Despite a better insight, the exact causes and mechanisms of brain 
death which  leads to decreased organ viability have not been determined.
Given the lack of knowledge about the underlying processes responsible for the systemic 
changes, it is very difficult to predict outcome after transplantation. With older and more 
marginal donors, a better assessment of organ quality in the DBD has become very impor-
tant. Obviously, it would be beneficial to know beforehand whether an organ is injured to 
such an extent that transplantation will not be successful. Unfortunately, in DBD kidney 
donors, plasma creatinine and creatinine clearance (either calculated by the Cockcroft-Gault 
equation or measured) are poor predictors of long term graft function and survival (11;12). 
This is especially important, as the criteria upon which donor organs are used have been 
extended in the last years to meet the shortage of donor organs (13). If a better prediction of 
transplantation success could be made in the donor, matching of organ and recipient charac-
teristics could be enhanced. Also, strategies for donor management, organ preservation and 
immunosuppression in the recipient could be optimized, leading to better transplantation 
outcome. 
Other approaches to assess organ viability are often based on post-transplant data, and not 
available prior to organ recovery and preservation. Therefore, we have searched for a marker 
that is able to better detect donor kidney damage prior to retrieval and that could predict 
transplantation success in terms of the likelihood of delayed graft function, long term func-
tion and graft survival.   
Previously, we performed DNA microarray studies comparing transcriptional changes in 
kidneys from brain dead (normo- or hypotensive) versus living donor rats (14). One of the 
genes that was identified to be upregulated during brain death is Kidney Injury Molecule-1 
(KIM-1 in humans, or Kim-1 in rodents). KIM-1 was first described by Ichimura et al in 
1998 (15) and is a type 1 transmembrane protein. It structurally resembles mucosal ad-96 97
dressin cell adhesion molecule 1 (MAdCAM-1) which is a member of the immunoglobulin 
gene superfamily. KIM-1 has been reported to be very specific and upregulated in renal 
tubular cells in a variety of injury models (16), in various human renal disease (17) and renal 
cell carcinoma in man (18). The same group showed that upon injury, KIM-1’s ectodomain is 
actively cleaved and shedded into the lumen of the renal tubules to appear in the urine (19). 
Urinary KIM-1 correlates significantly with tissue KIM-1 expression in protein overload 
nephropathy (20). Also, the rise of KIM-1 levels in urine precedes any increase of serum 
creatinine.  
We estimated that these characteristics make KIM-1 a promising and elegant marker for the 
detection of brain death-induced injury in a potential organ donor: not only specific for the 
kidney and in particular for tubular injury, but also as an early and sensitive marker. The fact 
that the ectodomain of KIM-1 is shed into urine obviously facilitates sampling in a clinical 
setting.
In this study, we have analyzed the effect of brain death on the expression of Kim-1 and  
evaluated its use as a new biomarker in organ donation and transplantation. We have used 
our slow induction model of brain death in the rat, simulating the clinical situation of 
cerebral injury due to hemorrhage. We have studied KIM-1 gene and protein expression 
in the kidney and in urine at different intervals after induction of brain death using various 
techniques. In addition, we report the first pilot with KIM-1 as a kidney injury marker in 
brain death in man, including multiple regression analysis to study the effect of KIM-1 on 
outcome after kidney transplantation.  
- Materials and Methods -
Animal model
Adult male Fisher F344 rats (250-300 g) were used. Animals received care in compliance 
with the guidelines of the local animal ethics committee according to the Experiments on 
Animals Act (1996) issued by the Netherlands Ministry of Public Health, Welfare and 
Sports.
Rats were randomly divided into five groups, each group consisting of six animals. Brain 
death was induced as described previously (21). Briefly, animals were anesthetised using 
isoflurane with a mixture of O2/NO2. A cannula was inserted in the femoral artery for blood 
pressure monitoring. Animals were intubated via a tracheostomy and ventilated through-
out the experiment. Through a frontolateral borehole in the skull a no. 4 Fogarty catheter 
(Edwards Lifesciences Co., Irvine, CA) was placed subdurally and slowly inflated (16 μl/
min) with saline using a syringe pump (Terufusion, Termo Co., Tokyo, Japan). Inflation of 
the balloon was stopped during the subsequent sharp rise in blood pressure, which reflects 
the autonomic storm at the beginning of brain death, and which typically took place after 
30 min. Brain death was confirmed by the absence of corneal and pupillary reflexes and an 96 97
apnea test. From the beginning of brain death, animals received no more anesthesia. If blood 
pressure fell below 80 mmHg, it was restored by the administration of 10% hydroxyethyl-
starch (HAES-Steril 10%, Fresenius Kabi AG, Bad Homburg, Germany). Temperature 
was monitored rectally and kept constant. Animals were kept brain dead for 30 minutes, 
1 hr, 2 hrs or 4 hrs. At the end of the brain death period, a laparotomy was performed and 
blood and urine were collected from the aorta and the bladder. Serum and urine were snap 
frozen and stored at -80˚C until further analysis. Then, kidneys were flushed with saline and 
removed. Kidney tissue was partly snap frozen in liquid nitrogen and partly fixed in formalin 
and embedded in paraffin. Sham operated rats served as controls. These animals were cannu-
lated and intubated as described before, but the subdurally placed Fogarty catheter was not 
inflated. After 30 minutes of ‘no-touch’, a laparotomy was performed and blood, urine and 
kidneys were collected as described for the study groups. 
Patient material
From 2004, kidney biopsy specimens, blood and urine samples were routinely obtained during 
organ recovery procedures from a consecutive series of DBD (N=20) and living kidney
donors (N=20). Donors whose kidneys were discarded for transplantation after retrieval 
were not included in this analysis. Biopsy specimens were collected just prior to organ per-
fusion using a 16G Acecut biopsy gun (TSK Laboratory, Tochigi, Japan). Specimens were 
cut in two halves. One half was immersed immediately in RNAlater (Ambion, Austin, TX, 
USA) until storage at -80˚C. The other half was embedded in Tissue-Tek (Sakura Finetek 
Europe, Zoeterwoude, The Netherlands) and snap-frozen in isopentane on dry ice (-80˚C). 
Serum and urine samples from the same donors were collected at two different time points. 
Baseline samples were collected at the time of brain death diagnosis; for living donors these 
samples were collected before donor nephrectomy (T0). Further, samples were collected 
during organ retrieval simultaneously with obtaining our biopsy specimens prior to cessation 
of heart beat and/or retrieval (T1). All samples were placed on ice; to urine samples 1 tablet 
of proteinase inhibitor cocktail (Roche) was dissolved. Blood samples were centrifuged and 
supernatants were stored at -80˚C until further analyses.
Biochemical determinations in serum and urine samples
In all human serum samples, creatinine, C-reactive protein (CRP) and lactate dehydrogenase 
(LDH) was determined in a routine fashion (Mega, Merck, Amsterdam, The Netherlands) 
to standardize serum values of parameters commonly used to assess kidney function in DBD 
donors during organ recovery. In urine samples of both rats and patients, urine creatinine 
levels were measured using the Jaffe reaction and total protein was measured using a modi-
fied Lowry’s protein assay (Biorad DC Protein Assay, Biorad, Hercules, CA, USA). 
Real-Time RT-PCR
Total RNA was isolated from snap frozen cross-section kidney slices, using the SV Total 
RNA Isolation Kit (Promega, Madison, WI, USA) following the manufacturer’s instruc-98 99
tions, including a DNase treatment step. RNA samples were verified for absence of genomic 
DNA contamination by performing RT-PCR reactions, in which the addition of reverse 
transcriptase was omitted, using β-actin primers.
For animal tissue, 1 μg of RNA was then reverse transcribed into cDNA in a reaction vol-
ume of 20 μl using M-MLV Reverse Transcriptase (Invitrogen). For human tissue 130 ng of 
RNA was reverse transcribed using the Superscript II Reverse Transcriptase kit (Invitrogen). 
Gene-specific primers for KIM-1 were designed using the computer program Primer Ex-
press 2.0 (Applied Biosystems, Foster City, CA, USA) using published gene sequences. For 
rat, primer sequences were as follows:
forward primer 5’-AGAGAGAGCAGGACACAGGCTT-3’ and reverse primer
5’-ACCCGTGGTAGTCCCAAACA-3’. For human tissue, primer sequences were 
5’-CGTCCACCGCAAATGCTT-3’ (forward) and 5’-TCTGCGCAAGTTAGGTTTTGTC-3’ 
(reverse). Amplification and detection were performed with the Applied Biosystems 7900 
HT Real Time PCR System (Applied Biosystems, Foster City, USA) using emission from 
SYBR Green (SYBR Green master mix, Applied Biosystems). All assays were performed in 
triplicate. After an initial activation step at 50 °C for 2 min. and a hot start at 95°C for 10 
min., PCR cycles consisted of 40 cycles at 95°C for 15 sec. and 60°C for 60 sec. Specificity of 
qPCR products was routinely assessed by performing a dissociation curve at the end of the  
amplification program and by gel electrophoresis. Gene expression was normalized with the 
mean of β-actin mRNA content and calculated relative to controls using the relative stand-
ard curve method. Results were finally expressed as 2ΔCT (CT threshold cycle). 
     
In Situ Hybridisation
In situ hybridisation was performed on 5 μm paraffin rat kidney tissue sections. Probes were 
made by subcloning Kim-1 PCR product into the pCRII-TOPO vector (Invitrogen) and 
labeling the probes using a DIG RNA labelling kit (Sp6/T7) (Roche, Mannheim, Germany) 
following the manufacturer’s instructions.
Tissue sections were deparaffinized and air-dried for 10 minutes. Slides were treated with 
Triton X-100 (Sigma-Aldrich, St Louis, MO, USA), followed by proteinase K (5 μg/ml 
in TBS) (Roche) at 37ºC for 10 minutes. After washing with phosphate buffered saline 
(PBS), slides were incubated with 10 ng/100 μl DIG labelled probe (anti-sense or sense) in 
a hybridization solution containing 50 μl 100x Denhardt’s solution overnight at 55ºC. After 
washing, slides were treated with 2 U/ml RNase T1 (Sigma-Aldrich) in 1 mM EDTA (pH 
8) and 2x SSC at 37ºC for 30 minutes. Positive cells were visualized with anti-DIG labelled 
alkaline phosphatase (Roche) for one hour at 37°C in 0.1 M maleic acid buffer containing 
0.15 M NaCl, 1% blocking buffer and 2% normal sheep serum. Staining reaction was per-
formed for 48 hours at 4°C with nitro-blue tetrazolium (NBT) and 5-bromo,4-chloride,
3-indolylphosphate (BCIP) in 1 ml AP buffer (pH=9.0) containing 50 mM MgCl2 and 
0.01 M levamisole.
Localisation and quantitation of staining was assessed by light microscopy in sham treated 
and 4h brain dead rats. At 400x magnification, 10 microscopic fields of the outer medulla/98 99
inner cortex region of each tissue section were quantified using computerized image analysis 
(Advanced QUIPS, Leica Imaging Systems, Cambridge, UK). Sections were projected on
a video screen and the KIM-1 positive parts in the outer medulla/inner cortex were outlined 
manually. Kim-1 positive areas were calculated as a proportion of total surface, with
exclusion of glomeruli and blood vessels.
Immunohistochemistry
Immunohistochemistry was performed on 5 μm paraffin rat kidney tissue sections. Tissue 
sections were deparaffinized and antigen retrieval was done by overnight incubation in 0.1 M 
Tris-HCl buffer (pH 9.0) at 80°C. Next, they were stained with primary polyclonal anti-
body rabbit KIM-1 R9 (22) using an indirect immunoperoxidase technique. After thorough 
washing, the sections were incubated with appropriate horseradish peroxidase-conjugated 
secondary antibodies (Dako, Glostrup, Denmark). The reaction was developed using 3,3-
diaminobenzidine tetrahydrochloride /H2O2. Sections were counterstained using Mayer’s 
hematoxylin solution (Merck, Darmstadt, Germany). Negative antibody controls were per-
formed. Localization of immunohistochemical staining was assessed by light microscopy. 
Protein Detection in Urine
For quantification of Kim-1 protein in rat urine, urine samples were measured using micro-
sphere-based Luminex xMAPTM technology (Liangos 2007). This technique is an adapta-
tion of the recently developed and validated sandwich ELISA assay (23). For quantification 
of human KIM-1 protein in urine, a sandwich ELISA was used as described previously (24). 
Levels were normalized using urine creatinine values, to account for the dilution effect due to 
brain death-induced diabetes insipidus. 
Statistical Methods
Statistical analysis was performed using the computer program SPSS version 14.0 (SPSS 
Inc., Chicago, IL, USA). Results are expressed as arithmetic means ± standard error of the 
mean. Statistical comparisons between unpaired groups were performed using the Mann 
Whitney test. 
Further, independent predictors of renal function in the kidney recipients of the tested 
donors were assessed using stepwise multiple regression analysis. Three multiple linear 
regression models were developed, examining serum creatinine in the recipient at 14 days, 3 
months and 1 year after transplantation as the dependent variables. The independent vari-
ables in each model were restricted to variables known during organ recovery, and included 
donor age and gender, duration of brain death, duration of hospital stay, cause of brain death 
(trauma, cerebrovascular incident (CVA) or other), serum creatinine, LDH, and CRP dur-
ing admission and at T0 and T1, urinary creatinine, total protein and KIM-1 at T0 and T1. 
All differences were considered to be significant at P<0.05 and all the statistical tests were 
two-tailed.100 101
- Results -
Gene expression of Kim-1 in the rat donor kidney
To quantify Kim-1 gene expression during brain death, real-time quantitative RT-PCR was 
performed. A profound increase of Kim-1 gene expression was found 4h after induction of 
brain death compared to sham operated control rats (46.1 fold induction ± 11.9 vs 1.0 ± 0.5; 
P < 0.01, see Figure 1). At the other, earlier time points, no difference in gene expression was 
seen between brain dead and control animals.
To study the localization of Kim-1 gene expression in the kidney, in situ hybridization of 
Kim-1 mRNA was performed. After 0.5h and 1h hour of brain death, as well as in sham 
operated animals, hardly any Kim-1 mRNA staining could be detected. After 2h of brain 
death, 1 out of 6 rats showed a weak staining for Kim-1 mRNA, while after 4h of brain 
death, 4 out of 6 animals showed a strong staining for Kim-1 mRNA. 
Kim-1 mRNA was primarily localized in those parts of the tubuli which are present in the 
outer medulla extending into the inner cortex, in proximal tubular cells. As expected in staining 
mRNA, staining seemed to appear dispersed throughout the entire cell (Figure 2A and B). 
Figure 1   Kim-1 gene expression in the rat kidney. Gene expression was normalized using  
  β-actin mRNA content and calculated relative to controls using the relative  
  standard curve method. Results are expressed as fold induction, with sham  
  group values fixed at 1. Differences were tested using the Mann-Whitney test.100 101
Kim-1 protein in the rat kidney
To analyze the localization of Kim-1 protein in the kidney immunohistochemistry was 
performed. From the 4 rats that had shown a strong staining for Kim-1 mRNA after 4h of 
brain death, 3 rats also showed a positive staining for subsequent Kim-1 protein formation 
in the kidney. At earlier points in time, as well as in sham operated controls, no Kim-1
protein expression was seen. Tissue sections were not morphometrically quantified, as stain-
ing was weak, compared to in situ hybridization. More importantly, Kim-1 protein expres-
sion co-localized with gene expression as seen with in situ hybridisation. The Kim-1 protein 
was detected at the apical side of tubular epithelial cells (Figure 2C and D). To test whether 
Kim-1 expressing cells are dedifferentiated in the brain dead rat, a staining for vimentin was 
performed. No vimentin staining in Kim-1 positive areas in the kidney was found. 
A B
C D
Figure 2  Kim-1 localisation in the rat kidney. Tissue sections are shown at 100x
  magnification. Localisation of gene expression is shown by in situ hybridisation  
  in a sham operated animal (A) and a 4h brain dead animal (B). Kim-1 protein  
  expression is shown in sham operated animals (C) and after 4h of brain death (D).102 103
Shed Kim-1 protein in rat urine
To quantify Kim-1 protein in urine, the Kim-1 levels shed were measured by Luminex 
ELISA. Kim-1 levels were normalized for the abundance of creatinine from the same sample. 
When urine from sham operated animals was compared to that of brain dead animals a 
significant elevation of Kim-1 protein levels was found in the urine of brain dead animals 
(Figure 3). After 4h of brain death, relative Kim-1 levels were 35.5 ng/mmol creatinine ± 
22.1 as compared to 5.4 ng/mmol creatinine ± 1.1 in sham operated counterparts (P<0.05).  
Assessment in human donors
Following our experiment in the rat model we studied the expression of the KIM-1 gene in 
human kidney biopsy specimens using qPCR. Demographics of the human donors are listed 
in Table 1. KIM-1 gene expression was found to be upregulated 2.5-fold in DBD donors 
compared to living donors (P=0.002) (Figure 4).
Figure 3  Kim-1 protein in rat urine. Kim-1 was measured by Luminex ELISA and
  normalized with urinary creatinine to account for dilution caused by diabetes  
  insipidus in brain death. . Differences were tested using the Mann-Whitney test.102 103
Table 1   Characteristics of human kidney donors.
Donor type  DBD donors  Living donors   P-value
Gender (M/F)  7/13  7/13
Age (years)  47.7±2.1  51.5±2.2  0.6
Death: CVA   11  0
Death: trauma  6  0
Death: other  3  0
Duration of brain death (min)  655±21  0
Hospital stay (h)  72.3±16.5  24a
Serum creatinine: adm/T0/T1  111±26 / 72±7 / 61±6  - / 67.1±4.3 / 60.9±2.1   - / 0.6 / 0.4
Serum LDH: adm/T0/T1  409±83 / 292±66 / 212±30  - / 131.0±3.5 / 141.5±12.9  - /<0.001 / 
                 0.02
Serum CRP: adm/T0/T1     10.8±3.9 / 80.4±19.2 / 60.1±9.7  - / 5.4±0.3 / 5.5±0.3  - / <0.001 /                                                                                     
              <0.001
Creatinine in urine: T0/T1  3.5±0.9 / 2.8±0.6  7.7±1.2 / 4.5±0.9  0.002 / NS
Total protein in urine: T0/T1  13.7±3.7 / 11.3±2.4  5.4±0.6 / 6.8±1.1  NS / NS
KIM-1 in urine: T0/T1  204±47 / 538±137  246±54 / 243±73  NS / 0.012
a Living donors were routinely admitted 1 day before donor operation.
Figure 4  Kim-1 gene expression in human kidney biopsy specimens. Gene expression  
  was normalized using β-actin mRNA content and calculated relative to controls
  using the relative standard curve method. Results are expressed as fold induction,  
  with living group valuesfixed at 1. Differences were tested using the Mann- 
  Whitney test.104 105
In addition, the amount of shedded KIM-1 was determined in urine samples taken from the 
same donors, collected before and during organ recovery. KIM-1 protein was measured in 
the urine using sandwich ELISA. At baseline (T0), no significant differences were found in 
urine KIM-1 levels between DBD and living kidney donors (DBD 203.7 ng/mmol creati-
nine ± 47 vs living 246.1 ng/mmol creatinine ± 54, NS). However, in the urine samples 
taken during organ recovery (T1) we found an increase in KIM-1 levels after the cerebral 
injury and the period of brain death as it rose to levels of 537.7 ng/mmol creatinine ± 137 
in samples from DBD donors compared to 243.0 ng/mmol creatinine ± 73 in samples from 
living kidney donors (P<0.05) (Figure 5). 
Figure 5  KIM-1 protein in human urine. KIM-1 was measured using a sandwich ELISA.  
  T0 living: sample taken at the beginning of living donornephrectomy; T0 BD:  
  sample taken after diagnosis of brain death; T1 living / BD: sample taken just  
  prior to organ retrieval and perfusion. Differences were tested using the Mann- 
  Whitney test.104 105
Next, multiple linear stepwise regression models were used to determine which donor fac-
tors in DBD donors had an independent effect on kidney function after transplantation. As 
we were primarily interested in variables which are known before organ retrieval, variables 
such as cold ischemia time were not included. For the analyses, one year-follow up from one 
kidney only from each DBD donor was randomly chosen. In this cohort, 4/20 recipients 
suffered from delayed graft function, and 1/20 recipients suffered from graft loss in the first 
year. Therefore, no models were made for these outcome variables. Instead, serum creati-
nine levels in recipients at 14 days, 3 months and 1 year after transplantation were taken as 
dependent variables. Outcomes are shown in Table 2.
 
Table 2  Multiple regression models for recipient kidney function after human kidney
  transplantation. Donor variables from Table 1 were entered in the analyses.
Recipient serum creatinine 14 days  Beta (Std.Error)  P-value  R2-value
Donor urinary KIM-1 at T0     0.106  <0.001  0.995
Donor gender    49.975  0.007
Donor urinary KIM-1 at T1    -0.022  0.033
Recipient serum creatinine 3 months
Donor age     1.102 (0.227)  0.008  0.854
Recipient serum creatinine 1 year
Donor serum creatinine at admission  -0.369 (0.016)  0.002  0.997
Cause of donor death: trauma vs   30.367 (2.250)  0.005
                                        non-trauma 
Donor urinary KIM-1 at T1     0.006 (0.001)  0.045106 107
- Discussion -
The major finding of this study, is the distinct rise of Kim-1 gene expression as well as pro-
tein shedding in the urine within 4h of brain death, while morphology of the epithelium is 
still well-retained and serum creatinine levels have changed only little, remaining within the 
normal range. Our results resemble those obtained with the folic acid nephrotoxic model of 
Ichimura et al (25) and suggest that Kim-1 may be a very sensitive biomarker for detection 
of low-level renal injury or early stages of repair during brain death in donors. 
The question arises how early in the injury/repair process of acute kidney damage in brain 
death Kim-1 is expressed. Upon noxious stimuli, surviving tubular cells react with a com-
plex process of dedifferentiation and proliferation, followed by regeneration with renewed 
differentiation (26). Ichimura et al showed (27) that Kim-1 protein is upregulated in 
vimentin-positive tubular cells, with vimentin as a marker of dedifferentiation. Also, Kuehn 
et al showed Kim-1 upregulation in dedifferentiated cells in murine polycystic kidney disease 
(28). In our experiment, we could not find any dedifferentiation as in Kim-1 positive areas in 
the kidney. 
The Kim-1 upregulation in brain death could be a reaction to local ischemia in the kidney 
as Kim-1 is known to increase upon ischemia/reperfusion injury (29). Also, the location 
of Kim-1 expression makes this hypothesis likely, as proximal tubular cells are known to 
be very sensitive to ischemic damage (30). Although all animals were kept stable at a mean 
arterial pressure of 80 mmHg during the period of brain death, a short phase of low systemic 
blood pressure preceding the moment of herniation of the brain stem is a hallmark of brain 
death induction and might have contributed to Kim-1 expression. One could also speculate 
that Kim-1 in the kidney has a role in the inflammatory response that takes place during 
brain death, as Kim-1 shows homology to MAdCAM-1, an adhesion molecule expressed in 
intestine and the nervous system which plays a role in leukocyte homing in intestinal inflam-
mation (31;32).  
To see whether our findings in the rat model are also present in the human situation we then 
investigated upregulation and shedding of KIM-1 in a consecutive series of regional donors 
retrieved by our team. We compared the results to those from living donor kidneys at our in-
stitution. This is the first study to report on KIM-1 shedding in the urine of in human DBD 
donors. As the brain death period in human donors typically amounts to over eight hours 
(33;34), the finding of increased KIM-1 levels could create a ‘window of opportunity’ for 
diagnostic and therapeutic measures during donor management and selection of recipients. 
To investigate whether KIM-1 shedding in DBD donors had any predictive value for kidney 
function after transplantation, we built three multiple linear regression models. In these 
models, we chose to include only donor variables which can be known before actual organ 
recovery. To our surprise, KIM-1 at T0 turned out to be an independent positive predictor 
of serum creatinine at 14 days and 1 year after transplantation. Although KIM-1 levels at T0
do not differ between DBD donors and living donors on average, the difference within the group 
of DBD donors reflects the differences seen in transplantation success of DBD donor grafts.  106 107
Summarizing, in this study we have shown that Kim-1, which is known to be a specific 
marker for renal tubular damage, is substantially upregulated after 4 h of brain death in the 
rat model and is shed into the urine. In addition, patient data show for the first time that 
KIM-1 is also upregulated in human DBD organ donors compared to living kidney donors. 
KIM-1 measured at the time of brain death diagnosis is an independent predictive factor for 
short time kidney function after transplantation. On the basis of our experimental and first 
clinical findings we feel that further clinical study is justified to assess the efficacy of KIM-1 
as a viability marker and predictor of outcome after donation and kidney transplantation.108 109
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- Abstract -
Objective:
We hypothesized that donor treatment of deceased brain dead donors would lead to a de-
crease in inflammatory responses seen in brain death and to a restoration of kidney function.
Design:
A standardized slow induction rat brain death model followed by evaluation of kidney
function in an isolated perfused kidney model.
Settings:
Surgery Research Laboratory, University Medical Center Groningen.
Subjects: Male Fisher rats.
 
Interventions:
Donor treatment with erythropoietin (EPO), carbamylated EPO (cEPO) which lacks
erythropoietic activity, or vehicle.
Measurements and Main Results:
In brain death, cEPO, and to a lesser extent EPO, was able to decrease the expression of
several proinflammatory genes and to decrease the infiltration of PMNs in the kidney. No 
effect on tubular injury parameters was seen. Kidney function decreased almost by 50% after 
brain death, but was fully restored after treatment with both cEPO and EPO.
Conclusions:
cEPO can inhibit the inflammatory response caused by brain death more effectively than 
EPO, while both substances can restore kidney function after brain death.112 113
- Introduction -
For most patients with end-stage renal failure kidney transplantation is the therapy of 
choice. The majority of donor organs is retrieved from heart beating deceased brain dead 
(DBD) donors, although donor shortage has lead to an increased use of kidneys from living 
donors (LD) or from donors after cardiac death (DCD). Living donor grafts are associated 
with better survival and lower rates of delayed graft function than kidneys retrieved from 
DBD donors (1;2). Also, cerebral injury and brain death in the donor may be a risk factor for 
developing vascular rejection after transplantation (3). 
This difference in success between LD and DBD donors can not be fully explained by factors 
such as warm and cold ischemia times or HLA mismatches (1). The difference can at least 
be partly attributed to pathophysiological changes in the donor which take place during the 
brain death process (4;5). Experimental as well as clinical studies have shown that brain 
death negatively affects hemodynamic stability and hormone regulation in the donor (6;7). 
Recently, our group as well as others have demonstrated that brain death induces a marked 
endothelial activation and substantial pro-inflammatory responses in potential donor organs, 
which may enhance the immunogenicity of the graft-to-be thereby affecting the allograft 
response in the recipient (8-10). Pretreatment of the DBD donor to counteract these effects 
may therefore be an elegant option to improve transplantation outcome.    
Erythropoetin (EPO) is a pleiotropic cytokine originally identified for its role in erythro-
poiesis (11). In the last years, it has become clear that EPO also exerts a number of cytopro-
tective functions. Treatment with EPO was found to be neuroprotective after ischemia, by 
diminishing apoptosis and necrosis in the brain (12). Also, EPO stimulates cardiomyocyte 
proliferation and decreases myocardial infarct size (13;14). In the kidney, administration of 
EPO leads to heat shock protein production, and decreases apoptosis and serum creatinine 
in ischemia/reperfusion (15). Furthermore, EPO helps to preserve endothelial integrity and 
to diminish inflammation (16-18). These effects make EPO an interesting candidate for 
improving graft quality in DBD donors. However, despite its promise, EPO treatment is also 
associated with some (detrimental) side effects: increasing the hematocrit, an elevation of  
blood pressure and increased risk of thrombosis (19).  
These disadvantages might be neutralized by using a modified EPO derivative. Recently, 
several studies have been published regarding the use of carbamylated EPO (cEPO). While 
EPO signals through the homodimeric erythropoietin receptor (EPOR2) to exert its hema-
topoietic effects, cEPO acts upon a heteroreceptor complex comprising both EPOR and the 
common β receptor subunit (βcR, also known as CD131). It has been shown that cEPO 
retains its tissue protective effects but does not have any hematopoietic activity (20;21). 
Recently, several studies have been published regarding the use of cEPO. It was shown that 
cEPO protects against radiation-induced brain injury and  ischemia/reperfusion injury in 
the myocardium (22;23). In a comparison of cEPO and EPO treatment in an ischemia/
reperfusion model of the kidney, cEPO was shown to be more successful in inhibiting apop-
tosis and stimulating proliferation in tubular cells (24).114 115
In this study we have investigated the cytoprotective effects from both EPO and cEPO on 
the endothelium and its anti-inflammatory properties. We postulated that both forms of 
erythropoetin would exert protective effects on the kidney graft-to-be during brain death. 
Therefore, we have investigated the effects of both EPO and cEPO in a rat brain death 
model. In addition, we have tested the effect of both substances on kidney function after 
donation.
- Materials and Methods -
Animals
Adult male Fisher F344 rats (250-300 g) were used. Animals received care in compliance 
with the guidelines of the local animal ethics committee according to the Experiments on 
Animals Act (1996) issued by the Netherlands Ministry of Public Health, Welfare and 
Sports.
Experimental groups
To study the effects of erythropoietin (EPO), as well as the effects of carbamylated erythro-
poietin (cEPO) administration in the DBD donor, four groups (n=6) were studied. 
  • Group 1: Administration of cEPO 10 μg/kg i.v., 4h brain death, kidney reperfusion  
    in isolated perfused kidney model (IPK)
  • Group 2: Administration of EPO 10 μg /kg i.v., 4h brain death, kidney reperfusion  
    in IPK model
  • Group 3: Administration of vehicle i.v., 4h brain death, kidney reperfusion in
    IPK model
  • Group 4: Sham operated control group, kidney reperfusion in IPK model
EPO and cEPO were provided by Warren Pharmaceuticals, Ossining, NY.
Brain death model
Brain death was induced as described previously (25). Briefly, the procedure was as follows: 
Animals were anesthetised using isoflurane with O2. A cannula was inserted in the femoral 
artery for blood pressure monitoring. Animals were intubated via a tracheostomy and 
ventilated throughout the experiment. Through a frontolateral borehole in the skull a no. 4 
Fogarty catheter (Edwards Lifesciences Co., Irvine, CA) was placed subdurally and slowly in-
flated (16 μL/min) with saline using a syringe pump (Terufusion, Termo Co., Tokyo, Japan). 
Inflation of the balloon was stopped during the subsequent sharp rise in blood pressure, 
which reflects the autonomic storm at the beginning of brain death. This typically occurred 
30min after starting balloon inflation. Brain death was confirmed by the absence of corneal 
and pupillary reflexes and an apnea test. During brain death, animals received no anesthesia. 
If blood pressure fell below 80 mmHg, it was restored by the administration of HAES 10% 114 115
(Fresenius Kabi AG, Bad Homburg, Germany). Temperature was monitored rectally and 
kept constant. Animals were kept brain dead for 4h. 
At the end of the brain death period, donors were heparinized with 500 IU heparin. A 
laparotomy was performed and blood and urine were collected from the aorta and the
bladder. Next, kidneys were flushed with saline and removed. The left kidney artery was 
cannulated, weighed and placed in an isolated perfused kidney setup (IPK) for evaluation of 
kidney function. Blood and urine were centrifuged for 10 min. at 960g. Urine supernatant 
and blood plasma were collected and stored at -80°C. Tissue from the right kidney was snap 
frozen in liquid nitrogen. Sham operated rats, which had been anesthetized for the sham 
operation (all procedures except intracranial balloon inflation) and for 30 min thereafter to 
mimic the induction of brain death served as controls.  
Reperfusion with the Isolated perfused kidney model
The left kidney was evaluated in the isolated perfused kidney (IPK) model as described 
before (26-28). In this model, the kidney artery is cannulated, placed in an organ chamber 
and perfused using a warmed and oxygenated perfusion fluid supplemented with creatinine. 
In this way, renal function can be measured without concomitant factors due to a recipient 
in a transplantation model. A draw back of the model is that fractional sodium reabsorption 
is less than in vivo. The kidney was continuously perfused via the renal artery with warmed 
(37°C) and oxygenated (95% O2 and 5% CO2 gas mixture) Krebs-Henseleit-bicarbonate 
(KHB) solution with added amino acids at a pH of 7.4 ± 0.05, PO2 > 100 kPa, by using 
a roller pump (Ismatec mv-ca/04, Ismatec, Glattbrugg, Switzerland) delivering a constant 
flow throughout the experiment. Creatinine 0.8 g/L was added to the perfusion solution to 
be able to measure creatinine clearance. After connecting the kidney, vascular responses were 
monitored by an electromechanical pressure transducer (Cobe, Arvada, USA) and the flow 
was gradually increased in the first 10 minutes to reach a kidney perfusion pressure of 100 
mmHg. Kidneys were perfused during 90 min. Samples of urine and perfusate were were 
collected at 15-min intervals throughout the experimental period and stored at -80°C.
Volumes of urine production were recorded during the experiment. A scheme of the experi-
mental setup is shown in Figure 1. 116 117
Biochemical determinations
At the Laboratory Center of the University Medical Center Groningen (Mega, Merck),
the following measurements were determined in a routine fashion: Creatinine in plasma, 
perfusate and urine (by the Jaffé method (29)), alanine aminotranspherase (ALAT) and
aspartate aminotranspherase (ASAT) enzyme activity in plasma (30), and lactate dehy-
drogenase (LDH) activity in plasma (based on the conversion rate of lactate to pyruvate). 
Sodium in urine and perfusate was determined by flame photometry. 
Glomerular filtration rate was approximated by creatinine clearance rate during the Isolated 
Perfused Kidney setup which was calculated using the formula:
Creatinine clearance = [creatinine]urine x urine volume / [creatinine]perfusion fluid.
Fractional sodium excretion was calculated during the Isolated Perfused Kidney setup using 
the formula :
Sodium excretion % = ([Na]urine x [creatinine]perfusion fluid / [Na]perfusion fluid x [creatinine]
urine) x 100.
Activity of the brush border enzyme alanine aminopeptidase (AAP) was measured in urine 
to determine the amount of tubular damage. The method used is based on hydrolysis of 
L-alanine-p-nitroanilide into p-nitroaniline. Enzyme activity was expressed as the amount of 
enzyme required to release 1 μmol of product per minute.
LEGEND
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Figure 1 Isolated perfused kidney (IPK) setup116 117
Malondialdehyde was estimated by measuring the amount of thiobarbituric acid-reactive 
substances (TBARS) in plasma. TBARS are formed when free oxygen radical molecules 
react with proteins and phospholipids in membranes and is therefore a measure of lipid 
peroxidation and oxidative damage. TBARS levels were determined by a method based on 
the reaction with thiobarbituric acid (TBA) at 92–97°C, producing a pink pigment having 
an absorption maximum at 530 nm.
Real-Time RT-PCR on renal tissue
To investigate differences in gene expression, total RNA was isolated from snap frozen cross-
section kidney slices, using the TRIzol method and including a DNase treatment step. RNA 
samples were verified for absence of genomic DNA contamination by performing RT-PCR 
reactions, in which the addition of reverse transcriptase was omitted, using GAPDH primers.
Gene-specific primers were designed using the computer program Primer Express 2.0
(Applied Biosystems, Foster City, CA, USA) using published gene sequences. Studied genes,  
primer sequences and product sizes are given in Table 1. 
Table 1  Primer sequences used
gene     primer sequences  accession number  bp
β-actin    GGAAATCGTGCGTGACATTAAA  NM_031144.2  74
    GCGGCAGTGGCCATCTC
Epo    TCACGAAGCCATGAAGACAGAA  NM_017001.1  100
    GCTGTTGCCAGTGGTATTTTTTAA
Epo-receptor  TTGGTGTGTTTCTGGGAGGAA  NM_017002.2  67
    AGCTGGTAAGAGAAGCTGTAGTTGAA
TNF-α    AGGCTGTCGCTACATCACTGAA  NM_012675.2  67
    TGACCCGTAGGGCGATTACA
IL-1β    CAGCAATGGTCGGGACATAGTT  NM_031512.1  75
    GCATTAGGAATAGTGCAGCCATCT
IL-6    CCAACTTCCAATGCTCTCCTAATG  NM_012589  89
    TTCAAGTGCTTTCAAGAGTTGGAT
e-selectin    GTCTGCGATGCTGCCTACTTG  NM_138879.1  73
    CTGCCACAGAAAGTGCCACTAC 
p-selectin    TCTCTGGGTCTTCGTGTTTCTTATCT  NM_013114.1  80
    GTGTCCCCCTAGTACCATCTGAA
VCAM-1   TGTGGAAGTGTGCCCGAAA  NM_012889.1  84
    ACGAGCCATTAACAGACTTTAGCA
Kim-1    AGAGAGAGCAGGACACAGGCTTT  NM_173149.1  75
    ACCCGTGGTAGTCCCAAACA
BAX    GCGTGGTTGCCCTCTTCTAC  NM_017059.1  74
    TGATCAGCTCGGGCACTTTAGT
BCL-2    CTGGGATGCCTTTGTGGAA  NM_016993.1  70
    TCAGAGACAGCCAGGAGAAATCA
PAi-1    GCACAGGAAGGTAACGTGAATCTA  NM_012620.1  72
    TTTTTTTCCAGTGGAGATGTAACG
HO-1    CTCGCATGAACACTCTGGAGAT  NM_012580.2  74
    GCAGGAAGGCGGTCTTAGC118 119
Amplification and detection of PCR products were performed with the Applied Biosystems 
7900 HT Real Time PCR System (Applied Biosystems, Foster City, USA) using emis-
sion from SYBR Green (SYBR Green master mix, Applied Biosystems). All assays were 
performed in triplicate. After an initial activation step at 50 °C for 2 min. and a hot start at 
95°C for 10 min., PCR cycles consisted of 40 cycles at 95°C for 15 sec. and 60°C for 60 sec. 
Specificity of qPCR products was routinely assessed by performing a dissociation curve at 
the end of the  amplification program. Gene expression was normalized using the mean of 
β-actin gene expression from the same sample and calculated relative to controls using the 
relative standard curve method. Results were finally expressed as 2ΔΔCT (CT threshold cycle). 
HIS-48 staining on renal tissue cryosections 
To detect polymorphonuclear cells (PMNs) in the kidney, immunohistochemistry was
performed on 5 μm kidney tissue cryosections. Sections were fixated for 10 minutes using 
acetone. Next, sections were stained with HIS-48 mAb (supernatant, two times diluted) 
using an indirect immunoperoxidase technique. Endogenous peroxidase was blocked using 
H2O2 0.01% in PBS for 30 minutes. After thorough washing, sections were incubated with 
horseradish peroxidase-conjugated rabbit anti-mouse IgG as a secondary antibody for 30 
min., followed by goat anti-rabbit IgG as a tertiary antibody for 30 min. (both from Dako, 
Glostrup, Denmark). The reaction was developed using 9-amino-ethylcarbazole as
chromogen and H2O2 as substrate. Sections were counterstained using Mayer’s hematoxylin 
solution (Merck, Darmstadt, Germany). Negative antibody controls were performed.
Localization of immunohistochemical staining was assessed by light microscopy. For each 
tissue section, positive cells were counted in 10 microscopic fields of the cortex at 40x magni-
fication. 
Statistical Methods
Statistical analysis was performed using the computer program SPSS version 14.0 (SPSS 
Inc., Chicago, IL, USA). Groups were tested for normal distribution using the One-Sample 
Kolmogorov-Smirnov Test. Results are expressed as arithmetic means ± standard error of 
the mean. To investigate differences in kidney function during IPK, AUCs (area under the 
curve) for creatinine clearance were calculated. Statistical comparisons between unpaired 
groups were performed using ANOVA. All differences were considered to be significant at 
P<0.05. 118 119
- Results -
Brain death experiments
Induction of brain death showed a consistent and uniform pattern in blood pressure as 
described before (25) and took approximately 30 minutes. All animals were kept at a mean 
arterial pressure of at least 80 mmHg during the experiment. In the brain dead groups,
infusion of 2.39 mL ± 0.42 of HAES 10% was needed to maintain stable blood pressures. 
No difference in required HAES infusion between brain dead groups was found (P=0.41).
Biochemistry after brain death
Blood was collected at the end of the animal experiments. After brain death, creatinine 
levels in plasma were 116 μmol/L ± 9.7, compared to 72 ± 6.5 in sham operated animals 
(P=0.002). EPO and cEPO administration had no effect on creatinine levels. In urine, no 
significant differences in creatinine levels were found between brain dead compared with 
sham operated animals (9.0 ± 1.2 mmol/L vs 9.8 ± 1.5 mmol/L, P=0.36). Both EPO 
and cEPO administration diminished urinary creatinine concentration (EPO: 4.5 ± 0.25 
mmol/L, cEPO: 5.3 ± 0.26 mmol/L). Calculation of creatinine clearance during brain death 
was not possible, as the total urine production could not be measured reliably during the 
brain dead period.
To evaluate cellular damage, urine alanine aminopeptidase (AAP), and plasma lactate dehy-
drogenase (LDH), alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), 
thiobarbituric acid-reactive substances (TBARS) were measured. LDH was increased 
significantly by brain death, but cEPO administration decreased LDH release to levels seen 
in the sham operated group. On the other damage markers, no effect from EPO or cEPO 
administration was seen.  
Table 2  Cellular injury markers in urine and plasma
    sham  BD  BD + cEPO  BD + EPO
AAP (mM/min)  0.7 ± 0.1  11.1 ± 2.0*  14.9 ± 2.5*  13.9 ± 1.7*
LDH (U/L)  150 ± 21  226 ± 49  148 ± 16†  309 ± 43*
ALAT (U/L)  48 ± 3  54 ± 7  52 ± 5  47 ±6
ASAT (U/L)  60 ± 4  88 ± 7  81 ± 10  80 ± 9 
TBARS (μM)  2.1 ± 0.1  2.4 ± 0.1  2.4 ± 0.4  2.6 ± 0.4
AAP: alanine aminopeptidase; LDH: lactate dehydrogenase; ALAT: alanine aminotrans-
ferase ; ALAT: aspartate aminotranspherase; TBARS: thiobarbituric acid-reactive
substances 
* significant at p<0.05 as compared to sham operated controls
† significant at p<0.05 as compared to BD120 121
Gene expression in the kidney
Outcomes of RT-PCR on kidney tissue collected after the animal experiments are summa-
rized in Figure 2 and Table 3.
As EPO administration can downregulate EPO production (31), gene expression of EPO 
and EPO receptor (EPOr) was determined in the kidney. EPO but not cEPO administra-
tion decreased EPO production significantly (mean fold induction 0.2 vs 1.1 in sham
operated animals, P=0.004, Fig 2). 
Inflammation and endothelial cell activation were studied by measuring gene expression
of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6, and the adhesion molecules 
e-selectin, p-selectin and vascular cellular adhesion molecule-1 (VCAM-1).
For IL-6 a profound 85-fold induction of gene expression was seen after brain death com-
pared to sham operated animals (P=0.002), while cEPO treatment reduced this to a 25-fold 
induction (P=0.003). EPO treatment did not have any beneficial effect (Fig 2). Treatment 
with cEPO reduced IL-1β expression from na 8.4- fold to a 2.6-fold induction (p=0.01 
compared to BD without treatment), whereas EPO treatment did not have this effect (Fig 
2). For e-selectin gene expression, an 9.2-fold induction was found after brain death, com-
pared with sham operated animals. This was only decreased significantly by cEPO admin-
istration. VCAM-1 gene expression was slightly but significantly downregulated after both 
EPO and cEPO administration. 
Figure 2  Kidney gene expression120 121
Kidney injury molecule (Kim-1) was studied to assess tubular damage. A 83-fold Kim-
1 gene induction was found after brain death, compared with sham operated animals 
(P=0.004). EPO and cEPO treatment had no effect on Kim-1 gene expression (Fig 2). 
Apoptosis was studied by calculating BAX/BCL-2 ratios, where an increased ratio signifies 
an increased level of apoptosis. cEPO and EPO did not have any effect on this ratio.
As EPO might exert some of its cytoprotective effects during hypoxia through stimulation
of the cytoprotective heme oxygenase-1 (HO-1) (32), HO-1 gene expression was deter-
mined. Finally, PAI-1 gene expression was determined, as even a short time of exposure to 
EPO is known to increase the production of plasminogen activator inhibitor-1 (PAI-1) in 
endothelial cells (35). In this study, EPO and cEPO administration had no effects on HO-1 
and PAI-1 gene expression.
 
Table 3  Kidney gene expression
Fold induction  BD  BD + cEPO  BD + EPO
EPO-receptor  0.4 ± 0.06*  0.3 ± 0.06*  0.3 ± 0.05 
TNF-α    6.2 ± 1.90*  4.8 ± 3.22  6.6 ± 3.23
IL-1β    8.4 ± 1.03*  2.6 ± 0.74†  6.8 ± 2.40
p-selectin    38.9 ± 7.9*  15.6 ± 1.2†*  34.2 ± 13.3† 
VCAM-1   3.5 ± 0.19*  2.4 ± 0.04†*  2.3 ± 0.28†
BAX    1.4 ± 0.09*  0.9 ± 0.08  0.9 ± 0.06†
BCL-2    0.7 ± 0.03*  0.5 ± 0.04†*  0.5 ± 0.01†
BAX/BCL-2 ratio  2.1 ± 0.22*  1.7 ± 0.24*   1.7 ± 0.08 
PAI-1    2.8 ± 0.53*  1.9 ± 0.16*  3.2 ± 0.74
HO-1    15.8 ± 3.9*  35.9 ± 20.1  36.1 ± 15.7
Gene expression in the sham operated control group was set at 1. TNF: tumor necrosis
factor; IL: interleukin; VCAM: vascular cell adhesion molecule; BAX: BCL-2 associated x 
protein; BCL: B-cell lymphoma; PAI: Plasminogen activator inhibitor; HO: heme oxygenase.
* significant at p<0.05 as compared to sham operated controls
† significant at p<0.05 as compared to BD123 122
PMN infiltration in the kidney 
To study influx of polymorphonuclear cells (PMNs) in the kidney, renal cryosections were 
stained with HIS-48 mAb. The number of positive cells per microscopic field was 3.3 ± 
0.3 in sham operated controls, but was elevated to 7.4 ± 0.7 positive cells in the brain death 
group  (P=0.001). Treatment with both EPO and cEPO diminished this effect to 5.1 ± 0.8 
and 4.0 ± 1.2 positive cells, respectively, the effect reaching statistical significance at cEPO 
treatment EPO vs brain death control: p=0.06, cEPO: P=0.03) (Fig 3A-D). On histology, 
no structural changes were seen in the different groups.
Figure 3  PMN infiltration in the kidney. 40x magnification.
A: sham operated controls  C: BD + EPO treatment
B: BD  D: BD + cEPO treatment123 122
Kidney function during IPK
Renal function was evaluated after the animal experiments by assessment of the kidney in an 
isolated perfused kidney model. Kidneys were evaluated during 90 minutes. Every 15 min., 
perfusate samples and urine production were collected to determine creatinine clearance. 
Area under the curve (AUC) was calculated for each experimental group. In kidneys from 
brain dead animals, creatinine clearance was clearly decreased compared with sham oper-
ated animals (P=0.035) (Fig 4). Treatment with both EPO and CEPO increased creatinine 
clearance to the level of sham operated animals (EPO: P=0.009, CEPO: P=0.016). Sodium 
concentration was measured in urine and perfusate, and fractional sodium excretion was 
calculated. As can be expected in an isolated perfused kidney model (27), fractional sodium 
excretion was increased to 20-30% of that in vivo, but no significant differences were found 
between the experimental groups.  
Figure 4  Kidney function during reperfusion in the Isolated Perfused Kidney model124 125
- Discussion -
In the present study, we demonstrated the beneficial effects on the kidney of EPO and cEPO 
treatment in brain death. The effects can be divided into two categories. 
In the first place, we examined the anti-inflammatory and endothelium preserving capaci-
ties of cEPO and EPO. EPO treatment reduced the expression of VCAM-1, an adhesion 
molecule that regulates leucocyte migration from the blood into tissues. Also, subsequent 
leucocyte migration was diminished, as shown by our staining for PMN infiltration in the 
kidney. cEPO, in addition, reduced the expression of p-selectin and e-selectin, both early 
adhesion molecules mediating the initial attachment of leucocytes to endothelial cells (34). 
Also, cEPO directly attenuated the expression of IL-1β and IL-6, both major pro-inflamma-
tory cytokines which stimulate immune cells, promote leucocyte adhesion to the endothe-
lium and thrombosis (35;36). Compared to EPO, cEPO treatment caused a lower PMN 
infiltration in the kidney, which can  be explained by the lower grade of inflammation found 
with the reduced expression levels of cytokines and selectines.
Secondly, the effect of cEPO and EPO on kidney function after brain death was evaluated 
using an isolated perfused kidney model. In this model, creatinine clearance can be deter-
mined very accurately, without interference of recipient related variables when a model of 
kidney transplantation is used. Our study reveals that brain death causes a significant de-
crease in kidney function. This phenomenon has not been described before, as the determi-
nation of kidney function in the DBD donor is complicated due to factors as hemodynamic 
instability and its treatment with fluids and inotropic medication, and the presence of brain 
injury related diabetes insipidus. Recently, Blasco et al however reported the incidence of 
a more than 20% increase of serum creatinine level between intensive care unit admission 
and graft harvest to be 41% in DBD donors (37). These results confirm our measurements 
at the end of the brain death experiments, when plasma creatinine is increased in all brain 
dead groups. Part of this ‘in vivo’effect may be explained by a state of low hydration in all 
brain dead animals, as intravenous infusion requirement was based on mean arterial pres-
sure and not on diuresis. In the IPK setup we were able to demonstrate the independent 
effect of brain death on kidney function. The treatment effect of either cEPO or EPO during 
brain death experiments could only be inferred indirectly: while urine creatinine concen-
trations are decreased in the treated groups suggesting an increased diuresis during brain 
death after treatment with cEPO and EPO, intravenous infusion requirement (defined as 
loss of haemodynamic stability) was not increased. However, the IPK setup, measuring true 
glomerular filtration rate, did show a complete neutralization of the brain death induced 
decrease in kidney function after treatment with both EPO and cEPO.
The decreased expression of pro-inflammatory cytokines and adhesion molecules as meas-
ured in this study indicates a protective effect of EPO and cEPO on the endothelium. In 124 125
contrast, we found no effect of EPO or cEPO treatment on tubular cells: Alanine amino-
peptidase (AAP) levels, a urinary marker for tubular damage, were not affected by EPO 
or cEPO administration, and the expression of kidney injury molecule-1 (KIM-1) which 
was highly increased in brain death, was not altered by EPO or cEPO either. Therefore, the 
improvement in kidney function as observed after EPO and cEPO administration is most 
likely caused by an improvement in endothelial and thus glomerular function of the kidney.  
The effects of EPO and cEPO administration in our model were observed after a single 
treatment and within a time period of several hours. This enlarges the clinical applicability 
and reduces the unwanted side effects of EPO. Parsa et al have shown that these effects take 
only place after a minimum of four days’ treatment with EPO (15). Treatment with cEPO 
was even more favourable, given its higher efficacy and the absence of erythropoietic and 
thrombotic activity (38). 
In this model we pretreated BD rats. Following experiments are needed to investigate whether 
EPO and/or cEPO are capable of improving renal quality after BD induction by repairing 
existing damage. Some studies indicate the EPO and cEPO are not only protective but also 
stimulate repair mechanisms. Fiordaliso et al showed that cEPO administration given 5 min 
before reperfusion after a 40 min period of coronary artery ligation resulted in a significant 
reduction of cardiomyocyte loss and improved left ventricle function (23). In a model of
cerebral injury, EPO administration up to six hours after occlusion of the middle cerebral 
artery attenuated the volume of cerebral infarction as much as 75% in rats (21).    
- Conclusions -
In this study, we show that pretreatment with a single dose of cEPO, a modified derivative of 
EPO without erythropoietic properties, can reduce several inflammatory responses induced 
by brain death and can preserve vascular integrity.Treatment with cEPO proved to be more 
effective than EPO in the reduction of inflammatory parameters as measured in the brain 
dead donor. In addition, cEPO and EPO are able to preserve kidney function after brain 
death. We conclude that cEPO could be an interesting renoprotective candidate for clinical 
intervention during donor management and prior to retrieval followed by ischemia/reper-
fusion injury.126 127
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- Summary -
In the last decades, kidney transplantation has become the treatment of choice for end-stage 
renal failure. The main source for donor organs in kidney transplantation has traditionally 
been heart-beating brain dead patients (donation after brain death, DBD). Due to the per-
sistent shortage of donor organs, however, living (un)related donors and, to a lesser extent, 
kidneys from non-heart-beating donors have been increasingly accepted for transplantation. 
Transplantation with well-matched living donor-recipient combinations was known to 
have superior results compared to those with DBD and NHB donor kidneys. During the 
past fifteen years it became obvious that fully mismatched living-unrelated grafts also have 
better survival outcomes than kidneys retrieved from DBD donors with a very reasonable 
match for HLA antigens. This difference in results cannot be fully attributed to prolonged 
cold ischemia times in grafts procured from DBD donors, since no significant effect of cold 
ischemia time on kidney transplantation outcome was seen with preservation times up to 24 
hr. Thus, other risk factors must be responsible and should explain the difference in success 
rates between living and cadaveric kidney transplantation.
In the past years, our group has focused on the unphysiologic state of brain death as a key 
player and potential risk factor that influences graft survival. Brain death has been known for 
many years to affect the circulatory and hormonal state of the donor. Attempts to neutral-
ize these effects by monitoring blood pressure and by hormone suppletion therapy have, 
unfortunately, not been able to reverse these adverse effects. In this thesis, we have focused 
on the progressive pro-inflammatory response to brain death in the kidney and the detec-
tion of these effects prior to transplantation. We have now studied the characteristics of this 
inflammatory response, hypothesized about its origin and also investigated mechanisms of 
repair. Protective mechanisms during brain death may lead to a better outcome after trans-
plantation, so we have evaluated the effect of the duration of brain death. The early detec-
tion of kidney injury due to cerebral injury was described. It was also our aim to test novel 
more specific biomarkers for their ability as early markers of kidney injury. Finally, we have 
included an intervention study using a modified form of erythropoietin to improve kidney 
quality during brain death.   
In the Introduction of this thesis, the current knowledge and concepts as regards the nature 
of brain death and its effects on organ quality is described. Irreversible cerebral injury leading 
to brain death is usually the result of intracranial hemorrhage or traumatic brain injury. Both 
lead to a mass effect in the brain and compression of brain tissue, ultimately forcing the brain 
stem to herniate with loss of brain stem reflexes and finally complete respiratory arrest. Dur-
ing the increase of intracranial pressure, a Cushing reflex is observed due to catecholamine 
release, followed by hypotension due to progressive sympathetic deactivation. Most patients 
suffer from complete dysfunction of the hypothalamo-pituitary axis, as reflected by the onset 
of diabetes insipidus, as well as dysfunction of the hypothalamic-pituitary-thyroid axis. 
130Whether substitution with triiodothyronine, cortisol, and insulin has beneficial effects on 
donor condition still remains questionable. In addition, shortly after brain death, high levels 
of proinflammatory cytokines such as interleukin-1β and interleukin-6, soluble cytokine 
receptors like sIL-2 receptor and sTNF receptor II, and vasoactive substances like endothe-
lin-1 can be detected in the peripheral blood of the donor. Release of these substances from 
the injured brain, as well as ischemia or vascular shear stress due to haemodynamic instability 
may be responsible for the effects seen in periferal organs. In the heart, systemic as well as
local release of catecholamines leads to myocyte necrosis, and endothelial cell injury is a 
starting point for allograft vasculopathy. In the lung, brain injury results in neurogenic pul-
monary edema, aggravated by the effects of mechanical ventilation. IL-8 is upregulated and 
PMNs are recruited to invade into the lung tissue. In the liver, an increase of transaminases 
is seen during brain death. Also, endothelial activation and influx of PMNs and macro-
phages can be seen. In an animal model, graft survival decreased significantly by using a liver 
from a brain dead donor, even without cold ischemia. In the kidney, a progressive inflamma-
tory response with endothelial activation is found, as well as a decrease in kidney function. 
On the other hand, HO-1 and Hsp70 are significantly elevated in DBD donors. HO-1 and 
Hsp70 encode proteins with several cytoprotective properties against ischemia, heat and tox-
ins. DNA microarray analysis of kidney tissue showed upregulation of several genes in brain 
death, which can be categorized in three groups: genes involved in inflammation and coagula-
tion, in cell division and fibrosis, and in protection and repair processes. These findings in 
brain death of an inflammatory response at organ level together with a first attempt of the 
organ to protect itself offer new opportunities in donor treatment and subsequent preserva-
tion. When focusing on specific blocking or stimulation of these processes, graft survival of 
kidneys retrieved from DBD donors may be enhanced. This Introduction is followed by a 
general Rationale outlining the chapters of this thesis. 
In Chapter 3, we focused on the effects of BD on inflammatory response and stress-related 
heat shock proteins in the kidney. Kidney biopsy specimens and serum were obtained during 
organ retrieval from DBD and living organ donor controls. With these biopsy specimens 
immunohistochemistry and semiquantitative reverse transcriptase-polymerase chain reac-
tion were performed. These data, as well as clinical and laboratory parameters from DBD 
donors were recorded and related to outcome data of recipients of those kidneys. Immuno-
histochemistry studies showed an increase of E-selectin and interstitial leukocyte invasion in 
DBD donors compared with controls. RT-PCR showed a threefold increased heme oxyge-
nase-1 and Hsp70 gene expression after BD. Levels of monocyte chemotactic protein-1 and 
transforming growth factor-β were twice as high after brain death but did not reach signifi-
cance. Transplantation outcome was influenced by several donor variables: positively most 
notably by donor treatment with desmopressin and negatively by high serum urea levels 
during brain death and by high intercellular adhesion molecule and vascular cell adhesion 
molecule expression in the kidney. Heme oxygenase-1 proved to have a protective function, 
but only in kidneys from living donors. The presence of interstitial leukocytes and the early 
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adhesion molecule E-selectin in DBD donor kidneys indicates an early-phase inflammatory 
process during organ retrieval. Elevated levels of monocyte chemotactic protein-1 and trans-
forming growth factor-β suggest a role for monocytes/macrophages in this phase. This leads 
to our conclusion that BD causes a stress-related response against which protective heat 
shock proteins are formed in the graft-to-be. This stress response in the DBD donormay be 
too severe to be fully counteracted by elevated heat shock proteins. Heat shock proteins may 
however be a promising starting point for interventions in the donor.
The upregulation of cytokines and adhesion molecules in the kidney may be aggravated by 
disturbances of the donor’s milieu intérieur by other organs. It has been known that many 
DBD donors have a higher endotoxin load and more bacterial translocation from the gut 
compared to living donors. Endotoxemia could trigger a decrease of vascular integrity lead-
ing to increased permeability in the intestine or lung by influencing the Angiopoietin-Tie 
ligand-receptor system. A decreased Angiopoietin 1/Angiopoietin 2 ratio is associated with 
increased morbidity and mortality during sepsis, while an increased ratio can maintain vas-
cular integrity and dampen the inflammatory response. Therefore, in Chapter 4 we studied 
Ang-1 and Ang-2 in donor serum, as well as the amount of Lipopolysaccharide Binding 
Protein (LBP) as a quantification of endotoxemia. Also, VEGF was studied as Ang-2 primes 
endothelium to respond to VEGF. DBD donors had higher serum levels of LBP, Ang-2 and 
VEGF than living kidney donors, leading to a decreased Ang-1/Ang-2 ratio indicative of 
pro-inflammatory activation. In the univariate regression analysis, high Ang-2 levels in DBD 
donors predicted the chance of rejection in the first year after kidney transplantation. This 
indicates that Ang-2 is a potential marker for organ quality assessment in the donor.
Possible leakage of detrimental substances from the brain into the circulation of DBD 
donors, as well as the rise in cytokine and chemokine expression of potential donor organs 
during brain death suggests that early organ retrieval in DBD donors may be beneficial. On 
the other hand, the expression of protective heat shock proteins could be seen as a mecha-
nism by which the body tries to repair present damage. Only little data is available but in two 
publications it is suggested that a longer BD period might be better for donor organ quality. In 
Chapter 5 of this thesis, we report a large retrospective analysis using data from the OPTN 
database to study the effects of duration of brain death (BDdur) on outcome after kidney 
transplantation. 20,773 kidney donor and recipient couple data were studied. BDdur was 
calculated as the period between declaration of brain death and aortic cross clamping. The 
effect of BDdur on delayed graft function (DGF), acute rejection and one- and three-year 
graft survival was calculated using binary logistic regression and Cox regression models. We 
found a median BDdur of 23.8h. BDdur had a small positive effect on the chance of imme-
diate function (odds for DGF 0.995) and 1- and 3-year graft survival (hazard ratios 0.995 
and 0.996), but not on acute rejection. These effects were not independent in a multivariate 
analysis: donor age and acute rejection were confounding factors. Yet, in a multivariate
subgroup analysis of donors aged ≤ 55 years BDdur was an independent predictor of imme-
132diate function. With each extra hour of BDdur the risk of DGF decreased with 0.4%. This 
analysis showed that a longer BDdur seems to be slightly beneficial in DBD donors
≤ 55 years, reducing the chance of DGF in the recipient. We concluded that long BDdur 
is not detrimental for kidney graft quality, as long as donor management is sufficient to 
adequately support the circulation of the donor. This fact may have major impact on the 
logistics of organ retrieval procedures in Western Europe as it implies that there is no need 
to hurry these procedures.
Although longer duration of brain death does not have a detrimental effect on organ quality
after transplantation, it is still difficult to predict organ quality at the moment of donor 
evaluation and management. An early prediction of the chance of transplantation success 
by specific markers would not only allow organ allocation in a fair and succesfull way, e.g. by 
programmes like the ‘old-for-old programme’, but also a better evaluation of interventional 
strategies in the donor or during preservation, aiming at improved graft quality. In Chapter 6
we have tested several interesting novel urine markers to discover kidney specific injury. 
We evaluated urinary levels of lactate dehydrogenase (LDH), kidney injury molecule-1 
(KIM-1), heart-type fatty acid binding proteins (H-FABP), alanine aminopeptidase (AAP), 
malondialdehyde (MDA), N-acetyl-β-D-glucosaminidase (NAG) and interleukin-18
(IL-18). These markers were compared to urinary creatinine and urinary protein as classic
parameters of kidney function. Two different populations were studied: urine samples were 
collected from 40 kidney donors during donation, and another set from 29 transplant
recipients during the first 10 days after kidney transplantation. Biomarker levels were related 
to delayed graft function, acute rejection and kidney function up to one year after trans-
plantation using regression analyses. We found that most biomarkers were elevated in urine 
samples from deceased donor kidneys compared to living donor kidney controls. In the 
urine samples collected during donation, AAP predicted short-term kidney function, and 
H-FABP and KIM-1 predicted 3-month’s function independently. LDH in donor urine pre-
dicted delayed graft function (DGF), defined as the need for dialysis in the first week after 
transplantation. In the urine samples collected during the first days after transplantation,
urinary creatinine, LDH and NAG predicted kidney function at 3 months and one year after 
transplantation, although sample collection was not complete due to lack of urine production 
in several recipients with DGF. Our analysis suggests that determination of urinary biomarkers 
at time of donation and kidney transplantation can be useful for an early evaluation of the 
kidney graft.  
Kidney Injury Molecule-1 was studied in more detail in Chapter 7. We were especially in-
terested in KIM-1 as a urinary biomarker because of its apparent high sensitivity for kidney 
injury and early upregulation during kidney injury. Also, KIM-1 gene expression had been 
shown to be upregulated during brain death in our microarray study. Therefore, we studied 
Kim-1 expression in a standardised rat brain death model, where brain death is induced by 
intracranial balloon inflation. Sham operated animals were compared to animals that had 
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been brain dead for 0.5, 1, 2 or 4h. In the kidney, real-time PCR revealed a 46-fold Kim-1 
gene upregulation after 4h of brain death. In situ hybridisation showed proximal tubular 
Kim-1 localization, which was confirmed by immunohistochemistry. Also, Luminex as-
say showed a 6.6-fold Kim-1 rise in urine after 4h of brain death. Data were confirmed in 
human DBD donors, where a 2.5-fold KIM-1 gene upregulation was seen in kidney biopsy 
specimens and two-fold higher urine KIM-1 levels were found compared to living kidney 
donors. Multiple regression analysis showed that urinary KIM-1 after diagnosis of brain 
death was a positive predictor of recipient serum creatinine on day 14 day  and 1 year after 
kidney transplantation. This suggests that KIM-1 is a promising novel and non-invasive 
marker for early brain death-induced kidney damage.   
The previous chapters of this thesis are merely descriptive, characterizing the effects of brain 
death. Obviously, the goal is to intervene during brain death and aim at a better balance 
between injury and repair, hopefully resulting in better graft survival and transplantation. 
In Chapter 8, the administration of (carbamylated) erythropoietin in brain death in a rat 
model is studied. In this experiment we used our standardised brain death animal model and 
after retrieval we evaluated kidney function with the Isolated Perfused Kidney (IPK) model. 
Animals were treated with EPO, carbamylated EPO (cEPO, which is a modified molecule 
without the erythropoietic properties of EPO), or a vehicle, and compared with sham oper-
ated animals. Both substances, but especially cEPO, were able to decrease the expression of 
several proinflammatory genes and to reduce infiltration of PMNs in the kidney. No effect 
on tubular injury parameters was seen. During organ evaluation in the IPK setup, kidney 
function decreased by approximately 50% after brain death, but was fully restored in the 
groups treated with both cEPO and EPO. These results are promising, and further studies 
are necessary to find out whether this inhibition of the inflammatory response and restora-
tion of kidney function will lead to better results in clinical kidney transplantation.
134- Future perspectives -
The research questions described in this thesis have been performed at an interface of labora-
tory science and clinical practice. As the Groningen Junior Scientific Masterclass motto 
states: from bed to bench and back. In the future, this starting point will become increasingly 
important, as our aim is to improve clinical outcome in transplantation. 
Improving early organ evaluation and monitoring interventions
This thesis describes the evaluation of urinary biomarkers for an early detection of kidney 
injury in organs from DBD donors. The studies presented are pilot studies, and should be 
extended. Also, several studies have suggested recently that more than one marker may be 
necessary to obtain sufficient sensitivity and specificity for the early detection of acute kidney 
injury. This may lead to the creation of ‘biomarker panels’ for more accurate evaluation. 
Organ specific injury markers may not only be valuable for a better evaluation of organ quality. 
They may also serve as a means to evaluate the therapeutic effect of interventions. In this
respect, the development of easy-to-use bedside tests, such as the new KIM-1 dipstick test 
that was described recently could be very helpful for monitoring the effect of donor treat-
ment. In contrast to serum markers, urinary markers may not only be used in the donor
during brain death, but also during the period of machine preservation of a kidney when 
‘urine’ production during perfusion may be collected from the ureter and analyzed as a
reflection of organ viability.
Improvements in intervention and study of its therapeutic effects
In this thesis, one intervention study in brain death is described. The results are promising, 
but we need to know whether cEPO administration does have an affect on outcome after 
transplantation. Our animal models are demanding and technically complex, but we will 
have to improve our models and our skills, to be able to test our interventions in the donor 
by subsequent evaluation in the (allogeneic) recipient. 
When thinking about new ways of intervention in brain death, there are several possibilities. 
As positive data are reported concerning corticosteroid administration in the donor, more 
specific stimulation or inhibition of the immune system may be effective, e.g. using tacro-
limus, complement inhibitors or interleukin ligands. Another approach may be a focus on 
(high fat) enteral feeding, increasing vascular integrity, and decreasing intestinal permeability 
and endotoxemia. The natural ability of kidneys in DBD donors to protect themselves by 
expressing heat shock proteins could also be a starting point for therapy, e.g. by geranyl-
geranylacetone administration.   
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One mechanism which may contribute to the inflammatory response during brain death was 
recently described in the thesis of Simone Hoeger, which she called the cholinergic anti-
inflammatory pathway. Normally, afferent signals carried in the vagus nerve can activate an 
efferent response that inhibits cytokine release. In Hoeger’s hypothesis, this so-called inflam-
matory reflex is disrupted by the brain damage of the DBD donor, which leads to cytokine 
production without central inhibition. Vagus stimulation in the donor by nicotine adminis-
tration may be a way to counteract this problem.
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- Samenvatting -
In de laatste decennia is niertransplantatie de behandeling van eerste keuze geworden bij 
eindstadium nierfalen. Van oudsher is de grootste ‘bron’ van nierdonoren de groep hersen-
dode patiënten met intacte circulatie (donatie na ‘brain death’, DBD). Vanwege het chro-
nische tekort aan donororganen worden echter in toenemende mate ook nieren gebruikt 
van levende donoren (al dan niet familie) en non-heart-beating donoren (NHB). Het was 
bekend dat transplantatie bij goed gematchte combinaties van levende donoren en ontvangers 
succesvoller was dan transplantatie met nieren van DBD- of NHB-donoren. Tijdens de 
laatste vijftien jaar werd het echter duidelijk dat ook nieren van levende donoren die vol-
strekt niet gematcht waren met de ontvanger een betere overleving vertoonden dan nieren 
van DBD-donoren met een goede HLA-antigenenmatch met de ontvanger. Dit verschil in 
uitkomst kan niet volledig verklaard worden door de langere koude ischemietijden in nieren 
afkomstig uit DBD-donoren, aangezien er geen significante verschillen in niertransplantatie-
uitkomsten werden gezien zolang de koude ischemietijd onder de 24 uur bleef. Daarom 
moeten er andere risicofactoren zijn die dit verschil in transplantatie-succes tussen nieren 
afkomstig van levende en overleden donoren kunnen verklaren. 
In de afgelopen jaren heeft onze groep zich gericht op de onfysiologische status van hersend-
ood als een belangrijke factor en mogelijke oorzaak voor verminderde transplantaatoverlev-
ing. Het is al vele jaren bekend dat hersendood invloed heeft op de circulatoire en hormonale 
status van de donor. Het is echter tot nu toe niet gelukt deze negatieve effecten tegen te gaan 
door de bloeddruk te controleren en door hormonen toe te dienen. In dit proefschrift hebben 
we ons gericht op de progressieve pro-inflammatoire respons op hersendood in de nier en 
op de ontdekking van deze effecten voorafgaand aan transplantatie. We hebben de karakter-
istieken van deze inflammatoire respons bestudeerd, hypothesen opgesteld over de origine 
ervan en mogelijke reparatiemechanismen onderzocht. Reparatiemechanismen tijdens de 
hersendoodperiode zouden kunnen leiden tot een betere uitkomst na transplantatie. Daarom 
hebben we het effect van de duur van hersendood op transplantatie-uitkomsten onderzo-
cht. Verder is de vroege detectie van nierschade door hersenschade onderzocht. We hebben 
hierbij ook een aantal nieuwe specifieke biomarkers voor nierschade getest. Tenslotte hebben 
we een interventiestudie verricht waarbij we een gemodificeerde vorm van erythropoietine 
hebben toegediend om nierkwaliteit tijdens hersendood te kunnen verbeteren.
In de Inleiding van dit proefschrift wordt de huidige stand van zaken beschreven wat betreft 
de kennis en concepten van hersendood en zijn effecten op orgaankwaliteit. Onomkeerbare 
hersenschade die leidt tot hersendood is over het algemeen het gevolg van een intracraniële 
bloeding of van traumatisch hersenletsel. Beiden leiden tot massawerking in het brein met 
compressie van hersenweefsel, waardoor uiteindelijk de hersenstam inklemt. Hierbij verd-
wijnen de hersenstamreflexen inclusief de ademhalingsprikkel. Tijdens de toename van de in-
tracraniële druk is een Cushingreflex waarneembaar als gevolg van een catecholaminestijging. 
138Hierna raakt de patient hypotensief vanwege een progressieve sympathische deactivatie.
Bij de meeste patienten is sprake van een complete dysfunctie van hypofyse-achterkwab, 
zoals blijkt uit het ontstaan van diabetes insipidus, en een dysfunctie van de hypothalamo-
hypofyse-schildklieras. Het is nog steeds niet duidelijk of hormoonsubstitutie met triio-
dothyronine, cortisol of insuline een gunstig effect heeft op de toestand van de donor. Verder 
zijn kort na hersendood in het perifere bloed van de donor hoge spiegels aanwezig van 
proinflammatoire cytokines, zoals interleukine-1β and interleukine-6, oplosbare cytokine-
receptoren zoals sIL-2 receptor and sTNF receptor II, en vasoactieve stoffen zoals endothe-
line-1. Zowel de afgifte van deze stoffen door het beschadigde brein als ischemie of shear 
stress van de vaatwand door hemodynamische instabiliteit zou verantwoordelijk kunnen zijn 
voor de effecten op perifere organen. In het hart zorgt zowel de systemische als een locale af-
gifte van catecholaminen voor necrose van myocyten, en endotheelcelschade is het startpunt 
voor allograft vasculopathie. In de long zorgt hersenschade voor neurogeen longoedeem, dat 
nog wordt verergerd door de effecten van beademing. Hierbij raakt IL-8 opgereguleerd en 
worden PMNs naar het longweefsel gerecruteerd. Wat betreft de lever: hier wordt tijdens 
hersendood een stijging van transaminases gezien. Verder wordt ook in de lever endotheelac-
tivatie en een influx van PMNs en macrofagen gezien. In een diermodel werd een significant 
lagere transplantaatoverleving gebruikt wanneer een lever werd gebruikt van een hersendode 
donor, zelfs zonder hieropvolgende koude ischemie.
In de nier wordt een progressieve inflammatoire respons met endotheelactivatie gezien, en 
een vermindering van de nierfunctie. Aan de andere kant zijn HO-1 en Hsp70 wel signifi-
cant opgereguleerd in hersendode donoren. HO-1 en Hsp70 coderen voor eiwitten met een 
aantal cytoprotectieve eigenschappen tegen ischemie, hitte en toxines. DNA microarrays 
hebben aangetoond dat er diverse genen zijn opgereguleerd in hersendood. Deze genen kun-
nen worden verdeeld in drie categorieën: genen betrokken bij ontsteking en stolling, in celde-
ling en fibrose, en in beschermende en reparatieprocessen. Deze bevindingen in hersendood 
van een inflammatoire respons op orgaanniveau, in combinatie met een eerste poging van het 
orgaan om zichzelf te beschermen, bieden nieuwe mogelijkheden voor donorbehandeling 
en orgaanbehandeling tijdens preservatie. Door ons te richten op specifieke blokkades of 
stimulatie van deze processen, zouden we transplantaatoverleving van nieren van hersendode 
donoren kunnen verbeteren. Deze Inleiding wordt gevolgd door een algemene Rationale 
waar de verdere hoofdstukken van dit proefschrift op een rij worden gezet. 
In Hoofdstuk 3 hebben we ons gericht op de effecten van hersendood op de inflammatoire 
respons en op stress-gerelateerde heat shock eiwitten in de nier. Er werden nierbiopten 
genomen en serummonsters verzameld van hersendode donoren en van een controlegroep 
van levende donoren tijdens de donatieprocedure. De biopten werden gebruikt voor
immuunhistochemie en semikwantitatieve polymerase-kettingreacties. De uitkomsten 
hiervan en de klinische en laboratoriumgegevens van de donoren werden gerelateerd aan 
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niertransplantatie-uitkomsten van de bijbehorende ontvangers. Immuunhistochemie toonde 
een toename van E-selectine-aankleuring en interstitiële leucocyteninvasie in DBD donoren 
vergeleken met de controles. RT-PCR toonde een drievoudige stijging van haemoxygenase-1 
en Hsp70 genexpressie na hersendood. De waardes van monocyte chemotactic protein-1 en 
transforming growth factor-β waren twee keer zo hoog na hersendood, maar dit resultaat 
was niet statisttisch significant. De transplantatie-uitkomsten werden door verschillende 
factoren beïnvloed: in positieve zin door donorbehandeling met desmopressine, in negatieve 
zin door hoge serum ureumwaardes tijdens hersendood en door hoge expressie in de nier 
van intercellular adhesion molecule en vascular cell adhesion molecule. Een hogere expressie 
van haemoxygenase-1 werkte protectief, maar alleen in de controlegroep. De aanwezigheid 
van interstitiële leucocyten en het vroege adhesiemolecuul E-selectine in nieren van DBD 
donoren wijst op een vroege fase van een ontstekingsreactie tijdens de donatieprocedure. De 
verhoogde expressie van monocyte chemotactic protein-1 en transforming growth factor-β 
doen vermoeden dat monocyten/macrophage in deze fase een rol spelen. Dit leidt tot onze 
conclusie dat BD een stressrespons veroorzaakt, waartegen het toekomstige transplantaat 
protectieve heat shock eiwitten aanmaakt. Deze stressrespons in de DBD donor is misschien 
te ernstig om volledig teniet gedaan te worden door verhoogde heat shock eiwitten. Opregu-
latie van  heat shock eiwitten zou echter wel een interessant aangrijpingspunt kunnen zijn 
voor interventies in de donor. 
De opregulatie van cytokines en adhesiemoleculen in de nier zou verergerd kunnen worden 
door verstoringen van het milieu intérieur van de donor door andere organen. Het is bekend 
dat veel DBD donoren een hogere endotoxinespiegel hebben en meer bacteriële translocatie 
vanuit de darm, vergeleken met levende donoren. Endotoxinaemie zou een vermindering
kunnen veroorzaken van de vasculaire integriteit, die weer zou kunnen leiden tot een 
vergrote vaatpermeabiliteit in de darm of de long door middel van beïnvloeding van het 
Angiopoietine-Tie ligand-receptor systeem. Een verlaagde Angiopoietine-1/Angiopoietine-2 
ratio wordt geassocieerd met verhoogde morbiditeit and mortaliteit tijdens sepsis, terwijl 
een verhoogde ratio de vasculaire integriteit kan behouden en de inflammatoire respons kan 
dempen. Daarom hebben we in Hoofdstuk 4 Ang-1 en Ang-2 gemeten in donor serum, 
evenals de hoeveelheid Lipopolysaccharide Binding Protein (LBP) als maat voor endotoxi-
naemie. Daarnaast hebben we VEGF gemeten, omdat Ang-2 het endotheel stimuleert om 
te reageren op VEGF. DBD donoren hadden hogere LBP, Ang-2 en VEGF-waarden dan 
levende nierdonoren, waardoor ze een verlaagde Ang-1/Ang-2 ratio hadden, die wijst op 
pro-inflammatoire activatie. In een univariate regressie-analyse was een hoge Ang-2 waarde 
in de donor voorspellend voor de kans op rejectie in het eerste jaar na niertransplantatie. Dit 
wijst erop dat Ang-2 een mogelijke marker is voor de beoordeling van orgaankwaliteit in de 
donor. 
Het mogelijke vrijkomen van schadelijke stoffen uit het brein in de circulatie van hersendode 
donoren en de toename van cytokine- en chemokine-expressie in de organen zelf tijdens de 
140hersendoodperiode suggereert dat een zo vroeg mogelijke donatieprocedure in hersendode 
donoren het beste zou zijn. Aan de andere kant zou je de expressie van beschermende heat 
shock eiwitten kunnen zien als een mechanisme waarmee het lichaam probeert de ontstane
schade te herstellen. Er is maar weinig literatuur beschikbaar hierover, maar in twee publica-
ties wordt gesuggereerd dat een langere periode van hersendood beter zou zijn voor orgaan-
kwaliteit. In Hoofdstuk 5 van dit proefschrift staan de resultaten van een grote retrospectieve 
analyse waarbij we gegevens van de OPTN database hebben gebruikt om het effect van 
hersendoodduur (BDdur) op de uitkomst na niertransplantatie te bestuderen. Data van 
20.773 nierdonor- en –ontvangerparen werden gebruikt. Als BDdur werd de periode 
genomen tussen het tijdstip van vaststellen van hersendood en het tijdstip van het zetten van 
de klem op de aorta. Het effect van BDdur op delayed graft function (DGF), acute rejectie 
and één- en driejaars transplantaatoverleving werd berekend met behulp van binaire logis-
tische regressie en Cox regressiemodellen. De mediane BDdur was 23,8 uur. BDdur had een 
klein positief effect op de kans op direct functioneren van het transplantaat (odds voor DGF 
0.995) en op de één- en driejaars transplantaatoverleving (hazard ratios 0.995 and 0.996), 
maar niet op de kans op acute rejectie. Deze effecten waren in een multivariate analyse niet 
onafhankelijk: donorleeftijd en acute rejectie waren confounding factoren. Wel bleek BDdur 
een onafhankelijke voorspeller van direct transplantaatfunctioneren te zijn in een multivariaat 
model bij een subgroepanalyse van donoren ≤ 55 jaar. Elk extra uur BDdur zorgde voor een 
vermindering van de kans op DGF met 0,4%. Deze analyse laat zien dat een langere BDdur 
iets gunstiger lijkt voor nieren van hersendode donoren ≤ 55 jaar door de reductie van de 
kans op DGF in de ontvanger. We trokken de conclusie dat een lange BDdur niet schadelijk 
is voor de kwaliteit van een transplantatienier, mits er een goede behandeling van de donor 
plaatsvindt gericht op het ondersteunen van de circulatie van de donor. Deze conclusie zou 
een grote invloed kunnen krijgen op de logistiek rond orgaandonatieprocedures in West-
Europa, omdat hieruit blijkt dat deze procedures in principe in alle rust kunnen worden 
uitgevoerd. 
Hoewel een langere hersendoodduur geen schadelijk effect heeft op orgaankwaliteit na 
transplantatie, is het nog steeds moeilijk om orgaankwaliteit te voorspellen tijdens de evalu-
atie van de donor en het donormanagement. Een vroege voorspelling van de kans op succes 
na transplantatie door middel van specifieke markers zou niet alleen een succesvollere en 
eerlijker orgaanallocatie mogelijk maken (bijvoorbeeld door specifieke programma’s zoals 
het ‘old-for-old’ programma), maar zou ook kunnen leiden tot een betere evaluatie van 
interventiestrategieën in de donor of tijdens de orgaanpreservatie, gericht op verbetering van 
orgaankwaliteit. In Hoofdstuk 6 hebben we een aantal interessante nieuwe urinebiomark-
ers getest, specifiek gericht op nierschade. We hebben gekeken naar urinespiegels van lactaat 
dehydrogenase (LDH), kidney injury molecule-1 (KIM-1), heart-type fatty acid binding 
protein (H-FABP), alanine aminopeptidase (AAP), malondialdehyde (MDA), N-acetyl-β-
D-glucosaminidase (NAG) en interleukine-18 (IL-18). Deze markers hebben we vergeleken 
met klassieke parameters voor nierfunctie en –schade, namelijk urinespiegels van creatinine 
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en totaal eiwit. We hebben urinemonsters van twee verschillende populaties onderzocht: ten 
eerste van 40 nierdonoren rond de donatieprocedure, en ten tweede van 29 niertransplan-
tatiepatiënten gedurende de eerste 10 dagen na niertransplantatie. De biomarkerspiegels 
werden door middel van regressie-analyses gerelateerd aan het vóórkomen van delayed graft 
function, acute rejectie en nierfunctie tot één jaar na transplantatie. In de donorurinemon-
sters bleken de meeste biomarkers in vergelijking met levende nierdonoren verhoogd te zijn 
bij de hersendode donoren. Bij deze monsters voorspelde de AAP-waarde nierfunctie op de 
korte termijn, en H-FABP en KIM-1 voorspelden onafhankelijk de transplantaatfunctie 
na drie maanden. Delayed graft function (DGF), gedefinieerd als de noodzaak tot dialyse 
gedurende de eerste week na niertransplantatie, werd voorspeld door LDH in de donorurine. 
In de urinemonsters die waren verzameld bij de transplantatiepatiënten gedurende de eerste 
dagen na transplantatie bleken creatinine, LDH en NAG in de urine nierfunctie na drie 
maanden en één jaar te voorspellen. Hierbij konden echter niet op alle tijdstippen monsters 
worden verzameld als gevolg van een gebrek aan urineproductie bij een aantal patiënten met 
DGF. Onze analyse suggereert dat de bepaling van urinebiomarkers rond de donorprocedure 
en de transplantatie zinvol kan zijn voor een vroege evaluatie van het niertransplantaat.    
In Hoofdstuk 7 hebben we Kidney Injury Molecule-1 meer in detail bestudeerd. We waren 
in het bijzonder in KIM-1 als urinebiomarker geïnteresseerd vanwege de kennelijk hoge sen-
sitiviteit voor nierschade en vanwege de vroege opregulatie tijdens nierschade. Bovendien was 
uit onze microarray resultaten al gebleken dat KIM-1 was opgereguleerd tijdens hersendood. 
Daarom onderzochten we Kim-1 expressie in een gestandaardiseerd hersendoodmodel in de 
rat, waarbij hersendood wordt geïnduceerd door het opblazen van een intracranieel geplaat-
ste ballon. Sham geopereerde ratten werden vergeleken met ratten die hersendood waren 
geweest gedurende een half uur, 1, 2 of 4 uur. In de nier vonden we met real-time PCR een 
46-voudige opregulatie van genexpressie na 4 uur hersendood. In situ hybridisatie liet Kim-1 
expressie zien in de proximale tubuli, en dit kon bevestigd worden met immuunhistoche-
mie. Daarnaast vonden we met een Luminex assay een 6,6-voudige stijging van Kim-1 eiwit 
in de urine na 4 uur hersendood. We konden deze data bevestigen in humane hersendode 
donoren, waarbij we een 2,5-voudige opregulatie van KIM-1 genexpressie vonden in nier-
biopten, en een verdubbeling van KIM-1 urinespiegels, vergeleken met levende nierdonoren. 
Multipele regressie-analyse liet zien dat KIM-1 in urine, afgenomen rond het vaststellen van 
de hersendood, een positief voorspellende factor was voor creatininespiegels in het serum 
van niertransplantatiepatiënten 14 dagen en één jaar na transplantatie. Dit suggereert dat 
KIM-1 een veelbelovende non-invasieve marker is voor vroege nierschade geïnduceerd door 
hersendood. 
De vorige hoofdstukken van dit proefschrift zijn vooral beschrijvend van aard, waarbij de 
effecten van hersendood worden gekarakteriseerd. Het is natuurlijk duidelijk dat het uitein-
delijke doel is om te interveniëren tijdens hersendood en daarbij te mikken op een gunstiger 
balans tussen schade en herstel, in de hoop een betere transplantaatoverleving te bereiken. 
142In Hoofdstuk 8 hebben we de toediening bestudeerd van (gecarbamyleerd) erythropietine 
tijdens hersendood in een rattenmodel. In dit experiment hebben we weer ons gestand-
aardiseerde diermodel voor hersendood gebruikt, waarbij we na uitname van de nieren de 
nierfunctie hebben geëvalueerd met het Isolated Perfused Kidney (IPK) model. De dieren 
werden behandeld met EPO, gecarbamyleerd EPO (cEPO, een gemodificeerd EPO-molecuul 
zonder de erythropoietische eigenschappen van EPO) of een placebo, en de uitkomsten
werden vergeleken met die van sham geopereerde dieren. Beide stoffen, maar met name 
cEPO, verlaagden de expressie van een aantal pro-inflammatoire genen en reduceerden de 
infiltratie van PMN’s in de nier. We vonden geen effect op parameters voor tubulusschade. 
Bij de evaluatie van de nierfunctie in het IPK-model bleek de nierfunctie met bijna 50% af 
te zijn genomen als gevolg van hersendood, maar de nierfunctie was volledig hersteld in de 
groepen die waren behandeld met cEPO of EPO. Deze resultaten zijn veelbelovend, maar 
er is nog verder onderzoek nodig om vast te stellen of deze remming van de inflammatoire 
respons en herstel van nierfunctie zal leiden tot betere resultaten in de klinische niertrans-
plantatiepraktijk.    
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- Toekomstperspectieven -
De onderzoeksvragen die beschreven zijn in dit proefschrift zijn uitgevoerd op een grensvlak 
tussen basaal laboratoriumonderzoek en de klinische praktijk. Zoals het motto van de
Groningse Junior Scientific Masterclass zegt: van ‘bed’ naar ‘bench’ en ‘back’. In de toekomst 
zal dit uitgangspunt alleen nog maar belangrijker worden, omdat het doel is om de uitkom-
sten van klinische transplantatie te verbeteren. 
Verbetering van vroege orgaanevaluatie en de monitoring van interventies
Dit proefschrift beschrijft de evaluatie van biomarkers in urine ten behoeve van een vroege 
detectie van nierschade in organen van hersendode donoren. De studies die hier beschreven 
staan zijn pilotstudies, en zullen nog uitgebreid moeten worden. Verder hebben diverse stu-
dies recentelijk gesuggereerd dat er misschien meer dan één marker nodig is om voldoende 
sensitiviteit en specificiteit te verkrijgen voor de vroege detectie van acute nierschade. Dit zou 
kunnen leiden tot de ontwikkeling van ‘biomarker panels’ voor een accuratere evaluatie.
Orgaanspecifieke schademarkers zijn waarschijnlijk niet alleen waardevol voor een betere 
evaluatie van donororgaankwaliteit. Ze zouden ook kunnen dienen als een manier om het 
therapeutisch effect van interventies te meten. In dat opzicht zou de ontwikkeling van een-
voudig te gebruiken bedside-testen, zoals de nieuwe KIM-1 dipstick die recent is beschreven, 
erg behulpzaam kunnen zijn bij het monitoren van het effect van behandeling van de donor. 
In tegenstelling tot serummarkers zouden urinemarkers bovendien niet alleen gebruikt kun-
nen worden in de donor tijdens hersendood, maar ook tijdens perfusaat-‘productie’ in nieren 
die machinaal gepreserveerd worden. 
Verbetering in interventie en studie van therapeutische effecten
In dit proefschrift is één interventiestudie beschreven. De resultaten zijn veelbelovend, 
maar we moeten weten of cEPO-toediening daadwerkelijk effect heeft op de uitkomsten na 
transplantatie. Onze diermodellen zijn uitdagend en technisch complex, maar we zullen onze 
vaardigheden daarin moeten verbeteren, om onze interventies in donoren daarna te kunnen 
testen in de (allogene) ontvanger.
 
Wanneer je nadenkt over interventiemogelijkheden in hersendood, heb je verschillende 
mogelijkheden. Naar aanleiding van de positieve resultaten die worden gemeld ten aanzien 
van corticosteroidtoediening aan donoren, zou een meer specifieke stimulatie of remming 
van het immuunsysteem misschien effectief kunnen zijn, bijvoorbeeld de toediening van
tacrolimus, complementremmers of liganden voor interleukines. Een andere aanpak zou 
kunnen zijn om te focussen op (hoog vet) enterale voeding, om hiermee de vasculaire
integriteit te vergroten, en intestinale permeabiliteit en endotoxinaemie te verlagen. De eigen 
mogelijkheid van nieren in hersendode donoren om zichzelf te beschermen door heat shock 
eiwitten te produceren, zou ook een aangrijpingspunt voor therapie kunnen zijn, bijvoor-
beeld de toediening van geranylgeranylaceton. 
144Een ander mechanisme dat zou kunnen bijdragen aan de inflammatoire respons tijdens 
hersendood is als de cholinerge anti-inflammatoire pathway recent beschreven in het proef-
schrift van Simone Hoeger. Normaalgesproken kunnen afferente signalen via de nervus 
vagus een efferente respons activeren die cytokinerelease blokkeert. Volgens de hypothese 
van Hoeger wordt deze zogenoemde inflammatoire reflex verstoord door de hersenschade 
van de hersendode donor, waardoor cytokineproductie kan plaatsvinden zonder centrale 
inhibitie. Vagusstimulatie in de donor door middel van nicotine-toediening zou een manier 
kunnen zijn om dit probleem aan te pakken.
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Dankwoord
Op 15 november 1888 verzond de dichter Herman Gorter vanuit Amsterdam een briefkaart 
aan zijn vriend, de latinist en componist Alphons Diepenbrock in ’s-Hertogenbosch. Op
de briefkaart stond de summiere tekst: ‘Het ding is af. Pans.’ Met ‘het ding’ doelde hij op zijn 
omvangrijke gedicht Mei, bestaande uit 4400 dichtregels, waaraan hij bijna drie jaar had 
gewerkt (1). 
De opluchting van Herman Gorter kan ik mij goed voorstellen. Ook ik ben blij dat ‘het ding’, 
in dit geval ‘het boekje’ af is. Maar anders dan bij Gorter, die zijn gedicht alleen in kleine 
kring besprak, is een medisch proefschrift tegenwoordig geen zaak van enkelen, maar van 
velen, die ik hierbij wil danken voor hun inspanningen.
In de eerste plaats natuurlijk prof. dr. Ploeg. Beste Rutger, vanaf het moment dat ik als
JSM-student jouw kamer binnenstapte, verwezen door Hauw The die bedacht dat ik als 
chirurgie- en niertransplantatie-geïnteresseerde bij jou aan het juiste adres was, ben je mijn 
onderzoeksbegeleider geworden, en later mijn promotor. Hartelijk dank hiervoor. 
Dr. Leuvenink, geachte co-promotor, beste Henri. Een lotgenoot noemde je ooit ‘mijn coach-
promotor’, en daar wil ik me van harte bij aansluiten. Niet alleen ben je altijd bereikbaar voor 
overleg, ook heb je me gesteund tijdens moeilijke periodes in mijn onderzoek.   
Prof. dr. Cremer, prof. dr. rer. nat. Yard en prof. dr. Navis, beste Gerjan, u wil ik allen hartelijk 
danken dat u plaats heeft willen nemen in de leescommissie voor dit proefschrift. Gerjan, 
door jou en prof.dr. Rob Henning raakte ik als eerstejaarsstudent enthousiast voor de weten-
schap tijdens de organisatie van (toen nog) het Studenten Congres Geneeskunde. Je bent 
sindsdien één van mijn rolmodellen; dank hiervoor.
Drs. Moers en dr. Koudstaal, beste Cyril en Lyan, dank dat jullie mijn paranimfen willen zijn. 
Als onderzoekers in opleiding deelden we aio-kamers, bekers slappe koffie en theezakjes; 
buiten het lab ook onze liefde voor de muziek. Ik ben blij met jullie support.
Prof. dr. Van Goor, beste Harry, dank voor je hulp op histopathologisch gebied, de vele
samenwerking en je morele steun. Ik ben blij dat je in mijn oppositiecommissie zit.
Hans Burgerhof leerde ik eigenlijk ‘te laat’ kennen. Zijn statistische hulp was van grote 
waarde tijdens de laatste helft van mijn onderzoeksperiode. Dr. Theo Schuurs ben ik dank 
verschuldigd voor zijn co-auteurschap van enkele hoofdstukken van dit proefschrift. 
Naast Henri Leuvenink wil ik ook de andere onderzoekers en medewerkers van het Chirur-
gisch Onderzoekslaboratorium bedanken. Petra Ottens, bedankt voor alle dierexperimenten 
(ook de mislukte) en de vele assays en PCRs. Dank ook voor je hulp bij de hersendood- 
experimenten die ik zelf uitvoerde, waarbij je op het kritieke moment altijd bereid was on-
146danks je zwangerschap en de isofluraandampen toch even bij te springen. Jacco Zwaagstra, 
bedankt voor je assays, je bestellingen, je coördinatie van de studenten op het lab en je nuch- 
terheid. Janneke Wiersema, bedankt voor het vele snijden en kleuren. Reni Freund en Antony 
van Dijk, dank voor jullie hulp en pipetteerlessen toen ik als student het lab opwandelde. 
Naast Cyril en Lyan heb ik op de aio-kamer(s) met veel collega-onderzoekers samengewerkt. 
Jullie hebben met mij diverse aio-kamerverhuizingen ondergaan, koffie gedronken en con-
gressen bezocht. Bovendien: gedeelde onderzoekssmart is halve onderzoekssmart. Bij name 
wil ik noemen: Joost van der Hoeven, wiens onderzoekslijn ik heb overgenomen, Erwin 
Geuken, Nils ’t Hart, Martijn de Groot, Ilona Pereboom, Carlijn Buis, Hugo Maathuis, 
Anne Margot Roskott, Jayant Jainandunsing, Eelke Bos, Aurora Morariu en Ton Lisman.  
  
De oprichting van de databank met humaan materiaal waaruit onder meer voor dit proef-
schrift is geput, was niet mogelijk geweest zonder de inzet van de studenten van het Pro-
metheus-team. De oprichting van dit team verloste mij van mijn 24/7 bereikbaarheid voor 
donorprocedures en niertransplantaties en van de soms bijbehorende 36-urige werkdagen.
Ik ben blij dat dit team zo’n succes is geworden en dat zoveel studenten hierdoor vroeg in 
hun studie met de klinische praktijk en met wetenschappelijk onderzoek van donatie en 
transplantatie in aanraking komen. Dames en heren, bedankt!
Door hun werkzaamheden voor dit team zijn verschillende mensen enthousiast geraakt voor 
het zelf verrichten van wetenschappelijk onderzoek. Ik wil hierbij vooral Jeffrey Damman en 
Bert Swart bedanken, die veel werk hebben verricht voor dit proefschrift. Jeffrey, succes met 
je eigen promotie. 
Naast fulltime wetenschappers hebben ook veel clinici bijgedragen aan dit proefschrift. 
Als eerste wil ik de donor- en transplantatiechirurgen bedanken die altijd bereid waren 
materiaal af te nemen en mee te helpen. Christina Krikke, Sijbrand Hofker, Henk ten Cate 
Hoedemaker, Vincent Nieuwenhuijs, Klaas Havenga, Ignace Tielliu en de chivo’s en fellows, 
bedankt. Ook de transplantatienefrologen Jaap Homan van der Heide, Willem van Son, 
Eltjo de Maar en Marc Seelen wil ik bedanken voor hun samenwerking. Hun database en de 
medewerking hierbij van Geertien van Dülmen was onmisbaar. Jaap en Willem, jullie waren 
de begeleiders van mijn keuze-coschap niertransplantatie. Hier heb ik de klinische praktijk 
van de niertransplantatie leren kennen en heb ik voor het eerst als ‘jonge dokter’ gewerkt. 
Dank voor jullie hartelijke ontvangst van deze vreemde chirurgische eend in de bijt.
Een speciaal woord van dank hier voor de Groningse transplantatiecoördinatoren, Daniëlle 
Nijkamp, Sjirk Fopma, Cees Brugman en Ernst Buiter. Jullie namen mij op sleeptouw bij 
donorprocedures, zochten Eurotransplantgegevens voor mij op en waren altijd vol belang-
stelling. Ook nu nog begeleiden jullie de Prometheus-studenten tijdens de donorprocedures. 
Dank voor jullie grote enthousiasme en hulp. 
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Ook een woord van dank voor Mariska Danker, secretaresse van mijn promotor, die altijd 
nog wel weer een gaatje wist te vinden in diens overvolle agenda, en die voor mij zoveel 
dingen heeft geregeld toen ik al naar Zwolle was verhuisd. Bridget Bensdorp, dank voor je 
prachtige ontwerp en layout van dit proefschrift. 
Dit onderzoek is tot stand gekomen in een ‘agikoïde’ constructie, waarbij een AGIKO-stipen-
dium van de Nierstichting ervoor zorgde dat ik afwisselend periodes aan het onderzoek kon 
werken en bezig kon zijn met mijn opleiding Chirurgie. Dank voor het mogelijk maken hier-
van aan mijn academische opleider, prof.dr. Ten Duis. Dr. Pierik, beste Robert, ik ben heel 
blij dat ik het tweede deel van mijn opleiding bij jou mag volgen en dat je me hebt gefacili-
teerd bij de totstandkoming van dit proefschrift. Ook de overige stafleden en vooral de 
A(N)IOS Chirurgie in het UMCG en de Isala Klinieken wil ik danken voor jullie collegia-
liteit en prettige werksfeer. 
Lieve vader en moeder, dank voor jullie liefde, steun en belangstelling in dit lange traject. 
Jullie hebben mij kritisch en onafhankelijk leren denken, en in jullie medische en verloskun-
dige praktijk (onbedoeld?) bij mij de fascinatie voor de geneeskunde laten ontstaan. Ik ben 
er trots op in de voetsporen te treden van jullie en jullie vaders als de derde generatie ‘dr. 
Nijboer’. Lieve broer, ik heb je misschien wel besmet met mijn interesses. Je bent een enthou-
siast lid van het Prometheus-team geweest en bent nu ook begonnen aan een carrière in de 
snijdende richting. 
Tenslotte: lieve Robert Jan, dank voor je enorme en onvoorwaardelijke steun, waardering 
en liefde. Vanaf onze eerste kennismaking was je geïnteresseerd in mijn werk. Je hebt me 
gestimuleerd om door te zetten, ook op momenten dat ik bijna de moed liet zakken. Volgens 
Rob Henning is promoveren een feestje dat valt te omschrijven als ‘trouwen in je eentje’. Ik 
ben niet alleen blij dat ik dit feestje met jou mag delen, maar ook dat we binnenkort gaan 
‘trouwen met ons tweetjes’. Ik hou van jou.   
1) Herman Gorter Documentatie 1864-1897, samengesteld door Enno Endt. v Oorschot Amsterdam 1986 2e druk